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SUMMARY
TR6, also called DcR3, M6$, is a soluble receptor of the TNFR superfamily. It bas
three identified ligands: FasL, LIGHT and TL1A, ail TNF ligand superfamily members.
TR6 can interfere with the interaction between FasL versus Fas, LIGHT versus HveA,
and TLI versus DR3. TR6 is over-expressed in some tumours. It has been proposed
that TR6-secreting tumours use this molecule to evade immune surveillance and gain
survivai advantage.
In this project, the function of TR6 in immune regulation was investigated. As we have
proven that human TR6 can cross-react with mouse LIGHT, and anti-human LIGHT
mAb can bind to mouse LIGHT on the mouse T-ceii surface, we use human TR6 and
anti-human LIGHT monoclonal antibody to study the function of TR6 in the mouse
system.
In the in vitro T celi response study, we have found that TR6 on solid phase can
costimulate mouse T celi response in terms of proliferation, cytokine production and
CIL activity. Blocking experiments indicate that soluble human LIGHT can block
TR6-costimulated CTL activity. Anti-LIGHT mAb on solid phase aso enhances T-cell
proliferation. These effects indicate that LIGHT reverse signaling involves in the solid
phase TR6 costimulated T celi response. Based on our findings in LIGHT signaling
transduction, il is likely that, during T-cell activation, LIGHT forms capping and
quickly moves into clustered TCR. The congregated LIGHT inside the 1CR cluster
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SHI ffl
interacts with other signaling molecules through its association with Grb2 to activate
downstream signaling molecules such as ERK1/2 to costimulate T ceil activation.
Further, we have explored the TR6 costirnuÏatory function in turnour immunotherapy.
As T ceils express two TR6 ligands, i.e. fasL and LIGHT, both of which can reversely
transduce positive costimulatory signais into T ceils, we have developed a tumour
vaccine based on surface TR6 expression on tumour celis. In vitro studies have shown
that TR6 surface expression on tumour celis is abie to costirnulate both human and
syngeneic mouse T-ce!! proliferation and cytokine production. In vivo studies have
shown that TR6 surface expression reduces P815 mouse mastocytoma ce!!
tumourigenicity, and induces specific anti-P815 tumour celi immunity. Vaccination
with surface TR6 expressing tumour ce!!s is effective in treating existing highiy
immunogenic as well as !owly immunogenic tumours; the therapeutic effects are
enhanced when the vaccine is used in combination with Baciiius of Ca!mette and
Guerin (BCG). These resu!ts indicate that expressing TR6 on tumour ce!! surface might
be a very usefu! strategy in tumour immunotherapy.
We have also found that TR6 in solution inhibits SDF-Œ—induced T-cell migration both
in vitro and in vivo. TR6-pretreated T celis have impaired actin-po!ymerization, and T
ce!1 pseudopodium formation; they aiso have reduced Cdc42 activity. Cross!inking T
ccl! surface LIGHT with anti-LIGHT monoc!ona! antibody aiso impairs the T-ce!!
migration in vitro. These resu!ts indicate that LIGHT reverse signaling is invoived in T
ceii migration.
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Our study has discovered two important functions of TR6 in the immune regulation,
i.e., costimulating T-cell activation and inhibiting T ce!! migration. For the first time
the princip!e of reverse signa!ing be applied in tumour vaccine development. Our
findings have broadened our knowledge of TR6 in the immune regu!ation. The surface
TR6 based vaccine can be further exploited in immunotherapy ofhuman tumours.
Key words: TR6/DcR3; LIGHT; reverse signaling; costimulation; migration; tumour
vaccine.
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Résumé
TR6, appelé également DcR3 ou M68, est un récepteur soluble de la grande famille du
TNFR. Trois ligands de TR6 ont été identifiés: FasL, LIGHT et TLIA, qui sont tous
membres de la famille TNF. Fortement exprimé dans certaines tumeurs, TR6 interfère
également dans les interactions entre FasL et Fas, LIGHT et HveA, ainsi qu’entre TL1
et DR3. Il a été donc proposé que les tumeurs secrétant TR6 pouffaient utiliser cette
molécule afin d’éviter la surveillance immunitaire et s’assurer un avantage de survie.
Le présent projet consiste à élucider les fonctions de TR6 dans la régulation du système
immunitaire. Comme nous avons déjà constaté que TR6 humain et LIGHT de souris
sont en mesure de réagir ensemble, et qu’un anticorps monoclonal de souris anti-
LIGHT humain peut également se lier à LIGHT de souris à la surface des cellules T
murines, nous nous permettons donc d’utiliser le TR6 humain et l’anticorps monoclonal
de souris anti-LIGHT humain pour étudier la fonction de TR6 dans le système
immunitaire de souris.
Par des études in vitro de la réponse des cellules T, nous avons constaté que TR6,
présenté sur une surface solide, costimule la résponse des cellules T de souris incluant
la prolifération, la production de cytokines et l’activité cytotoxique de CTL. Des
expériences de competition démontrent que LIGHT humain sous forme soluble, est
capable de bloquer l’activité cytotoxique de CTL costimulé par TR6, tandis que
l’anticorps monoclonal de souris anti-LIGHT humain, prèsenté sur surface solide,
augmente également la prolifération des cellules T. Ces effets indiquent que LIGHT
joue un rôle de signalisation inverse sur TR6 en costimulant la réponse des cellules T.
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Selon nos résultats sur les voies de signalisation de LIGHT, il semble que pendant
l’activation des cellules T, LIGHT change de conformation et interagit rapidement avec
le TCR oligomérizé. LIGHT associé aux agglomérats de TCR interagit avec d’autres
molécules de signalisation cellulaire en s’associant à Grb2, et active les molécules de
signalisation en aval, tels que ERK 1/2, dans l’activation des cellules T.
De plus, nous avons étudié la fonction de TR6 costimulé dans l’immunothérapie des
tumeurs. Comme la cellule T exprime deux ligands de TR6, FasL et LIGHT, qui
peuvent être impliqués dans une signalisation inverse, provoquant la transduction de
signaux positifs dans des cellules T, nous avons développé un vaccin de tumeur basé
sur la réaction que TR6 produit à la surface des cellules tumorales. Des études in vitro
prouvent que cette réaction costimule la prolifération des cellules T humaines ou
murines syngénéiques, ainsi que la production de cytoldnes. En même temps, des
études in vivo démontrent que cette réaction réduit également la tumorigénicité des
cellules de mastocytes de souris P8 15, et produit une immunité spécifique vis-à-vis les
cellules P815. Le susdit vaccin semble être efficace dans le traitement des tumeurs
fortement et faiblement immunogèniques. Il a été également remarqué que les effets
thérapeutiques deviennent encore plus évidents, lorsque le vaccin est utilisé en
combinaison avec le bacille de Calmette-Guerin (BCG). Ces résultats nous indiquent
que cette méthode pourrait devenir une stratégie importante dans l’immunothérapie de
tumeur.
Nous avons découvert egalement que TR6 sous forme soluble, inhibe la migration des
cellules T induite par SDF-la in vitro et in vivo. Les cellules T pré-traitées par TR6
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démontrent une altération de la polymérisation de l’actine, de la formation de
pseudopodes des cellules T, et une réduction de l’activité de Cdc42. La liaison de
LIGHT à la surface des cellules T à l’aide de l’anticorps monoclonal anti-LIGHT, a
également altéré la migration des cellules T in vitro. De ces résultats, on comprend que
la signalisation inverse de LIGHT joue un rôle important dans la migration des cellules
T.
La présente étude révèle deux rôles importants de TR6 dans la régulation du système
immunitaire, soit la co-stimulation/activation des cellules T, ainsi que l’inhibition de la
migration des cellules T. Ces principes ont été appliqués pour la première fois dans le
dévoleppement d’un vaccin contre les tumeurs. Les résultats obtenus nous permettrons
d’élargir notre connaissance sur le rôle de TR6 dans la règulation de la réponse
immunitaire. Le vaccin basé sur l’expression de TR6 à la surface des cellules présente
une nouvelle avenue thérapeutique contre le cancer.
Mots clé: TR6/DcR3; LIGHT; signalisation inverse; costimulation; migration; vaccin
anti-cancer.
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I. INTRODUCTION
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I. INTRODUCTION
1. The TNF/TNFR superfamily
Since the first two tumour necrosis factor family members (TNFa and lymphotoxin)
were isolated in 1984, researchers have proven the existence of a TNF superfamily and
a TNF receptor (TNFR) superfamily. There are 19 members in the TNF superfamily
and 30 members in the TNFR superfamily have been identified. The TNF family
members are predominantly expressed in the immune system, and play very important
roles in immune responses and immune related diseases. The TNF/TNFR superfamily
proteins become therapeutic targets in many human diseases. for example, TNFa
blockers have aiready been clinically proven effective in treating rheumatoid arthritis (1)
and some other bowel diseases (2). These proteins are also pivotai in embryonic
deveiopment, as weil as in wide rage of organ and tissue functions.
1.1. The TNF lïgand superfamily
The first two TNF family members were identified as lymphocyte and macrophage
products that caused the lysis of certain types of celis, especially tumour celis,
approximateiy 3 decades ago, and it was believed that they have a therapeutic potential
in the treatment of cancer. These products were called lympliotoxin (LT) and tumour
necrosis factor (TNF), respectively (3, 4). In 1984 these two proteins were cloned (5, 6)
and were identified as two members of a gene superfamiiy. As of today, 19 different
members of the TNF superfamily have been identified in mammaiians (7). As iisted in
table 1 (http ://www . gene.ucl . ac.uklnomenciature/genefamily/tnftop.htmi), the TNF
family members now include TNFu, LTŒ (iymphotoxin-a), LTf3 (lymphotoxin—),
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FasL, 0X401, CD27L, CD3OL, CD4OL, 4-1BBL, TRAIL, TRANCE/RANKIJOPGL,
TWEAK, APRIL/TALL-2, ED1, BAFF/TALLI, LIGHT, TRANCE, VEGI, TLIA and
AITRTJTL6/hGITRL (7). Ail these ligands signal through at least one of TNF receptor
family members (fig. 1). Some of the iigands can also work as receptor reversely
transducing signais into ceils (8).
Ail the TNF ligand superfamily members, with the exception of LT-Œ and vascular
endothelial ceIl-growth inhibitor, are type II (intracellular N terminus and extraceliular
C terminus) transmembrane glycoproteins with limited homology (about 20% overali)
to TNF in their extracellular region (7, 9), cailed “TNF homology domain” (THD). The
THD folds into an antiparaliel fi-sandwich that assembles into trimers, and thus each
ligand has three receptor binding sites, forming a groove between adjacent subunits
(10). No significant homology exists in other regions of these molecules. Aithough most
ligands are synthesized as membrane-bound proteins, soluble forms can be generated by
limited proteolysis (11). The crystal structure of TNF and LT indicates that these
cytokines are biologically active as tnmers, and it is generally assumed that the other
TNF family members are also tnmeric (11, 12, 13, 14, 15, 16, 17).
The expression of aimost ail of the TNF family members is limited to ceils of the
immune system, including B celis, T ceils, NK ceils, monocytes and dendritic ceils, the
only exception is VEGI and TL1A, which are expressed mainly by endothelial cells (7,
18). The function of TNF famiiy members is as ligands triggering signais through their
receptors, meanwhiie some TNF members can also work as a receptor reversely trans
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Table 1. Members of the TNf Ligand Superfarnily
Approved Name Aliases ReferencesSymbol
TNFSf 1, TNfB,LTA lyphotoxin alpha (5, 19)LT
TNFSF2, TNFA,TNF tumour necrosis factor (6)DW
lyphotoxin beta (TNF superfamily,TNFSF3, TNFC,LTB (20)
member3) p33
tumour necrosi s factor superfamil y,
TNFSf4 member 4 (tax-transcriptionally activatedO4OL gp34, (21)TXGPYglycoprotein 1, 34kD)
CD4OLG, IMD3,
tumour necrosis factor superfamily,HIGM1, CD4OL,TNFSF5 (22, 23)
member 5 hCD4OL, TRAP,
CD 154, gp39
tumour necrosis factor superfamilyTNFSF6 ‘FasL, APT1LG1 (24, 25)
member 6
tumour necrosis factor superfamily, CD7O, CD27L,TNFSF7 (26)
member 7 CD27LG
tumour necrosis factor superfamily,TNFSF8 CD3OLG (27)
member 8
tumour necrosis factor (ligand)41 (26)TNFSF9
superfamily, member 9
tumour necrosis factor (ligand)TRAIL, Apo-2L,TNFSF1O (28)
superfamily, member 10 TL2
TRANCE,
umour necrosis factor
OPGL, (29)TNFSFÏ 1
superfamily, member 11
ODF
tumour necrosis factor (ligand) TWEAK,TNFSF12 (30,31)
superfamily, member 12 DR3LG, APO3L
tumour necrosis factor (lïgand) APRIL (32)TNFSF13
superfamily, member 13
tumour necrosis factor (ligand) LIGHT, LTg,TNFSF14 (33, 34)
superfamily, member 14 HVEM-L
tumour necrosis factor (ligand)1 VEGI (1$)TNFSF15
superfamiÏy, member 15
tumour necrosis factor (ligand) AITRL TL6TNFSF1$ (35)
supeffamily, member 18 hGITRL
EDY ED1 EDA,EDA1 (36)
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ducing signaling after binding with their receptors (detailed in section 1.1.3).
1.2. The TNF receptor superfamily
Currently, the TNF receptor superfamily contains 30 members, as summarized in table
2. The mammalian TNFR superfamily now includes: TNFR-I, TNFR-IT, LTI3R, Fas,
0X40, CD4O, CD27, CD3O, 4-ÏBB, DcRÏ, DcR2, DcR3/TR6, OPG, DR3, DR3L, DR4,
DR5, DR6, HVEM (TR2), RANK, TACT, BAFFR, EDAR, BCM, GITR, RELT, NGFR,
SOBa, Tnfrhl and TAJ (TROY) (7, 10, 19, 37, 38, 39, 40). The number of this family is
stili growing.
Most of the TNFR family members are characterized as type I transmembrane proteins
(extraceiluiar N-terminus and intracellular C-terminus). The B-cell maturation anti gen
(BCMA), transmembrane activator and cyclophilin ligand interactor (TACI), BAFf
receptor (BAFFR) and X-linked EDA receptor (XDAR) belong to type III
transmembrane protein group, because they lack a signal peptide sequence (7). Ail the
TNFR famiiy members contains one to six conserved motif, calied “cysteine-rich
repeats” or “cysteine-rich domain (CRD)”, in their extracellular portion (7, 10, 17, 23,
41, 42, 43). Unlike TNF ligand famiIy members, which are predominantly expressed by
ceiis of the immune system, the TNFR family members are expressed by a vanety of
celis (7).
According to the structura1 and biological features, TNFR family members can be
divided into three subgroups:
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Table 2. Members of TNf Receptor Superfarnily
Approved Name Aliases References.Symbol
p55-R, CD12Oa,
TNF-R-T p55,
tumour necrosis factor recepto TNF-R, TNFR1,TNFRSF1A (44)
superfamily, member lA TNFAR, TNF
R55, p55TNFR,
TNFR6O
CD12Ob, p75,
TNF-R, TNF-R-II,
tumour necrosis factor recepto; TNFR8O,TNFRSF1B (45,46)
superfamily, member lB TNFR2,TNF-R75,
TNFBR
p75TNFR
TNFRSF3,
TNFR2-RP,lymphotoxin beta receptor (TNFRCD1$ TNFR-RP, (39)LTBR
superfamily, member 3) TNFCR, TNF-R
III
tumour necrosis factor receptol 0X40, ACT35,TNFRSF4 (21)
superfamily, member 4 TXGP1L
tumour necrosis factor receptolTNFRSF5 p50, Bp50, CD4O (47)
superfamily, member 5
tumour necrosis factor recepto] FAS, CD95, APOTNFRSF6 (48)
superfamily, member 6 1, APT1
tumour necrosis factor recepto]
TNFRSF6B superfamily, member 6 b, decoyDcR3 (49, 50)
without transmembrane domain
tumour necrosis factor receptolTNFRSF7 Tp55, S 152, CD27 (51, 52)
superfamily, member 7
tumour necrosis factor receptoi Ki-1, D1S166E,TNFRSF8 (27, 43)
superfamily, member 8 CD3O
tumour necrosis factor receptor4-1BB, CD137,TNFRSF9 (26, 53)
superfamily, member 9 ILA
tumour necrosis factor receptorDR4, Apo2,TNFRSF1OA (54)
superfamily, member lOa TRAILR-1
DR5, KILLER,
tumour necrosis factor receptoi TRICK2A,TNFRSF1OB (55, 56)
superfamiÏy, member lOb TRAIL-R2,
TRICKB
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU Su 6
tumour necrosis factor receptol DcRI, TRAILR3,
TNFRSFIOC supeffamily, member lOc, decoy LIT, TRID (56)
without an intracetiular domain
tumour necrosis factor receptol DcR2, TRUNDD,
TNFRSFYOD superfamily, member bd, decoyTRAR4 (57)
with truncated death domaïn
tumour necrosis factor receptol
TNFRSF11A superfamily, member lla,RANK (58, 59)
activator of NFKB
tumour necrosis factor recepto
TNFRSF11B superfamily, member IÏbOPG, OCW, TRi (60)
(osteoprotegenn)
tumour necrosis factor recepto] DR3, TRAMP,
supeffamily, member 12WSL-1, LARD, (61)TNFRSF12 (transiocating chain-association WSL-LR, DDR3,
membrane protein) TR3, APO-3
tumour necrosis factor recepto.TNFRSF12L DR3L (62)
superfamily, member 12-like
tumour necrosis factor receptoTNFRSF13B TACT (63, 64)
superfamily, member 13B
tumour necrosis factor receptoTNFRSfI3C BAFFR (65)
superfamily, member 13C
tumour necrosis factor recepto HVEM, ATAR,
TNFRSFY4 superfamily, member 14 (herpes TR2, LTGHTR, (33, 66)
virus entry mediator) HVEA
NGFR nerve growth factor recepto; TNFRSF16 (43)(TNFR superfamily, member 16)
tumour necrosis factor recepto;TNFRSFÏ7 BCM, BCMA (67)
superfamily, member 17
tumour necrosis factor recepto;TNFRSF1$ AITR,GITR (68)
superfamily, member 18
tumour necrosis factor receptolTNFRSF19 TROY, TAJ (69)
superfamily, member 19
tumour necrosis factor receptolTNFRSF19L FLJ14993, RELT (70)
superfamily, member 19-like
tumour necrosis factor receptolTNFRSF21 DR6 (71)
superfamily, member 21
tumour necrosis factor receptol SOBa, Tnfrh2,TNFRSf22 (72)
superfamily, member 22 2810028K06Rik
tumour necrosis factor receptolTNFRSF23 mSOB, Tnfrhl (72, 73)
superfamily, member 23
EDAR EDAR -___________ (74)
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a. The TRAF (TNFR-associated subgroup). This group includes TNFR1, TNFR2,
CD4O, CD3O, CD27, LTf3R, 4-1BB, 0X40, NGFR, fN14, HVEM, GITR and
RANK. This subgroup of receptors bind to a family of adaptor proteins, TRAFs
(75, 76, 77, 78). There are six known TRAFs in mammalian ceils; only TRAF2,
TRAF5 and TRAF6 are shown to mediate the activation of NFKB and JNK.
TRAF2 can bind to TNFR1 through their TNFR-associated death domain
(TRADD) protein (7).
h. The death receptor subgroup. This subgroup of TNFRs contains CRDs in their
extracellular region and a “death domains” in their intracellular portion. They
function as a mediator of apoptotic celi death, and are therefore also called “death
receptors” (DRs). Celi killing from such receptors occurs because of recruitment
to the receptor of the adaptor protein FADD (Fas-associated protein with death
domain), which in turn recruits the pro form of caspase-8. Aggregation of pro
caspase-8 leads to its auto-activation and subsequent activation of effector
caspases such as caspase-3 (41, 79). The death receptor subgroup contains eight
members: TNFR1 (80, 81), Fas (81, 82), DR3 (61, 79), DR4 (54), DR5 (55), DR6
(71), EDAR (74) and NGfR (83).
c. The decoy receptor subgroup. This subgroup of receptors includes DcR1 (decoy
receptor 1, also known as TRifi or TRAIL-R3) (54, 56, 84, 85, 86), DcR2 (decoy
receptor 2, also known as TRUNDD or TRAIL-R4) (87, 88), DcR3 (TR6) (50)
and OPG (60, 87). DcR1 is a glycosy!phosphatidylinosito! (GPI)-Iinked protein
with out an intraceflular death domain whereas DcR2 is a transmembrane receptor
but with a partially deleted death domain. Both of DcR1 and DcR2 are incapable
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of transmitting apoptotic signaIs (40). The product of OPG is a secreted protein
that also binds to TRA1L but with much weaker affinity compared with other
receptors. DcR3 (TR6), as wiIl be descnbed in details below, is doser to OPG and
exists as a secreted protein. This group of receptors has been shown to interfare
signaling of other TNFR family members (7).
The interaction of TNF-TNFR family members play very important roles in immune
response, haematopoiesis and morphogenesis (7, 37, 89, 90, 91, 92).
1.3. The reverse signaling via TNF family members
The interactions between TNF and TNFR superfamily members are summanzed in
Fig. 1. The 19 members of TNF ligand family signal through 29 TNFR family members,
and play a very important role in regulating immune response, haematopoiesis and
morphogenesis (7). Studies in TNF and TNFR family members also find that some TNF
ligand members can function as a receptor reverseiy transducing signais into celis after
engaging with their receptors. This phenomenon is termed “reverse signaling”.
The TNF iigand family members capable of reverse signaling are FasL, CD4OL, CD3OL,
OX-40L, TRANCE, TRAIL, DR4 and LIGHT. Studies on FasL have found that Fas-Ig
on solid phase augments CD8 T-cell proliferation in the presence of suboptimal anti
CD3; FasL CD8 T ceil responded better to alloantigen in vitro than FasL CD8 T celis
(93, 94). Moreover naive CD4 T celis are responsive to FasL-mediated costimulation
on encountering with antigen, if Fas-mediated death is prevented (94). These data
indicate that FasL can reversely transduce signaIs into T celis
FACULTÉ DES ÉTuDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SHI 9
Fig. 1 The interaction between TNF-TNFR famïly members
(Adapted from Bodmer et al. Trends in Biochemical Sciences, 2002;27:19)
Fig. 1. Interactions between Iigands and receptors of the human tumour necrosis
factor (TNF) famlly: TNF ligands (top) and TNF receptors (bottom). The TNF
Iigands are represented as type II homo- or heterotrimeric transmembrane
proteins (with the exception of VEGI, which Iacks a predicted transmembrane
domain and is therefore drawn as a soluble ligand). TNF homology domains
(THD5) are shown as green boxes. Filled black arrowheads indicate processing
by furin family members, and open black arrowheads by other types of
proteases. The TNF receptors are typically type I or type III transmembrane
proteins, but also occur as glycolipid-anchored or soluble proteïns. Ni, Ai, A2,
Bi, B2, C2 and X2 modules are colour-coded as shown in the inset. The
positions of individual cysteines are indicated by horizontal bars, and stars show
modules whose cysteine pattern does not conform entirely to that of cannonical
A, B, C and N modules. The lengths of intracellular domains are indicated for
each ligand and each receptor and the intracellular homoIogy domains, known
as the ‘death domains’, are indicated as red boxes. Red arrows show
documented interactions.
86
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Cayabyab et al. found that CD40 murine transfectants substantially augment anti-CD3-
induced T celi proliferation and resuit in the generation of CTL. CD4 T ceils respond
better than CD8 ceils to CD4O costimulation (95). These resuits suggested that CD4OL
reversely transduces signais into T ceils. Van Essen et ai. using CD4O
knockout mice, found that CD4OL reverse signaling is responsible for germinal centre
formation (96). Brenner et ai. reported that activation of T-lymphocytes via
gp39/CD4OL induces strong activation of Jun-N-terminal kinase (JNK) and p38 MAPK,
and it also induces tyrosine phosphorylation of cellular proteins including PLC y (97,
98). Blair et al. found that CD4 T ceils costimulated with anti-CD3ICD4OL have
enhanced production of interieukin (JL)-10, interferon gamma, and tumour necrosis
factor alpha but flot IL-2 or IL-6. The anti-CD3/CD4OL-mediated activation of these
celis is foiiowed by apoptosis in a significant fraction of the celis (99). Wiley et al.
found that cross-iinking of CD3OL by a mAb or by CD3O-Fc fusion protein induces the
production of IL-8 by freshiy isoiated neutrophils (100). Another study proved that
CD3OL reverse signaling can inhibit 1g class switch and antibody production in human
IgD IgM B ceils (101). Chou et ai. reported that cross-linking TRAIt by a plate
bound rTRAIL receptor, i.e., death receptor 4-Fc fusion protein, dose dependently
enhances T-celi proliferation and ]FN-gamma production in conjunction with
immobiiized suboptimal anti-CD3 stimulation in mouse splenocytes (102). A subset of
B-celis proliferates vigorousiy in response to CD7O mAb but not to CD27 mAb. This
resuit proved that CD27L, which is CD7O, can transduce signais reverseiy into B ceils
(103). Further, the CD27L iigation-induced B-ceil response is synergisticaiiy enhanced
by iigation of CD4O, but inhibited by the presence of IL-4 (103). The cross-linking of
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OX4OL on CD4OL-stimulated B ceils, alpha IgD dextran-stimulated B ceils, or both,
resuits in a significantly enhanced proliferative response with no change in the ceil
survival rate. The 0X40 stimulation increases immunoglobulin heavy chain mRNA
levels and immunoglobulin secretion, and it also down-regulates the transcription factor,
B celi lineage-specific activator protein (BSAP) (104, 105). Chen reported that cross
linking TRANCE by its receptor augments IFN-gamma secretion by Thi celis, and the
enhanced secretion of WN-gamma mediated by TRANCE correlates with the activation
of p38 mitogen-activated protein kinase (106). Our group studied another TNF family
member, LIGHT. We found that cross-linldng of LIGHT with anti-LIGHT mAb or its
receptor TR6/DcR3 can dose dependently enhance both proliferation and cytoldne
production of anti-CD3-stimulated CD4 and CD8 T ceils. The cross-Ïinking of LIGHT
also enhances mouse spleen CTL activity (8, 107). In general, unlike costimulatory
members of the TNFR family, the costimulation through reverse signaling of the TNF
ligand famîly members in vanous animal disease models is flot well investigated.
1.4. TR6JDcR3 and its lïgands
TR6, a member of TNFR superfamily, belongs to the decoy receptor subgroup. It lias 3
ligands, FasL, LIGHT and TL1A. FasL and LIGHT are expressed on T cells.
1.4.1. TR6
TR6 (TNFRSF6B, tumour necrosis factor receptor superfamily member 6 b), a secreted
protein, due to lack of the transmembrane domain in its coding sequence, belongs to the
decoy receptor subgroup. The mature form TR6 lias 271 amino acid residues. It contains
two incomplete cysteine-rich domains (49, 50, 108). TR6 is expressed by many types of
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cancers (49, 50, 109, 110, 111, 112, 113). The DcR3 gene is significantÏy over
expressed in peripheral blood mononuclear ceils of silicosis and SLE patients (114). A
recent study showed that TR6 protein is overexpressed in monocytes and myeloid
denved dendntic ceils (MDC), after stimulation of Toli-like receptor 2 (TLR2) and
TLR4 by gram-positive and gram-negative bacterial antigens. It is expressed in
plasmacytoid dendritic celis, activated by bacterial antigens via TLR9 or by viral
infection (115). In the normal lymphoid organs, TR6 is highly expressed in both lymph
nodes and spleen, but its expression in thymus is weak (49, 50).
TR6, as a decoy receptor, can neutralize the biological function of FasL by interfering
with the Fas and FasL interaction. As a consequence, it can block FasL-ïnduced
apoptosis and FasL dependent CTL killing (50, 116). TR6 can interfere with the
interaction between LIGHT and TR2, and between LIGHT and LTj3R, and inhibit
LIGHT-induced cytotoxicity in HT29 cells (108). TR6 can modulate dendntic celis
differentiation and maturation, and such modulation leads to enhanced human T-ceIl IL-
4 production (117). Studies also showed that TR6 modulates monocyte and macrophage
differentiation and activation (117, 118, 119). TR6 can block the interaction between
DR3 and TLA1; as a resuit, TR6 inhibits TL1A-costimulated T-cell proliferation and
cytokine production, inhibits TLÏA-induced apoptosis of DR3-expressing cells (117,
120), and induces angiogenesis by neutralization of TL1A- induced angiostatic action
through its receptor DR3 (121). A recent study using transgenically expressed TR6 on
mouse islets further proved the function of TR6 in downregulating immune response.
The transgenically expressed TR6 protects islets from spontaneous and chemical
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU 13
induced diabetes; the transgenic islets have a higher transplantation success rate, and
survive longer than wild-type islets (122). Data from our group indicate that TR6
inhibits the anti-alloantigen immune response and prolongs the survival of transplanted
heart graft in a mouse mode!. We have also shown that TR6 prevents islet pnmary
nonfunction after transplantation (123, 124), We have proven that TR6, when placed on
solid phase, can costimulate T celi response; TR6 also modulates T-cell migration in
vitro and in vivo (8, 107, 125). These findings will be detailed in Chapter 2 and 3. The
signaling pathways, which TR6 interfers with, are summanzed in Fig. 2
Figure 2: TR6 interferes with multiple ligand-receptor interactions (adapted from
Xiaochun Wan)
TR6
Fas FasL
J
C
112
—I
Stroiiial Celis
The naines and major expressing ceÏt types of TR6 ligands and their receptors are
indicated. Arrows indicate direction(s) of signalling transduction.
T ceils
ells, Dendrific Cefis
TL1A
Endothelial Ceils
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1.4.2. LIGHT
LIGHT is a member of the TNf ligand superfamily, with TNFSF14 as its officiai
symbol. It is also called LTy or HVEM-L. The term “LIGHT” stands for “homologous
to iymphotoxins, showing inducible expression, and competing with HSV glycoprotein
D for herpes virus entry mediator, a receptor expressed by T lymphocytes” (33, 126).
LIGHT binds three distinct members of the TNF receptor famiiy, i.e., the herpes virus
entry mediator (HVEM) (33, 127), the lymphotoxin receptor (LTf3R) (34, 128), and the
soluble decoy receptor 3 (DcR3) (108). Among these receptors, TR2[HVEM is
consistentiy expressed on T celis, and the LTf3R on stromal celI (33). Northem blot
analysis bas shown that LIGHT is expressed predominantly in the spleen; it has weak
expression in the heart, placenta, liver, lung, appendix, and kidney (33). Cells that
express LIGHT include activated lymphocytes, natural ldller (NK) ceils and immature
dendntic cells (33, 34, 129). In T cells, ceil surface levels of LIGHT are detectable by
4 h following T cell activation, peak at 24—4$ h and gradually decline by day 5 (130,
131). Our group, using fluorescence and confocal microscopy, bas studied LIGHT
expression on T ceils and found that LIGHT was also detectable in resting T cells (8),
probably due to higher sensitivity of our methods.
The functions of LIGHT have been intensively studied in recent years. It bas been
proved that LIGHT plays a very important role in regulating immune responses by
interacting with its receptors.
LIGHT is able to trigger apoptosis. Zhai et al. reported LIGHT protein triggers apoptosis
of various tumour celis expressing both lymphotoxin P receptor (LTPR) and TR2[HVEM
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receptors, and its cytotoxicity can be blocked specificaliy by addition of a LTPR-Fc or a
TR2/HVEMFc fusion protein. They also found that LIGHT was flot cytolytic to the
tumour celis that express oniy the LTf3R or the TR2/HVEM (34). Meanwhile, Rooney et
ai. reported that LTPR is sufficient for LIGHT-mediated apoptosis of tumour celis
through both caspase-dependent and caspase-independent pathways (132).
LIGHT was first proven as a costimulation molecule in T-cell response; it can transduce
costimuiatory signais into T ceils through its receptor HVEM. In mixed lymphocyte
reactions (MiRs), the introduction of soluble LIGHT enhances T-celI proliferation
(126) . Another group observed the same effect which is reduced by the introduction of
soluble HVEM—Fc decoy receptor (66). When recombinant human LIGHT is added to T
celis in the presence of sub-optimai levels of agonistic anti-CD3 monoclonal antibodies,
enhanced proliferation occurs in vitro, while the soluble LTf3R —Fc biocks this effect
(133). Other studies further confirmed that LIGHTand HVEM co-stimulates TCR
mediated T-cell proliferation (133, 134, 135). LIGHT co-stimulation enhances IFN-7
and GM-CSF production; the IL-4 production is slightly increased, and IL-10
expression is flot affected (129, 133). Moreover, the LIGHT triggered T celi activation
is independent of the B7/CD28 pathway (129, 133).
Our group proved that LIGHT can function as a receptor that reverseÏy transduces
costimulatory signais into T celis, it can costimulate TCR stimulated T celÏ response in
terms of proliferation, cytokine production, and CTL activity (8, 107). Further we found
that LIGHT reverse signaling can be used in tumour therapeutic vaccine design. The
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LIGHT reverse signaling also modulates T ceil migration and T ceil aggregation (125,
136). These findings will be detailed in Chapter 2 and 3.
Constitutive expression of human or munne LIGHT in transgenic mice resuits in
profound inflammatory phenotypes and enhanced Thi cytokine activity in mucosal T
cells (137, 138). Transgenic expression of LIGHT in T celis leads to abnormalities in
both lymphoid tissue architecture and the distribution of lymphocyte subsets. The
transgenic mice developed severe autoimmune disease featured by lymphadenopathy,
glomerulonephritis, splenomegaÏy, enhanced levels of autoantibodies and severe
lymphocyte infiltration of different tissues (138). These resuits further prove the two
way costimulatory function of LIGHT and HVEM in T-cell activation and immune
response.
In the LIGHT knockout or deficient animal models, one study from LIGHT deficient
(LIGHY’) mice showed that lymphoid organs are intact, and T cells and APCs function
normally. But induction of cytokines from CTL (CD8+) were reduced from LIGHT’
mice (139). Scheu et aï., found that LIGHT-deficient T ceils displayed reduced
proliferation following TCR stimulation with anti-CD3 mAb in vitro, and LIGHT’
mice were deficient in the activation of CD8 T celis in vivo. They also also found that
LIGHT spienocytes are impaired in their abilïty to lyse allogeneic target celis in vitro
(134). Together, these studies support the importance of LIGHT in the generation and
maintenance of CD8 T ceil responses in vivo.
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SHI 17
In allograft rejection studies, it was found that the mean allograft survival time of
LIGHT’ mice is only slightly prolonged, while in combined with CsA, the survival
time is significantly enhanced compared with normal LIGHT mice (140). Scheu et al.,
found that LIGHTCD28’ showed prolonged skin graft survival than single deficient
or WT mice (141). These resuits suggest that LIGHT plays important role in allo-graft
rejection. The reason could be the impired function of cytotoxic T lymphocytes in
LIGHT’ mice (134). It also suggested that LIGHT is necessary for development and
activation of CD8 but flot CD4 T lymphocytes (139, 142). Together, these resuits
suggest that the two-way signaling between LIGHT and HVEMITR2 contributes to the
organogenesis of secondary lymphoid tissues and the costimulation in T celi mediated
immune responses.
1.4.3. Fas lîgand
Fas Iïgand (FasL, CD95L, Apo-1L, CD 178, TNFSF6, APTÏLG1) is the ligand of Fas, a
TNF receptor family member (25). FasL is well conserved at the amino acid level
among different species (11). It is expressed on activated T ceils (25), NK ceils (143),
and tumour cells (144, 145, 146, 147, 148). It is also expressed in lung (149),
thymocytes (150), CD68thistiocytes in the dermis (151) intervertebral discs (152), and
in immune privileged sites such as the eye (145, 148), testis (153), uterus and placenta
(154). FasL expression can be induced on a host of tissues throughout the body (155).
FasL induces apoptotic celi death in ceils expressing its receptor, Fas (25). fas is widely
expressed in tissues such as the heart, liver, spleen, and thymus (156). The death
inducing function of Fas is best documented in the context of AICD (activation induced
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SHI 18
ccli death) in T cells (157). fas expression has been associated with the establishment of
immune priviiege and tumour survival (14$). FasL also binds to TR6IDcR3, a decoy
receptor of TNf receptor family. DcR3 competitively binds to FasL, and therefore
biocks the Fas/FasL engagement; the biockage of this interaction resuits in the inhibition
of apoptosis (50). Under physiological conditions, FasL is implicated in the control of
immune responses (157, 158, 159), erythroid differentiation (160), angiogenesis in the
eye (161), skin homeostasis (162) and CTL-mediated killing of virally infected or
transformed ceils (163). If flot controiied properiy, this function can cause autoimmune
diseases (164).
FasL can also transduce non-apoptotic signaling, such as ccii proliferation or NFRB
activation through its receptor Fas (165). As mentioned in section 1.1.3, fasL also bas
costimulation function by reversely transducing signais into both CD4 and CD8 T celis
(93, 94, 166, 166, 167).
2. T-cell costimulation
The two-signals or costimulation model of T ccli activation was first proposed by
Lafferty and coileagues (168, 169), before the T ccli antigen receptor (TCR) and
costimulatory moiecules were identified (170). They postulatcd that full activation of
naïve T celis requires engagement of an antigen receptor by foreign antigen (signal one)
as well as engagement of a “costimuiatory” receptor by a soluble or ccli surface ligand
provided by the antigen-presenting ccli (signal two). This two-signals model is
consistent with a considerable body of experimental data and is now widely accepted.
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SF11 19
Evidence also showed that delivery of signal one alone inactivates T celis by killing
them (171) or rendering them unresponsive (anergic) (172).
There is no general agreement on exactly how the term “costimulation” is defined. In
some cases it is used broadly to mean nearly any interaction that enhances antigen
receptor signaling, while in other cases it is more narrowiy construed, meaning only
signais that have no stimulatory capacity on their own, but whose synergism with the
antigen receptor is required to allow fuii activation of a naive lymphocyte (173).
Because some cytokines, such as IL-1, IL-2, and IL-4, have been found to enhance the
activation of B and T ceils, it had been considered as costimuiation. However, it has
become ciear that interactions between receptor/ligand pairs of cefl surface molecules on
the responder lymphocyte and an “accessory” ceil represent cntical events in the
activation process, and it is those events that are generaily referred to as costimuiation
(173). There are two kinds of costimulatory signais, “positive” and “negative” signais.
The “positive” signai enhances immune response and the “negative” signal resuits in
physioiogic termination of immune responses (174).
2.1. Candidate costimulatory molecules
CD28 is the prototypic T-ceii co-stimuiatory moiecuie (170, 175). Since the
identification of CD28, the number of proposed costimuiatory molecules has grown
significantiy (173, 176, 177, 178, 179). Based on their sequence homoiogies, most of
costimulatory molecuies can be divided into two classes.
The first class is the costimulatory members of the 1g superfamiiy; thïs includes CD28
family members and their ligands, which are members of 37 family (180). The CD28
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family consists of CD28, CTLA4 (181), ICOS (H4, AILIM) and PD-l. The 37 family
consists of B7-1 (CD8O), 37-2 (CD86), ICOSL (B7h, B7-H2, GL5O, B7RP-1, LICOS,
K1AA0653), PD-L1 (B7-H1) and PDL-2 (182) (183).
The second class of costimulatory molecules is some members of the TNF receptor
(TNFR) and TNF famiÏy. Members of TNFR family belong to this class include 0X40,
4-1BB, CD27, CD3O, HVEM and BAFFR (183). Members ofTNF family belong to this
c!ass are the Iigands of the above TNF receptors (8, 176, 184, 185).
Beside the above two classes of costimulatory molecules, some other molecules can also
costimulate T ceils. For example, Yu et al. proved that mouse Ephnn 32 and Ephnn B3
can costimulate T celi proliferation and cytoldne production, and costimulation
enhances mouse CTL activity (186, 187). Leta et al. found that CD7 has T-cell
costimulatory function (188).
2.2. Costimulatory molecules of the 1g superfamily.
Members of the CD28 family and their ligands are depicted in Figure 3.
2.2.1. The B7/CD28/CTLA-4 pathway
The CD2$/CTLA-4/B7-1/B7-2 family provides a paradigm of T ce!! costimulation. The
multiple B7 ligands bind to both activating (CD28) and inhibitory (CTLA-4) receptor
(181, 189, 190, 191, 192, 193). These receptors do not stimulate T ceil activation
independently, but they modify responses delivered by engagement of the antigen
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specific TCR on T ceils. The expression of both receptors and ligands is tightly
regulated, aliowing discrimination between signais that resuit in activation or inhibition
figure 3. Summary of CD28 family and their Iigands (Adapted from Carreno, B.M et
ai. Ann Rev Immunol, 2002).
these iigands are also expresseU on non-Iymphoid tissues,
The ;iarnes of receptors and ligands are indicated, as wetÏ as a brief suminaiy of
predorninant expression patterns for ecch. The conserved structure of a single IgV
extracellutar domain for receptors and IgV and IgC extracettular dornains for ligands is
depicted at the top. Function arrows summarize whether the pathway is thought
predominantty to costirnulate or inhibit the response of the receptor-bearing ceil.
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of an immune response. CD28 is constitutively expressed on T ceils. Ligation of CD2$
on naive T celis by either 37-1 or B7-2 ligand on antigen-presenting celis provides a
potent costimulatory signal to T celis activated through their T ccli receptor (181,
189,190, 191, 192, 193, 194). This leads to IL-2 production, CD25 expression, and
entry into the cdl cycle. CD28 costimulation is necessary for the initiation of most T
ceil responses, and biockade of CD28 signaling results in ineffective T celi activation
(190, 192). CTLA-4 expression is flot detected on naïve T celis, but its expression is
transcnptionally induced after T ceil activation (191). CTLA-4 plays a critical role in
regulating T-cell activation. Its function as an inhibitory receptor of T-cell activation is
proven in CTLA-4 knockout mice, which die within 3 to 4 weeks of birth from massive
lymphocytic infiltration and tissue destruction in critical organs (194, 195, 196, 197).
Both CD28 and CTLA-4 bind to 37-1 (CD8O) and 37-2 (CD86) Iigands. The
interaction between B7 and CD2$ is weaker than the interaction between B7 and
CTLA-4. Human B7-1 binds to human CTLA-4 and CD28 with Kd values of 0.42 and 4
jiM, respectively (198). The affinity of B7-2:CTLA-4 interaction is similar to that of
B7-1:CD28, and the affinity of B7-2:CD28 interaction is the lowest (199). Mice
deficient in B7-1 or B7-2 have significant abnormalities in both humoral and celiular
immune responses, again illustrating the pivotai role of the CD28 and CTLA-4
pathways (200). Based on the differences of the interaction affinity between CD28 and
CTLA-4 with B7, undesired immune responses can be biocked with soluble CTLA-4 1g
(201, 202, 203, 204, 205, 206).
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2.2.2. The ICOS/ICOSL pathway
ICOS (AILIM) is an inducible costimuiatory receptor homologous to CD28 and CTLA
4 (207, 208). It is expressed on activated, but flot resting, T celis (207); it is identical to
the H4 T-celi activation antigen (209). ICOS expression is stimuiated by both TCR and
CD28 signais (183). However, ICOS expression is not absoiuteiy dependent upon CD28
signais, because some T-ce!! responses in CD28-deficient mice can be moduiated with
ICOS-Fc (210). The iigand for ICOS (ICOSL), a B7-iike moiecuie, is capable of
binding to ICOS and de!ivenng a costimulatory signal to T ceils (210, 211, 212, 213,
214).
ICOSL is expressed at iow leveis on resting B cei!s, some macrophages and dendritic
celis, and can be induced by WN-y and TNFa (180, 215). ICOSL is aiso expressed on
other ceii types, inciuding fibroblasts (183). A study showed that ICOSL is
constitutiveiy expressed on endotheiiai ceiis (216). Uniike CD28 signais, which are
crucial for the initiai co-stimulation of interieukin 2 (IL-2) production, ICOS signais
oniy modestly influence T-celi proliferation and IL-2 production (183, 207, 210, 214,
217). ICOS signais are most important for regulating cytokine production by activated
and effector T ceils: ICOS can regulate both TH1 and TH2 effector cytokine production
(180, 218), and it is particuiariy important in regulating IL-10 production (207, 219).
ICOS has a cruciai foie in T-ceii—B-ceil coilaboration and IgGi affinity maturation
(220).
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2.2.3. The PD-1/PD-L pathway
PD-1 (program death-1) is a type I transmembrane receptor that was identified in a T
ceil une undergoing activation-induced ceil death (221). In normal murine tissue, PD-1
mRNA expression is confined to the thymus (221). Under resting conditions, neither T
nor B ceils express PD-1. However, activation of T or B ceils through the antigen
receptor or with PMA and ionomycin resuits in ceil surface expression of the PD-1
receptor (222). PD-l is also expressed in activated macrophages (223). PD-l has two
Iigands: PD-L1 and PD-L2 (224). PD-L1, also termed B7-H1 in humans (225), is
expressed in a variety of lymphohematopoietic ceil types, including a minor proportion
of T and B celis in the spleen, a majonty of pre-B celis, and myeloid cells in bone
marrow and subsets of thymocytes (226). Peripheral tissues such as the heart and lung
also express PD-L1. PD-L1 expression is induced by WN7 on monocytes, dendntic
cells (DCs) (227), and human keratinocytes (180). Using PD-L1—Ig fusion proteins,
Freeman demonstrated that engagement by PD-L1 inhibits T-cell responses (228). The
PD-1 knockout mice have a enhanced immune response to alloantigen (229) and suffer
from autoimmune disorders (229). A recent study a!so showed that endothelial ceils
expression of PD-L1 and PD-L2 down-regulates CD8+ T-cell activation and cytolysis
(230). The second ligand for PD-1, PD-L2 (231) is also termed B7-DC (182); it is
predominantly expressed on DCs (227). Although most of the studies showed PD-L1
and PD-L2 as negative regulators (180, 183), there are some report suggesting that PD
Li and PD-L2 positively stimulate T ce!! response (182, 232).
2.2.4. B7-H3: A new B7-like ligand
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Human 37-H3 was recently identified as a new costimulatory ligand belonging to the
B7 family (233). B7-H3 protein is expressed on GM-CSf-stimulated monocytes and
LFN-Y activated dendritic celis, as well as on CD3 T celis activated with PMA and
ionomycin (233). The receptor of B7-H3 is currently unknown. B7-H3—Ig fusion
protein can costimulate proliferation of CD4 and CD8 T celis through a receptor other
than CTLA-4, CD28 or ICOS.
2.3. Costimulatory molecules of the TNF/TNFR famity
2.3.1 Costimulation via TNfR family members
Evidence showed that several members of the tumour—necrosis factor receptor
superfamily deliver positive costimulatory signais both in early and late stage after T
celi encountering with antigen. Six interactions between the TNFR-TNF family
members have emerged as positive regulators of the T-cell response. They are: 0X40-
0X40L, 4-1BB-4-1BBL, CD30-CD30L, CD27-CD70, HVEM-LIGWf (185) and TACI
BAFF (184, 234).
a. The 0X40 (CD134) and 0X40-ligand pathway
0X40 was originally identified as a ceil surface antigen on activated rat CD4 T
celis (176, 235, 236). Expression of 0X40 is restricted to activated T celis in
humans and rodents (237, 238). Expression of OX4OL has been documented on
activated murine B ceils (104, 237), human dendritic cells (239), human vascular
endothelial celis (240), and HTLV-1-transformed T celis (241). Studies of
0X40- and OX4OL-deficient mice showed that CD4 responses to various
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antigens are markedly reduced in vivo, and in vitro (242, 243, 244, 245). These
mice have deficiency in numbers of antigen-specific CD4 T celis generated late
in the primary response, and additionally after 5 weeks when the T ceil memory
population is formed (246). Overexpression of OX4OL on dendritic ceils ieads to
greater numbers of pnmed CD4 cells (247). It was proposed that 0X40 signals
act in a temporal manner after CD28 signais, and aiiow effector T ceils to
survive and continue proliferation late in response (176, 185),
b. The CD3O-CD3OL Pathway
CD3O was onginally descnbed as a marker of Reed-Stemberg celis in Hodgkin
lymphoma (248). CD3O is expressed on activated but flot resting B or T celis
(249, 250, 251, 252). T ceil expression of CD3O is dependent on the presence of
CD28 costimulatory signais or exogenous IL-4 during primary T-cell activation
(250). CD3OL is a transmembrane protein, expressed on T and B lymphocytes,
macrophages, and a variety of hematopoietic celis and tumours (27, 253). On T
cells, CD3O is expressed primarily on activated CD8 T celis and CD3OL is
expressed primariiy on activated CD4 T cells (249). Although the function of
CD3O-CD3OL interaction is largeiy unknown, studies have shown that it has
effects on both ceil activation and ceii death (249, 250, 253, 254, 255, 256). Mice
deficient in CD3O show a mild impairment in thymie negative selection, and
activation-induced death of thymocytes after CD3 crosslinking is impaired both
in vivo and in vitro (257). Costimulation of human peripheral blood T ceils with
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anti-CD3O antibody resuits in preferential development of antigen-specific T ceil
unes and clones with a Th2-like profile of cytokine secretion (258).
C. The CD27 and CD27-ligand (CD7O) Pathway
CD27, another TNf-R superfamily member, has been implicated in T ceil
activation, T celi development, and T ceil—dependent antibody production by B
cells (259, 260). CD27 is consistently expressed on T ceils and its expression on
T celis is strongly upregulated by reagents that cross-link TCR or CD3 (261,
262). CD27 is ineversibly lost on a subset of long-term repeatedly stimulated T
ceils, and this is consistant with CD2T phenotype of small numbers of memory
phenotype cells (261). The expression of CD27L is found on medullary thymie
epithelium and is rapidly induced on both T and B celis after activation. The
activated B celis synthesized much higher levels of CD27L mRNA than
activated T celis. CD27L expression on B ceils is enhanced by CD4O signaling
and is downregulated by IL-4 (263, 264). The specific interaction of CD27 with
its ligand CD27L has been shown to support clonai expansion of both antigen
stimulated CD4 and CD8 T lymphocyte populations and to enhance the
generation of cytolytic T cells (265). Resuits from CD27 knockout mice indicate
that CD27 supports antïgen-specific expansion (but flot effector ceil maturation)
of naïve T ceils, and this function is independent of the ceil cycle-promoting
activities of CD28 and IL-2. Effects of CD27-deficiency are most profound on
T-cell memory, particularly in of CD8 T ceils (266). Stimulation with
immobilized anti-CD27 mAb or CD27L induces proliferation and WN- )
FACULTÉ DES ÉTUDES suPÉRIEuRES UNIVERSITÉ DE MONTRÉAL GUIXIU SHI 28
production of freshly isoiated NK cefls and enhances the proliferation and WN-’Y
production of anti-NKI.1-sitimulated NK ceils, but the NK cytotoxic activity is
flot enhanced. The enhanced cytotoxic activity of anti-CD27 prestimulated NK
celis is WN4-dependent (259).
U. The 4-1BB-4-1BBL Pathway
4-1BB (CD 137, ILA), exists as both a 30-kD monomer and a 55-kD homodimers
(267). 11 is primariiy expressed on activatedCD4 and CD8 T ceils (267, 268)
as well as on activated NK cells (269), B ceils, macrophages, dendritic ceils and
eosinophiis (53, 269, 270, 271). 4—1BBL is expressed on mature DC and on
activated B celis and macrophages, and its expression can be regulated by LPS,
1g or CD40 signais (26, 53, 272, 273). Stimulation of 4—1BB induces higher
leveis of CD8 than CD4 T-cefl proilferation (268, 274) and appears to be
criticai for CD8 T celi survival (275, 276). In 4-ÏBBL-deficient mice, 2—10-fold
fewer antigen-reactive CD8 ceiis are generated in the pnmary responses to
LCMV and influenza viruses, and fewer memory T ceils are deveioped weeks
after the priming (277, 278, 279). As compared to wild type mice, anti-4-1BB
antibodies or tumour celis transfected with 4-1BBL greatly increase the antigen
specific CD8 T ceil and CTL response (276, 280, 281, 282). Recent reports
showed that anti-4-1BB antibody blocking can reverse autoimmune diseases
(283, 284).
e. The HVEM-LIGHT Pathway
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As mentioned above, LIGHT, a member of the TNF ligand family, is expressed
on T ceils and DCs. Its expression is inducible by T-ce!! activation, and is
constitutive on “immature’ denditic ce!ls. It binds three distinct members of the
TNF receptor fami!y, i.e. HVEM; LTPR and DcR3. LIGHT exhibits inducible
expression on lymphocytes and can block HSV from entering cells via HVEM, a
receptor prominently displayed on T ce!!s. Effects of LIGHT—HVEM signaling
define LIGHT as a co-stimulatory molecule for T celi activation (129, 135, 285),
and a modulator of T-cell responses. T-cells activated by LIGHT—HVEM co
stimulation produce cytokines, such as WN-7 and GM-CSf, centra! for T-helper
celi type 1 (Thi) immune responses. On the other hand the IL-4 and IL-10
production are only slightly or flot increased, respectively (129, 133, 286).
LIGHT-deficient mice display defects in T cel! activation and effector functions.
In vitro assays showed that LIGHT-deficient T celis have reduced proliferation
following TCR stimulation with anti-CD3 mAb (141, 286). LIGHT-transfected
tumour ceils evoke antitumour immunity. The b!ockage of LIGHT prolongs the
allograft survival (133, 141). The costimulation between LIGHT and HVEM ïs
in both forward and reverse directions, as described in the section of 1.4.2.
f. The BAFF-TACI Pathway
The B celi-activating factor (BAFF; Blys, TALL-1, zTNF-4, THANK) is a
recently identified member of the TNF ligand fami!y (184, 287), and is
expressed on monocytes/dendritic celis and T ceils. It can bind to three receptors,
BCMA, TACI and BAfF-R, which are ah TNF receptor famihy members (65,
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184). Among the three receptors, TACI is expressed on activated T cells (234,
288). BAFf has been desciibed as a potent survival factor for B cells (289).
Huard and colleagues found that recombinant BAFF protein costimulates T celi
proliferation and cytokine production. The costimulation function is obvious on
naive, as well as on effcctor/memory T celis (both CD4 and CD8 subsets)
(184). Wang (234) reported that TACI-Fc blocks the activation of T celis in vitro
and inhibits antigen-specific T celi activation and pnming in vivo. TACI-Fc
treatment substantialiy inhibits inflammation, bone and cartilage destruction and
disease development of rheumatoid arthntis in a mouse model (234).
2.3.2. Costimulatory reverse signaling through members of the TNF family
Some TNF family members can transduce signais into celis, and such signais can
function as costimulatory signais. This is detailed in section 1.1.3.
3. Cancer vaccines
Using vaccination to treat cancer is not a novei concept and can be traced back to the
1890s when a New York surgeon Wiliiam B Coiey successfully treated some patients
with sarcoma using bacterial toxins (290). In 1909, Paul Ehnlich successfully camed
out immunization in animals with tumour ceils, and suggested that tumours occur at a
high frequency in humans but are kept under controi by the immune system (291).
Although the early attempts in cancer vaccination had some beneficiai resuits, the effect
was not significant. Most importantly, at that time, there was no evidence showing that
cancers have specific antigens, which can be recognized by the immune system. In
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1929, based on the available information concerning cancer immunotherapy, W. H.
Woglom wrote, “It would be as difficult to reject the right ear and leave the left ear
intact as it is to immunize against cancer” (292). A widely quoted article published in
1976 in the British Journal of Cancer reported no evidence of immune response to 27
different spontaneous tumours in mice and concluded that: “transplanted tumour
systems entail artifactual immunity associated with viral or chemical induction” (293).
In the past 20 years, the field of cancer immunotherapy has changed. Advances in the
molecular characterization of human tumours and a better understanding of tumour
immunology has lcd to the identification of tumour-associated antigens (TAAs) (294,
295, 296, 297). More importantly, it was shown that administration of IL-2 to humans
with metastatic kidney cancer or melanoma could cause the regression of established
cancers (298). Also, a number of therapeutic cancer vaccines have already been tested in
animals and subsequently humans, yielding prelimïnary encouraging resuits (292, 295,
297, 299). These results have supported the idea that therapeutic vaccines should be
useful in restonng immune defenses against cancer.
3.1. Tumour Antigens
The number of tumour antigens has increased rapidly in recent years. They can be
categorized in the following groups (292, 300): 1. Cancer testis antigens. This group
includes MAGE, BAGE, RAGE, and NY-ESO. These antigens are expressed in
melanomas and several other tumours, but flot in normal tissues except testis; 2.
Differentiation antigens, such as MART-1/Melan-A (MART-1), gplOO, gp75, mda-7,
tyrosinase and tyrosinase-related protein, the prostate specific membrane antigen, and
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prostate-specific antigen. They are expressed in normal and neoplastic celis derived
from the same tissue, but in normal tissues they are expressed at relatively low
concentration or on a small subset of cells; 3. Tumour-specific antigens, such as
immunoglobulin in B-cell NI-IL (non Hodgkin Iymphoma) and myeloma, ACDK4 in
melanoma, mutated p2 liras and p53. These are unique antigens specific for each
individual tumour. They represent normal proteins that contain mutations or gene
fusions that resuit in the generation of unique proteins. 4. Over-expressed “self’
antigens. These are normal “self’ proteins that are expressed constitutively in tumour
cells such as carcinoembryonic antigen and alpha-fetoprotein, normal p53. 5. Viral
antigens. This group of antigens are expressed on the virous-associated tumours, such as
HPV E6/E7 in cervical and penile cancer, EBV LMP2a in EBV + Hodgkin’s disease,
HCV or I-lEV in liver cancer and HHV-8 in Kaposi sarcoma.
3.2. Mechanisms of tumour’s escape from immune attack
Two different models for the immune response to tumours have been proposed: the
immunosurveillance model and the danger model. According to the immunosurveillance
model, tumour antigens expressed by tumours are regarded as “nonself” by the immune
system, and a major function of the immune system is to survey the body for the
development of malignancy and to eliminate tumour celis as they arise (301). In the
“danger” model, the immune system uses professional antigen-presenting cells (APC) as
sentinels of tissue damage—the “danger” signal. In the presence of danger signals, APC,
such as dendritic celis, activated macrophages, and B cells, stimulate the T ceil
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responses. The danger moUd proposes that cancer celis do flot appear dangerous to the
immune system, so that T celi responses to tumours is not initiated (171, 302, 303).
It had long been suspected that tumours have evolved multiple mechanisms to overcome
the immune system (144, 304). This includes the production of soluble
immunosuppressive factors, such as TGFI3, IL-10 and prostaglandins. In recent years,
the molecular basis for the escape mechanisms, which might impact the efficacy of
cancer immunotherapeutics, has been better understood (305).
3.2.1. FasL and tumour escape
Since the finding of FasL overexpression on some tumour cells (146, 306, 307), it was
proposed that the FasL on cancer ceils plays a role in tumour celi escape from immune
attacks (144, 146, 304), because, FasL is physiologically expressed in sites that are
“immunoprivileged”, such as the eye or the testis. Engagement of Fas by FasL leads to
apoptosis of Fas cells (146). The Fas protein is expressed on activated T cells. As a
consequence, certain FasL tumours could induce apoptosis of activated T celis, which
are tumour antigen-specific and migrate to tumour site to ldll the tumour ceils. This
clearly represents a possible mechanism through which tumours evade the immune
system, but the situation quickly becomes more complex. It was recognized in murine
models that a polymorphism in FasL could dramatically affect its ability to induce
apoptosis in target ceils (308). Vanous studies have shown that the overexpression of
FasL in murine tumour ceils resistant to Fas-mediated apoptosis does flot affect tumour
ceil growth in vitro, but causes tumour rejection by neutrophils in vivo (309, 310, 311).
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This suggests that the killing of T ceils by fasL expressing tumour ceils might be
involved in some, but flot necessarily most turnour evasion mechanisrns. On the other
hand, tumours might indecd manipulate the Fas-FasL interation to gain survival
advantage. Soluble Fas is expressed in vanous malignancies, and elevated levels can be
found in the sera of cancer patients (312, 313, 314, 315). High soluble Fas (sFas) serum
levels were associated with poor prognosis in melanoma patients. It is conceivable that
sfas blocks the death stimuli coming from FasL on CTL andlor NK cells, and thus
protects tumour cells from apoptosis. Similarly, DcR3 is secreted by many human
cancers, and such secretion may also interfere with tumour cell apoptosis mediated by
Fas (49, 50, 109, 110, 111, 112, 113).
3.2.2. MHC Class I molecules and tumour escape
Loss of MHC Class I molecules by a variety of solid tumours may serve as another
mechanism for tumours to evade the immune surveillance. Approximately 40-90% of
human tumours derived from various MHC class 1+ tissues were reported to be MHC
class I deficient. It was reported that decreased or absent MHC class I expression is
frequently associated with the invasive and metastatic tumour phenotype (316). In a
number of cases, this is associated by a down regulation of components of the antigen
processing and presentation machinery (316, 317, 318). It is hypothesized to be a
mechanism that leads to a deficit of tumour recognition by cytotoxic T celis.
Interestingly, this deficit can be at least partially restored by WN-7 treatment. However,
some observations cannot be explained with this hypothesis. 1. According to the NK
cell physiology, when a celi loses or decreases its MIIC class I antigen, it wiIl activate
NK celis and be eliminated; nevertheless, the NK ceil adaptive therapy for tumours
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seems flot as effective as expected (319), also the TFN-recoverable NK activity is flot
reduced in patients compared to matched controls (320). The cancer patient does not
appear to be abnormal in immunity to antigens other than tumour antigen, except in the
late stage of disease. 2. Tumours derived from professional antigen presenting celis,
which are flot have deficient, can stili escape the immune attack.
3.2.3. TCR and tumour escape
Some studies reported the alteration in the TCR component expression in peripheral or
intratumoural T lymphocytes isolated from cancer patients (321, 322, 323). The signal
transduction components, such as p56tck and Zap7O tyrosine kinases, were also reported
to be somewhat downregulated in T lymphocytes obtained from cancer patients (321).
In addition, the deficits in TCR could be restored by IL-2 therapy (324). These were
proposed to be a mechanism of tumour escapes from immunosurveillance. A recent
study showed that there is no evidence to suggest that loss of TCR C chains is a
mechanism for immunocompromise in patients with cervical carcinoma (320).
3.2.4. Tumour associated antigen (TAA) and tumour escape
One obvious mechanism for tumour’s resistance to the immune system is the down
regulation of tumour-associated antigen (TAA) expression. This phenomenon was
clearly demonstrated by monitoring over time the sensitivity of primary tumours versus
subsequent metastases to CTL clones (325, 326, 327). Certain tumour cells may transfer
antigens from their surface into the cytoplasm, making themselves immunologically
invisible. Alternately, tumour ceils may stop expressing certain surface antigens (327).
Analyses conducted in vitro have clearly established that optimal recognition and
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activation of tumour specific T ceils depends on a minimal level of TAA expression
(326). This feature of tumours reveais a disadvantage of tumour antigen-based cancer
vaccine; which is based on the premise that it is eliciting immune responses to particular
TAA. Due to the diversity of tumour ceils in a tumour mass; the effect of the tumour
vaccine immunization may only eliminate a fraction of the tumour ceils, which are TAA
positive on their surface. However, even these initially TAA-positive tumour ceils might
escape the vaccine-induced immune attack once their TAA is downregulated.
3.2.5. Costîmulation molecules and tumour escape
The understanding of the two-signals model in T-ceIl activation is crucial to the
development of nove! strategies to enhance antitumour immune responses. The we!!
organized immune system could effectively eliminate a nearly infinite repertoire of
foreign invaders to prevent damage of self. Unfortunately, the immune response to
tumours is often ineffective. A major mechanism of immune evasion is the lack of
costimulatory !igand expression, which renders tumour-antigen-specific T ce!!s
impotent (328, 329, 330, 331). Because cancers usually lack the second signal for full
activation of T ceil and are short of “danger” signais, tumour antigens need to be
presented by other types of celis to stimulate the immune system. This can be achieved
by a process known as cross-presentation, which is also involved in responses to vira!
infection and transplanted organs (332). APCs will pick up tumour antigens released
from tumour celis; after processing, APCs will present the tumour antigens on their celi
surface restricted by their own MIIC class I or II molecules; APC will then present the
tumour antigen to T celis, together with the costimuiatory molecules expressed on their
cel! surface; this will be sufficient to stimu!ate naïve T cel! activation. However, this
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same process of cross-presentation has been shown in some cases to induce T-cell
tolerance, which may play an important role in maintaining toierance to self antigens
(332), as well as in tolerance to tumour antigens.
3.3. Approaches to cancer vaccine
Although approaches to manufacturing cancer vaccines vary and include
— but are not
iimited to — the use of vectors, peptides, or genetically modified ceils, they are ail geared
toward the same end, namely, to stimulate the host’s immune system to respond to
antigens charactenstic of cancer ceils.
3.3.1. Peptide and protein vaccine
The development of therapeutic vaccines specifically targeting TAA bas the advantage
that the immune response would be directed mainiy against the tumour celis but few
other normal tissues. Also, this kind of vaccines can be used in ail patients, whose
cancer ceil express the targeted TAA. However, one potential major disadvantage of
peptide vaccines is the possibility of raising oniy an irrelevant peptide-specific response,
which is flot necessaniy against intact TAA proteins. For instance, it was reported that
patients immunized with her2 peptide developed her2-specific T-celi responses;
however, the reactive T ceils faiied to recognize her2 tumour cells (333, 334). Another
potentiai disadvantage is that the antigen specific immune response may only eliminate
a fraction of the cancer ceif s, because of the diversity and the genetic instability of the
cancer celis in terms of TAA expression. Combining antigenic peptides with adjuvants,
such as QS2Y, incomplete Freund’s adjuvant, GM-CSF, IL-2 or IL-12 has been proven
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to increase efficacy of tumour vaccines, either by improving antigen presentation or by
supporting the effector function of vaccine-induced T-cell response (335, 336).
Clinical trials using TAA peptide vaccines recently have begun, and have provided
substantial information about the type of immune responses that are elicited (336, 337).
In general, the therapeutic outcomes in clinical trails to date have been disappointing
(338). The resuits of these trails can be summanzed as the following: first, CTL
responses can be induced by peptide vaccination (339, 340, 341); second, the presence
of an expanded pool of TAA-specific T ceils does flot lead to tumour regression (342,
343, 344); third, incrcasingthe affïnity of the peptide for the MHC can greatly increase
the potency of a vaccine by converting a subdominant epitope into a dominant one (340,
345, 346). The modified gplOO peptide vaccine elicited peptide-induced T-cell
responses in 91% of the melanoma patients immunized. In contrast, vaccination with the
unmodified peptide failed to induce a T-cell response in most patients (340).
Heat shock proteins (HSPs) are involved in protein maturation and functional regulation
(347, 348, 349). They have been implicated in numerous processes such as protein
folding, transport, assembly, and peptide trafficking in antigen presentation (347, 350).
It was observed that certain HSPs (gp96, hsp9o, and hsp7o) puiified from a given
tumour could elicit specific immunity against that particular tumour (347, 351, 352).
Biochemical and functional studies indicate that the immunogenicity of tumour-derived
HSPs is due to the assoiated antigenic peptides (347, 353, 354). In addition to carrying
antigenic peptides for presentation, HSPs also stimulate antigen presenting ceils (APC),
such as macrophages and dendritic cells (347, 355, 356) to secrete pro-inflammatory
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cytokines as weIl as to promote maturation of dendritic celis (357, 358, 359). Clinical
tials using tumour-derived HSP are underway (360, 361, 361).
Most tumour antigens identified so far are poorly immunogenic in vivo (362). Studies
indicated that using altered agonistic peptide ligands dramatically increases the
magnitude of T celi responses and sensitivity to antigen stimulation in both human and
mouse models (345, 363, 364). The enhanced T ce!! responses can retain their specificity
to the native antigen, which allows T celis to kil! target tumour ceils ex vivo and,
presumably, in vivo (362).
3.3.2. DNA vaccine
Direct vaccination with DNA encoding a tumour antigen has the advantage of simplicity
and low cost of production. DNA vaccine can induce both humoral and T-cell-mediated
immunity (365).
“Naked” DNA-encoding cancer antigens can be injected intradermally or
intramuscularly as vaccines. However, the immune responses induced by naked DNA
vaccination are generally weak, possibly due to the poor efficacy of in vivo transfection
of “naked” DNA (336, 365). The efficacy of DNA vaccines can be improved by fusing
the coding sequence of TAA with that of “adjuvant-like” elements such as cytokines, the
constant region of a foreign immunoglobulin (366), or a known highly immunogenic
camer protein, e.g., fragment C of tetanus toxin (367). A recent study showed that DNA
encoding TAA fused with DNA encoding a pan-MHC Class II peptide analogue
augments antigen-specific cellular immunity (368).
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A variety of gene therapy vectors have been adapted to cancer imrnunothetapy. The
TAA coding sequences can be inserted into viral vectors (335, 369), such as rnodified
vaccinia virus, fowipox virus, or canarypox virus, and recombinant replication
incompetent viral vectors (adenovirus, retrovirus, lentivirus) (335, 369). Unfortunately,
this form of genetic immunization bas also resulted in weak immunologic responses in
humans (300).
3.3.3. CeIlular vaccine
Dendritic celis (DCs) vaccine
Vaccination of cancer patients with DCs presenting TAAs bas been believed to be a
promising anticancer strategy (370, 370). The use of dendntic ceils (DCs) as adjuvants
in order to induce tumour-specific killer and helper T celis directly in patients is
supported by many animal expenments as well as initial human trials (371, 372, 372,
373, 374). Several strategies have been used to load DCs with tumour antigens,
including peptides, proteins, tumour celi lysates or tumour-derived RNA. Some other
studies use DCs transfected with viral vectors expressing tumour antigens or fused with
the whole tumourcelis (291). The demonstration that immunisation of animais withDC
based vaccines can Iead to rejection of established tumours, and the fact that functional
DCs can be generated ut vitro in large quantities from cancer patients, bas made DCs an
attractive vehicle to oe used in human clinical trials. Some clinical trials have shown
quite promising resuits (291, 371, 374, 375). However, pulsing of DCs with particular
peptides has several disadvantages: j) short duration of antigen-MI{C complexes, ii) a
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requirement for matching defined peptides with MHC complexes, and iii) exclusive
presentation of single antigen epitopes (370). Therefore, DC vaccination stiil needs to be
optimized (337).
A phase 1111 clinical trial of DC-based vaccine loaded with PSMA peptides in treating
prostate cancer, showed that the vaccination can induce anti-PSMA specific T-cell
response, and the numbers of the DCs given correlats to the duration of the immune
response, with the majority of the patients (58%) still responding at the end of the
follow-up penod (374, 376). In a clinical tnal of 17 patients with advanced renal
carcinoma, the tumour celis were fused with normal allogeneic donor DCs and were
given as subcutaneous injections over several months. A 41% response rate (with 4
patients showing a prolonged complete response) was recorded (377).
In several animal models, DCs modified with genes encoding immunostimulatory
proteins have been shown to be effective in the induction of antitumour immune
responses (375, 378). The genes being used to modïfy DCs include costimulatory
molecules, such as CD4O, CD8O, or CD86, and cytokines, such as IL-1f3, -2, -6, -10,
-
12, TNF-a, GM-CSF (370, 370, 375, 378).
Tumour ceil vaccine
Whole tumour celis have been used to vaccinate cancer patients. The fact that tumour
ïtself is not able to induce an adequate immune response in patients Ied to attempts to
overcome such unresponsiveness by introduction of cytoldne genes or co-stimulatory
molecules into the genome of the vaccine tumour cells. This should create micro
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environmental conditions that prevent anergy and allows tumour destruction to take
pi ace.
a. Cytokine gene modified tumour vaccine
Cytokine gene-modified tumour vaccines are usually composed of autologous
tumour ceils stably transfected with a cytokine gene. The original hypothesis was
that the paracnne expression of cytokines such as IL-2 or JFN-y allows the tumour
celis to directly activate cytotoxic T ceils, bypassing the need for host CD4 T
lymphocyte help (379). Some cytokine gene-modified tumour celi vaccines are
conducted in clinical trials in different cancers; the cytokines tested are IL-2, -4, -7, -
12, TNF, TNFr3, LNFŒ, INFf3, INFy and GM-CSF (300, 369, 375). The study in
preclinical models showed that the GM-CSF gene-modified tumour ceils represent
the most active vaccine (300). GM-CSF is known to contribute to the maturation of
DCs, which in tum enhances antigen presentation in vivo. The GM-CSF-transfected
autologous tumour celi vaccine lias been explored in phase 1111 human clinical trials
for melanoma (380), renal carcinoma (381), and prostate cancer (382). These trials
have shown some success in generating specific immune responses against tumours
(291). Some studies indicated that GM-CSF-modified allogenic vaccines also induce
immune response towards TAA under the restriction of allogeneic MHC. For
example, allogeneic K1735 melanoma celis provides significant protection to mice
against B16 syngeneic tumour ceil challenge (383).
b. Costimulatory molecular gene-modified tumour celi vaccine
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Lack of costimulation is a very important mechanism of tumour escape from
immune attack. It is a highly promising approach to evoke an effective anti-tumour
immunity by immunization with tumour ceils genetically modified to express
costimulatory molecules (384), because such a measure will direct-prime anti
tumour T ceils, this can also cross-prime T celis when administered with adjuvant,
or when the tumour antigens are captured by APCs in the immunization site. Many
studies have exploited the various costimulatory pathways to elicit a more potent
antitumour immune response (300, 384, 385).
1). B71CD28
Based on the fact that B7/CD28 interactions enhance, and B7/CTLA-4
interactions inhibit, T-ceT! activation, many investigators demonstrated that
confemng B7 expression on tumour celis augments the antitumour response to
tumours of varied origins (386, 387, 388, 389). Chen et al reported that B7
expression on tumour ceil is flot sufficient to induce immunity against
nonimmunogenic tumours (390). However, combining B7 expression with
cytokine expression (IFN-y, IL-12, GM-CSF) leads to enhanced tumour
immunity in some models (391, 392, 393).
2). ICOS[ICOSL
ICOSL (B7h) expression on tumour ceils was demonstrated to enhance
recognition of tumour celis by T ceils. B7h expression on SaliN fibrosarcoma
and J558 plasmocytoma celis enhance tumour rejection in a CD8-dependent
manner (394, 395). Zuberek et al. recently studied the in vivo efficacy of
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CD281B7 and ICOS/ICOSL costimulatory pathways in murine MethA
fibrosarcoma and the B 16Ff melanoma tumour models (385).They found that
each of these pathways is equally effective in promoting tumour immunity and
that the efficacy of both ICOSL and B7.1 vaccines are WN-7
- but flot IL-10-
dependent (385). These resuits suggest that CD28 or ICOS costimulation-based
strategies may be equally efficacious in cancer immunotherapy. Meanwhile,
another report of human glioma showed that ICOSL gene transfer into glioma
celis does flot alter their immunogenicity under primary or secondary
alloreactive coculture assays in vitro (396). These resuits demonstrated that
vaccines based on ICOSL expression might elicit anti-tumour immunity in some,
but flot ail, types of tumours.
3). 0X40/0X40-L
The vaccine based on 0X40-L expression on tumour celi vaccine was studied as
a therapeutic vaccine in the C26 munne colon adenocarcinoma model. Mice
injected with C2610X40L ceils displayed only a delay in tumour growth, while
the C26/GM (GM-CSF)/OX4OL tumours regressed in 85% of mice. Subset
depleted and knockout expenments showed that tumour rejection requires
granulocytes, CD4+, CD8+ T ceils, and APC-mediated CD4O-CD4O ligand
cosignaling, but flot WN-y or IL-12 (397).
4). CD4O/CD4OL
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There is iirnited evidence suggesting that CD4OL directly provides signais to the
T celis. The CD4O/CD4OL interaction initiaily delivers signais to CD4O1 APCs
rather than to T ceiis. However, because such signais significantly augments the
ability of APCs to present antigen, it strongly enhances T-ce!! activation as a
resuit (398). CD4O/CD4OL costimuiation is important for effective antitumour
responses. Biocking CD4O/CD4OL interactions prevents the generation of a
protective antitumour response foliowing vaccination with GM-CSf—expressing
B16 melanoma cefls (399). Several methods using forced CD4OL expression in
tumour celis as vaccines have significantiy enhanced responses to pooriy
immunogenic tumours (398, 400, 401, 402, 403, 404).
5). 4-1BB/4-1BBL
Immunization with tumour ceiis transfected with 4-1BBL-expressing vectors can
significantly expand CD8 mediated antitumour responses, and is therapeutically
efficacious in mouse models (281). The efficacy of such a vaccine has been
shown to increase when it is given together with tumour ceiis producing IL-12
(405). However, immunization with tumour ceiis expressing 4-1BBL aione is
much iess efficacious than administration of anti-4-ÏBB. Ye et ai. expressed the
anti-4-1BB antibody singie chain on iow immunogenic mouse K1735 meianoma
ceils, and found that these ceils induce a strong type 1 T-heiper celi response, for
which CD4 but flot CD8 T lymphocytes are necessary. Moreover, such
vaccination is NK cei! dependent. The vaccinated mice reject established wild
type K1735 tumours growing as subcutaneous nodules or in the iung (406).
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6). CD27/CD27L
Kelly et al. reported that CD27L expression on MHC class 1-deficient RMA-S
tumour celis enhances primary tumour rejection i,z vivo as well as T-ecu
immunity against secondary challenge of the RMA-S tumour celis. The killing
of CD27L tumour ceils is mediated by NK celis and is by perfonn- and
interferon-gamma-dependent mechanisms (407).
7). LIGHTJHVEM
Introduction of LIGHT cDNA into MDA-MB-231 human breast carcïnoma
causes complete tumour suppression in vivo. Histological examination shows
marked neutrophil infiltration and necrosis in LIGHT-expressing but not in the
parental or the neo-transfected MDA-MB-23 1 tumours (34). Vaccination with
LIGHT gene-transferred P815 tumour celis induces tumour rejection of P815-
tumour-beanng mice, accompanied by tumour-specific CTL activity (40$).
Direct rejected LIGHT-expressing tumour ceils into tumour mass Ieads to
eradication of established tumours with a massive infiltration of naïve T
lymphocytes (409). The proposed mechanisms are that 1) LIGWf-expressing
tumour ceils costimulate CD8 celis through HVEM and 2) they stimulate
fibrolast stroma ceil via LTf3R to secrete chemokines, and the secreted
chemokine further recmit T celis into the tumour site. (409).
8). Costimulatïon via reverse signaling
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Aithough reverse costimuiatory signais through some TNF ligand family
members has been documented, tumour vaccination using such reverse
costimulation has flot been explored to date.
4. Hypothesis of the study
As illustrated in figure 1,2. TR6 can bind to three identified ligands: LIGHT, FasL, and
TL1A. The aim of this project is to study the function of TR6 in modulating T-cell
responses. Since TLI is flot expressed on T ceils, our study wili focus on the
interactions among TR6, fasL and LIGHT. Based on our pilot studies, we hypothesized
that:
4.1. TR6 on solid phase might costimulate T celi response by triggering reverse
signalîng through its ligand, LIGHT.
As mentioned above, several TNF ligand famiiy members including FasL, which is a
ligand of TR6, reversely transduces signaling into ceils. Our pilot expenments also
indicated that TR6 on solid phase can augment T-cell proliferation, and the enhanced T
ccli proliferation cannot be completely blocked by soluble fas recombinant protein. So,
we hypothesize that the other ligand of TR6, LIGHT, may reversely transduce
costimulatory signais into T celis.
4.2. TR6 expressing on tumour celi surface might be useful as therapeutic vaccine.
It is well accepted that full activation of T ceils requires two signais; and Jack of second
signal is a very important mechanism of tumour escape immune attack. If our first
hypothesis is proven correct, expressing TR6 on tumour ceil surface can trigger
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costimulatory signais reversely through both of its iigands, i.e., FasL and LIGHT, and
these costimulation signais should enhance the anti-tumour immune responses.
4.3. TR6 mïght regulate T-cell migration.
As reported by our group (136), both soluble and soiid-phase TR6 are abie to prevent
mitogen-induced T-cell aggregatÏon in vitro. Further, we found that TR6 pretreatment
reduces actin polymerization and pseudopodium formation. Based on these findings, we
hypothesized that TR6 might regulate T-cell migration in vivo, and it shouid be one of
the mechanisms for TR6-secretïng tumour ceils to escape immune attack.
.
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Article 1.
Mouse T ceils receive costimulatory signais from LIGHT, a TNf famïly
member
Guixiu Shi, Hongyu Luo, Xiaochun Wan, Theodora W. Salcedo, Jun Zhang and
Jiangpïng Wu
Btood. 2002 Nov 1; 100(9): 32 79-26.
Note: In this paper, Jun Zhang and Theodora W. Salcedo performed cytoldne assays as
shown in Figures 2, 3 and 4. They also supplied valuable regents, such as TR6, TR2,
LIGHT and TR11 proteins, and anti-human LIGHT Abs. Hongyu Luo and Xiaochun
Wan contnbuted in idea development and expenmental design. Guixiu Shi camed out
the rest of the work.
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ABSTRACT
LIGHT is a tumor necrosis factor (TNF) family member and is expressed on activated T
ceils. Its known receptors are TR2 and LTPR on the ccli surface and TR6/DcR3 in
solution. TR6IDcR3 is a secreted protein belonging to the TNF receptor family. It binds
to fas ligand (fasL), LIGHT, and TLÏA, ail of which are TNF familymembers. In the
present study, we report that solid-phase TR6-Fc costimulated proliferation, lymphokine
production, and cytotoxicity of mouse T celis upon T-cell receptor (TCR) ligation. A
monoclonal antibody against LIGHT similarly costimulated mouse T celis in their
proliferation response to TCR ligation. These data suggest LIGHT, although a ligand,
can receive costimulation when expressed on the T-cell surface. Mechanistically, when
T ceils were activated by TCR and CD2$ co-cross-linking, TCR and rafts rapidly formed
caps where they colocalized. LIGHT rapidly congregated and colocalized with the
aggregated rafts. This provided a mo]ecular base forthe signaling machinery of LIGHT
to interact with that of TCR. Indeed, LIGHT cross-linking enhanced p44142 mitogen
activated protein kinase activation after TCR ligation. This study reveals a new function
and signaling event of LIGHT.
Key words: TR6/DcR3; LIGHT; costimulation; reverse signaling; mouse T ceils
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INTRODUCTION
LIGHT/TL5 is a new member of the tumor necrosis factor (TNF) family, with its protein
expressed on activated T celis (1) and immature dendritic cells (2). It is a ligand for
TR2/HVEM, LTPR, and TR6[DcR3, ail of which are TNF receptor (TNFR) family
members (1,3,4). Recent studies show that LIGHT can costimulate T-cell responses via
TR2 (2,5,6) LIGHT can also induce apoptosis in celis expressÏng both TR2 and LTPR
(7), although Rooney et aI (8) reportedthat LTf3R is necessary and sufficient for LIGHT
mediated apoptosis in tumor ceils. However, LTPR is flot expressed on lymphocytes (9).
Several TNF members on ceil surfaces can reversely transduce signais into celis.
Cayabyab et al (10) and Van Essen et al (11) have shown that CD4OL transduces
costimulation signais into T ceils. Wiley et al (12) have reported that CD3OL cross
linking activates neutrophils, and Cerutti et al (13) showed that such reverse signaling
inhibits the immunoglobin class switch in B celis. Reverse signaling through membrane
TNF-cc confers resistance of monocytes and macrophages to lipopolysaccharide. (14)
Cross-hnking of TRANCE enhances interferon-Y (WN-Y) secretion by activated Thi
cells (15). Reverse signaling through Fas ligand (FasL) can promote maximal
proliferation of CD8 cytotoxic T cells (16-18). Cross-Iinking of TRAIt by its solid
phase death receptor 4 increases IFN- Y production and T-ceil proliferation. (19).
Whether LIGHT can reverseiy transduce signals into T celis has flot been assessed.
TR6IDcR3 is a new member of the TNFR family. Human TR6 iacks an apparent
transmembrane domain in its sequence and is a secreted protein (3,20). Mouse TR6 lias
not been cloned. Human TR6 has 3 known ligands, FasL (13), LIGHT (3,4), and TL1A
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(21). FasL binding by TR6 interferes with the interaction between Fas and fasL.
Consequently, FasL-induced apoptosis of lymphocytes and of several tumor celi lines
can be repressed by TR6 (20). We have recently reported that soluble human TR6-Fc
can suppress cytotoxic T lymphocyte (CTL) and lymphokine production of mouse
lymphocytes and inhibit mouse heart allograft rejection (3). These findings have raised
thepossibility that TR6 inhibits LIGHT-tnggered costimulation viaTR2 in Tcells.
We have presented evidence in this article that TR6 can tngger LIGHT to transduce
signals into T celis and enhance the T-celÏ response to TCR stimulation in a mouse
mode!. Such signaling is preceded by rapid congregation of LIGHT into the T-cell cap
on the cell surface, followed by p42144 mitogen-activated protein kinase (MAPK)
activation. Thus, although a ligand, LIGHT can function as a receptor as well. The
biologic significance of this finding is discussed.
MATERIALS AND METHODS
Lymphocyte preparation and culture
Mouse total spleen celis were prepared by lysing red blood cells with 0.84% NH4C!, as
descnbed elsewhere (22). Spleen T cells were punfied by deleting Ig and adhesion cells
with T-ce!! columns according to the manufacturer’s instructions (Cedarlane, Hornby,
ON, Canada). CD4 and CD8 T cells were prepared from total spleen cells by positive
selection, using magnetic beads according to the manufacturers instructions (Miltenyi
Biotec, Auburn, CA). The cells were cultured in RPMI 1640 supplemented with 10%
fetal calf serum (FCS), L-glutamine, and antibiotics. RPMI 1640, FCS, penicillin
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streptomycin, and L-glutamine were purchased from Invitrogen (Burlington, ON,
Canada). Solid phase TR6-Fc and anti-CD3 were prepared by coating Nunc plates with
5 ig/mL goat anti-human IgG (Southem Biotechnology, Birmingham, AL) along with
various concentrations of anti-CD3 in phosphate-buffered saline (PBS) ovemight at 4°C.
After washing, the plates were incubated with TR6-Fc or a control fusion protein TRi 1-
Fc of desired concentrations in PBS at 37°C for 2 hours. After washing, the coated plates
were used for culture. 3H-thymidine uptake was measured as descnbed previously
(23,24).
Lymphokine assays
Interleukin 2 (IL-2) and WN-Y in culture supernatants were measured by commercial
enzyme-linked immunosorbent assay (ELISA) kits from R & D Systems (Minneapolis,
MN).
Cytotoxic T-cet1 assay
The assay was performed as detailed previously (3). Briefly, 2C mouse spleen celis
(4 x 106 cells/2 mJJwell, H-2”) were stimulated with an equal amount of mitomycin C
treated BALB/c mouse spleen cells (4 x 106 cells/2 mL/well, H2c) in flat-bottomed 24-
well plates, which were precoated with goat anti-human IgG (5 g/mL) followed by
TR6-Fc (10 1ugImL) or normal human IgG (10 cgImL), in the presence of 10 U/mL IL-2
for 6 days. Human LIGHT (20 gImL) was added to the culture in the beginning of
certain cultures. On day 6, cells receiving the same treatment in 24-well plates were
pooled and counted, and their CTL activity was measured by a standard 4-hour 51Cr-
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release assay, using 5tCr-labeled P815 cells (H_2d) as targets at different effector-target
ratios. The lysis pe;-centage of the test sample was calculated as follows:
% lysis = cpm of the test sample - cpm of spontaneous release
cpm of maximal release
- cpm of spontaneous release
flow cytolnetry
Mouse spleen cells, cultured in medium or stimulated with concanavalin A (Con-A;
2 gImL) for 24 hours, were first cross-linked by anti-CD3 and antï-CD28 hamster
monoclonal antibody (mAb) followed by goat anti-hamster IgG, as detailed in the
section on confocal microscopy below. After fixing with 3.7% formalin, the celis were
stained with a human anti-human LIGHT mAb (clone 1.2.2, 0.1 LgI106 cells), followed
by phycoerythnn (PE)-f(ab)’2 of goat anti-human IgG (Southem Biotechnology) and
fluorescein isothiocyanate (FITC)-anti-Thy- 1.2 (clone 53-2.1, Pharmingen, San Diego,
CA). In some samples, TR6 without the Fc tag (5 g/sample) or human LIGHT
(5 .tgIsample) was present as inhibitors dunng the staining process. Thy-1.2 celis were
gated and analyzed for anti-LIGHT intensity.
Confocat rnicroscopy
Five million BALB/c T cells were first blocked with 100 IIL PBS containing 2% bovine
serum albumin (BSA) for 30 minutes. Then, 5 tg anti-CD28 (clone 37.51.1, hamster
mAb, Cedarlane) and 2 ig biotinylated anti-CD3 (clone 2C11, hamster mAb) were
added to the celi suspension, which was incubated for an additional 30 minutes. After
washing with cold PBS, the celis were reacted with goat anti-hamster IgG (5 agIsample)
for 30 minutes. AlI the procedures above were conducted at 4°C. The cells were washed
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with cold PBS and transferred to 200 iL warm PBS to start the 10-minute cross-linking
process at 37°C. They were then fixed imrnediately with 3 mL 3.7% formalin at room
temperature for an additional 10 minutes. For T-cell receptor (TCR) and LIGHT
staining, the fixed ceils were reacted with TR6-fc (2 Lg/106 ceils) for 30 minutes on ice.
After washing with PBS, the celis were stained with Alexa 488-goat anti-human IgG
(1 ig/106ce1ls) and Alexa 594-streptavidin (1 gJ106 celis) on ice for another
30 minutes. For raft and LIGI-IT staining, the procedure was similar to that described
above, but Alexa 594-conjugated choiera toxin (1 fLg/sample) was used instead of Alexa
594-streptavidin. The stained celis were then washed with PBS and mounted on slides
with Prolong antifade mounting medium (Moiecular Probes, Eugene, OR). The siides
were examined under a confocal microscope. Digital images were processed with
Photoshop (Adobe, Seattie, WA).
Innnunoblouing
Plates (24-well) were coated with anti-human IgG (5 1ug/rnL, 300 ILL/well) and a
suboptimal concentration of anti-CD3 (0.2 g/mL, 300 t.LJJwe11) ovemight at 4°C. After
washing, the wells were incubated with TR6-Fc (10 g/mL, 300 iUwell) or a control
fusion protein TR1Ï-Fc (10 fLg/mL, 300 tLUwell) at 37°C for 2 hours. Mouse spleen T
ceils were treated with cytochalasin D (15 !LM) in complete culture medium or medium
containing a similar percentage of vehicle (dimethyl sulfoxide [DMSOj) for 2 hours.
After washing, the cells were seeded in precoated plates at 5 x 106 cells/well, and the
plates were centnfuged at 228g for 5 minutes to achieve rapid contact between the cells
and the bottom of the culture wells. The cells were then cultured at 37°C for 90 minutes
before being harvested. The remaining procedures were detailed in our previous
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publication (22). Briefly, the ceils were washedand lysed in lysis buffer for 10 minutes;
the cleared lysates were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). The proteins were then transfened to nitrocellulose
membranes, which were sequentially hybndized with rabbit anti-phospho-p44!42 MAPK
and anti-p44142 MAPK antibody (New England Biolabs, Mississauga, ON, Canada).
Immunoreactive protein hands were visualized using horseradish peroxidase-conjugated
goat anti-rabbit IgG followed by enhancedchemiluminescence.
RESULTS
Solid-phase TR6-Fc enhances protife ration of mouse T celis sti,nulated by suboptimat
concentrations ofanti-cD3
We investigated whether LIGHT, aithough a ligand, couid transduce stimulating signais
reversely into T celis. To this end, we used one of the receptors of LIGHT, TR6, in soiid
phase to cross-link LIGHT on mouse T ceils. Because mouse TR6 has not been cloned,
and human TR6 can bind to mouse LIGHT (3), recombinant human TR6 with an Fc tag
was used. As shown in Figure lA, human TR6 in solid phase (10 Lg/mL, ail the
concentrations in this section refer to those used during coating of the welis) could
enhance the proliferation of total spleen celis stimulated with anti-CD3 in solid phase,
compared with a control fusion protein TRi 1-Fc. The enhancement was obvious with
anti-CD3 at 0.25 Lg/mL or 0.5 Lg/mL. To assess whether both CD4 and CD8 ceils were
responsive to the TR6 stimulation, they were purified from total spleen ceils with
magnetic beads and stimulated with a fixed amount of anti-CD3 (0.2 g/mL) and various
concentrations of TR6-Fc. At 10 tg/mL, TR6-Fc had an obvious stimulatory effect on
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the proliferation of both CD4 and CD8 ceils (Figure 1B,D). Next, TR6-Fc was tested at a
fixed optimal concentration of 10 1ugImL along with different concentrations of anti
CD3. As shown in Figure 1, panels C andE, both CD4 and CD$ T celis were responsive
to TR6 costimulation when anti-CD3 was used at several suboptimal concentrations
from0.125 to 0.5 fLg/mL. The results of this section show that LIGHT ligation by TR6
costimulates CD4 and CD$ T ceils in their proliferation response to TCR cross-linking.
Costinzulation through LIGHT enhances tymphokine secretion by T cetis
b understand the immunologic consequences of costimulation through LIGHT, we
examined lymphokine secretion by total spleen ceils and CD4 and CD8 T cells. As
shown in Figure 2, solid-phase TR6-Fc (10 tgJniL, the concentrations indicated in this
section refer to those used during coating of the wells), compared with control fusion
protein TRi 1-Fc, significantly augmented WN-Y and IL-2 secretion of total spleen ceils
stimulated with 0.25 Lg/mL or 0.5 Lg/mL anti-CD3, which was also in solid phase.
Lymphokine secretion by CD4 (Figure 3) and CD8 (Figure 4) ceils was evaluated next.
TR6-Fc in solid phase dose-dependently enhanced WN-Y and IL-2 secretion by CD4
celis in the presence of a suboptimal concentration of anti-CD3 (0.125 ug!mL). With an
optimal concentration of TR6-Fc (10 g/mL), an increased amount of anti-CD3 dose
dependently augmented the secretion of these lymphokines (Figure 3), compared with
cultures stimulated with TRi 1-Fc. CD8 T celis produced more WN-Y than CD4 celis on
costimulation through LIGHT, but did flot augment IL-2 secretion when different TR6-
Fc or anti-CD3 concentrations were used in combination (Figure 4). These data show
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that costimulation through LIGHT differentially augments lymphokine production by
CD4 and CD8 T ceils in mice.
Costimulation throitgh LIGHT augments CTL activity
b further assess the functional consequence of LIGHT costimulation, we examined
CTL development in the presence of solid-phase TR6-Fc. We used an established CTL
assay system, in which the responders were spleen celis from transgenic 2C mice (in H
2b background), and the stimulators were mitomycin C-treated BALB/c (H-2<’) spleen
cells (3). Almost all T ceils in 2C mice carry transgenic Ldspecific TCR, and the
majonty (about 75%) of their T cells are CD$ (25). Compared with control human IgG,
in the presence of solid phase TR6-Fc, CTL development was significantly enhanced, as
shown in Figure 5. Such enhancement could be neutralized by soluble human LIGHT,
indicating that the stimulation by TR6-fc was specific. Therefore, costimulation through
LIGHT enhances CTL activity.
Anti-humai; LIGHT mAb binds to mouse LIGHT and costimulates mouse T ceÏts
In the previous sections, human TR6 was used to engage mouse LIGHT, because human
TR6 can bind to mouse LIGHT and because it is a physiologically relevant receptor for
LIGHT. However, we could flot exciude the possibiÏity that human TR6 exerted its effect
through FasL or other so-far unidentified TNF family members other than LIGHT. We,
therefore, used a human anti-human LIGHT mAb to further pinpoint LIGHT on mouse T
ceils as the molecule receiving costimulation. We showed that it could bind to about 30%
of resting spleen T celis, and binding increased to 65% after T-cell activation with Con-
A ovemight (Figure 6A). This binding pattern was consistent with the documented
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expression pattern of LIGHT in T celis in that its expression was augrnented afterT-ceII
activation (26). The binding could be blocked by soluble human LIGHT, indicating that
the mAb was specific. Moreover, the binding could also be blocked by soluble TR6,
suggesting that both TR6 and the mAb competitively interacted with the same ligand on
the T-cell surface, Taken together, these results indicate that the anti-human LIGHT
mAb binds to mouse LIGHT. We next assessed whether the mAb could costimulate T
celis, as with TR6-Fc. This human mAb (10 g/mL) was anchored on plates via goat
anti-human IgG (5 g/mL) in the presence or absence of a suboptimal concentration of
anti-CD3 (0.2 g/mL). As shown in Figure 6B, the anti-LIGHT mAb significantly
promoted T-cell proliferation, compared with control normal human IgG. Thus, these
data confirm that LIGHT on T ceils can indeed receive costimulation.
Signating events after costimutation through LIGHT
To understand the molecular basis of LIGHT costimulation, we examined the molecular
migration of LIGHT and TCR and their relationship with lipid rafts on T-celi
membranes ïmmediately after TCR and CD28 co-cross-linking. T ceils were
preincubated with anti-CD3 and anti-CD28, followed by a second antibody on ice. CD3
and CD28 co-cross-linking started when the celis were transferred to 37°C. The lipid
rafts in the T-cell membrane were stained by Alexa 594-choiera toxin in red; TCR was
stained by Aiexa 594-streptavidin in red; LIGHT was stained in green by TR6-Fc
foliowed by Alexa 4$8-anti-human IgG. TCR and LIGHT were distnbuted throughout
the surface in the resting T celis, with TCR spreading more evenly, whereas rafts and
LIGHT appeared in speckies (first row, Figure 7). After 10 minutes of co-cross-linking
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with anti-CD3 and anti-CD28, TCR rapidly polarized and formed a cap in one end of the
cet!. LIGHT atso congregated, and it colocalized with TCR (second row, Figure 7).
LIGHT obviously comigrated and colocalized with rafts as shown in row 3 of figure 7.
Taken together, these data indicate that TCR and LIGHT both congregate to a raft cap on
the ccli surface immediately after TCR and CD2$ cross-Iinking. This provides a
molecular base for LIGHT to enhance TCR signaling because now both of them are
closely associated and located in aggregated rafts, which are scaffolds accommodating
many signaling molecules.
We also investigated signaling events further downstream from the ceil membrane.
Mouse spleen T ceils were plated on we]ls coated with TR6-Fc alone, a suboptimal
concentration of anti-CD3 alone, or both, for 90 minutes, and p44142 MAPK activation
was monitored according to their phosphorylation. As shown in Figure 8A, the level of
phosphorylated p42 MAPK was augmented in celis stimulated with both anti-CD3 and
TR6-fc, compared with anti-CD3 or TR6-fc alone, whereas p44142 MAPK protein
levels remained unchanged in ail treatments. When ceils were preincubated for 2 hours
in cytochalasin D, which prevents actin polymenzation, the level of phospho-p42 MAPK
no longer increased in the presence of anti-CD3 and TR6-Fc costimulation. This
suggests that MAPK activation depends on actin polymerization. MAPK activation in
this case was an essentiai and relevant event in T-cell activation after TCR and LIGHT
cross-linking because a p44142 MAPK-specific inhibitor PD98059, but not its
nonfunctionai analog SB202474, strongly suppressed the T-celi proliferation triggered
by CD3 and LIGHT stimulation (Fig. 8B).
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These resuits indicate that LIGHT can indeed transduce signais into T ceils, and such
transduction depends on eariy membrane events, actin poiymenzation and MAPK
activation.
DISCUSSION
In this study, we have reported that costimuiation through LIGHT enhances T-ceii
proliferation, cytokine production, and CIL deveiopment. Immediateiy after T activation
by anti-CD3 and anti-CD28, LIGHT congregates to the raft cap where it colocalizes with
1CR. Ibis membrane event is foiiowed by MAPK activation.
Because mouse TR6 bas not been cloned, we used human TR6 to cross-iink LIGWf on
mouse T ceils. This was a legitimate choice because human TR6 cross-reacts with mouse
LIGHT (3). However, the observed stimuiatory effect of soiid-phase TR6 could operate
via molecules other than LIGHT, because TR6 is known to bind FasL, which is also
capable of reversely transducing signais into T cells (16-18), and because human TR6
binds to mouse FasL (data not shown). Moreover, TNF and TNFR family members are
known to cross-react among themselves, as discussed in the “Introduction” on
interactions among TR6, LIGHT, FasL, IL-lA, TR2, and LTPR. To ascertaïn that
LIGHT couid receive costimulation, we used mAb against human LIGHT, which shares
67% homoiogy with mouse LIGHT in its amino acid sequence, for costimulation. The
binding of this mAb to activated mouse T celis could be inhibited by soluble TR6,
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indicating that TR6 and the mAb share a common ligand. Considenng the fact that the
mAb is specific to human LIGHT, unless there was an extremely rare and unlikely
coincidence in which the mAb and TR6 both bind to an unknown molecule X on the T
celi surface, we have to conclude that the anti-human LIGHT mAb is specific to mouse
LIGHT as well. Because this mAb could costimulate T celis in the presence of TCR
ligation, reverse signaling through LIGHT was thus established. Although we cannot
totalÏy exciude the possibility that the costimulating effect of TR6 on T celis might, to a
certain extent, be due to its binding to molecules other than LIGHT, we believe that the
major effect of TR6 occurs via LIGHT, because the binding of mouse T cefls by TR6
was largely eliminated when the LIGHT gene was knocked out (data flot shown).
Questions are inevitably raised regarding whether the stimulatory effect of TR6 is due to
its positive stimulation to LIGHT or due to its blocking of an existing negative autocrine
ioop in which LIGHT acts as a receptor. The latter possibility is best argued against by
the fact that in our model, solid-phase TR6 could stimulate T celis. When TR6-Fc was
used to coat the plate, although a concentration of 1 to 2 tg/l00 LUwell was used, only
a very small fraction of it actually went onto the plate, and more than 99.9% of the
protein was washed away after the coating process. Thus, no more than 2 ng TR6 was
actually coated on a well. If we consider how small a fraction of this wilI Ïeak into
solution, it is unlikely such a minute amount of soluble TR6 could interfere with an
autocnne loop. Indeed, soluble TR6-Fc up to 10 ig/mL had no effect on anti-CD3-
stimulated T celis (data not shown). Can TR6 on the solid phase block an autocrine
loop? We are flot aware of any example in an experimental system that this can be
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achieved. Because a ccli is a 3-dimensional entity, solid-phase TR6 can interfere only
with a part of the celi surface that has contact with the weli. Therefore, the solid-phase
TR6 cannot preventthe interaction between a putative soluble suppressive autocnne and
LIGHT on most part of the celi surface that is not in contact with TR6. Consequently,
most LIGHT molecules on a celi surface shouid stiil receive negative signais from the
putative suppressive autocnne, if there is one. It is therefore very difficuit to exptain the
positive effect of solid-phase TR6. In addition, recent studies showed that LIGHT
transgenic mice overexpressing LIGHT on T ceils have enhanced immune response
(27,28). This resuit does flot fit to the model in which LIGHT transduces negative
signais into T celis, because if so, the LIGHT transgenic mice shouid have suppressed
immune response instead. Lastly, there are about 4 to 5 TNF family members capable of
transducing signais into ceils, but none of them transduces a negative one. Based on
these arguments, it is concluded that TR6 exerts its effect by stimulating T cells via
LIGHT, but flot by interfenng with a putative negative autocnne loop.
Several studies have explored the pathways of reverse signaling. In the case of CD4OL,
its ligation results in generai protein tyrosine phosphorylation, Ca influx, and
activation of Lck, PKC, JNK, and p38 MAPK in EL4 thymoma cells (29,30). TRAIt
cross-linking aÏso induces p38 MAPK activation (19). We examined the mechanisms of
reverse signaling through LIGHT. A recent study showed that plasma membrane
compartmentation plays an essential role in T-celI activation and costimulation.
Detergent-insoluble, glycolipid-enriched rafts function as scaffolds and contain many
signaling molecules such as Src kinases (31). After cross-linking, TCR translocates to
the rafts, where it gains access to the signaling pathways (32,33). We explored the
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interaction among TCR, LIGHT, and rafts in this study. Anti-CD3 and anti-CD28 were
used to mimic antigen-presenting celis (APCs) for T-cell activation. TCR rapidly formed
caps, which colocalized with aggregated rafts, as expected. We found that LIGHT
immediately congregated and colocalized with the TCR cap and aggregated rafts. This is
a novel finding and is consistent with the costimulatory function of LIGHT. If LIGHT
were to costimulate T ceils, the best place it should go is aggregated rafts, where its own
signaling machinery can interact with that of TCR, and enhance the latter. It is to be
noted that in our T-ce!! activation mode!, we used TR6 a!ong with suboptimal anti-CD3
to stimulate T ceils in the absence ofanti-CD28. Under such a condition, the percentage
of T suboptima! anti-CD3 a!one and the capping was flot as drastic and clear-cut as with
anti-CD3 plus anti-CD28 treatment (data not shown). It is still possible that a small
degree of colocalization of LIGHT, TCR, and raft is present and is sufficient for the
costimulation of LIGHT for TCR, but such a small degree is flot discernable by our
current technology. The anti-CD3 p!us anti-CD2$ model gave a much stronger
stimulation and proves in pnnciple that TCR and LIGHT can !odge together in the raft
scaffold. Under the physiologic condition, TCR ligation is normally accompanied by
CD28 costimulation. Therefore, LIGHT wi!l be likely recrnited to the TCR-raft complex,
and our model using anti-CD3 plus anti-CD28 is physiologically relevant.
The activity of p42 MAPK, which is a downstream signaling mo!ecule in the TCR
signaling pathway, was enhanced by LIGHT signaling. How this is achieved is flot
presently clear. LIGHT has a short and featureless cytoplasmic tau incapable of
sigialing by itself(1); hence, its signaling most likely depends on molecules with which
it associates. In our experiment, a MAPK inhibitor was able to inhibit TR6-augmented
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SF11 67
T-cell proliferation in the presence ofsuboptimai anti-CD3. Because anti-CD3-induced
T-ceil proliferation is aiso dependent on MAPK, this kinase might be in the common
pathway shared by TCR and LIGHT, and its activation is augmented by upstream signais
from both TCR and LIGHT. The MAPK inhibitorobviously wiIl not differentiate TCR
denved signais from those that are LIGHT dcii ved.
What is the biologic significance of reverse signaling through LIGHT? LIGHT
expressing T celis can costimulate TR2-expressing T celis. Reverse signaling through
LIGHT allows TR2-expressing T celis to stimulate LIGHT-expressing T celis as well,
and such 2-way stimulation provides a theoretical base for T celi-to-T ceil cooperation,
which is flot a well-explored topic. It is known that T ceils need to reach a certain density
in culture to optimally respond to TCR stimulation, and such a phenomenon is often
attnbuted to the need for cytokines in culture. Without discounting the importance of
cytokines, bidirectional costimuiation via TR2 and LIGHT between T celis may well
contnbute to the celi density requirement during their activation. Such T cell-to-T ceil
cooperation can aiso explain why in vivo T-cell responses tend to occur in regions
densely popuiated with T ceiis in lymphoid organs. Recently, it has been shown that
LIGHT overexpression in the T-cell compartment in LIGHT transgenic mice results in
profound inflammation andthe deveiopment of autoimmune syndromes (27,28); T celis
overexpressing LIGHT have an activated phenotype (27). Probably, such an up
regulated immune response of T celis is due to stimulation of TR2/HVEM on dendntic
ceils by T cell-derived LIGHT, and the dendritic ceils in tum augment T-cell activity;
TR2 on T celis can also receive LIGHT stimulation directly from their fellow LIGHT-
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expressing T cells (28). On the other hand, it is entirely possible that overexpressed
LIGHT on T celis receives stimulation reversely, which augments their responsiveness
to TCR ligation. in this study, we used recombinant TR6-Fc and anti-LIGHT mAb as
artificial binding partners of LIGHT. In vivo, the molecules that can tngger LIGHT
signaling are probably ceil surface TR2 or LTPR. To support this hypothesis, we found
that when TR2 was put on solid phase, it could enhance T-cell response tnggered by
suboptimal anti-CD3, as with TR6 (data flot shown). On the other hand, endogenous
TR6 might act as an inhibitor of the bidirectional costimulation between TR2 and
LIGHT, or function as a costimulating factor for LIGHT, depending on whether it exists
as monomers or tnmers like other ceil surface TNFR family members. This aspect is
worth further investigation. Because dendntic ceils also express LIGHT, TR2 on the T
celi surface might activate dendntic ceils through LIGHT to modulate their APC
function. If so, this will represent a new mechanism for T-cell and dendntic ceil
interaction and cooperation.
We recently reported that soluble human TR6-Fc inhibited CTL in vitro and allograft
rejection in vivo in mice (3). In that paper, we proposed that soluble TR6 blocked the
costimulation from LIGHT to TR2, or reversely from TR2 to LIGHT (3), or both,
although, at the time, solid evidence of reverse signaling through LIGHT was flot
available. Our current findings have fulfilled one of our initial predictions that the
inhibitory effect of human TR6 in the mouse system should be attnbuted to the
interference of TR6 with the bidirectional costimulation between TR2 and LIGHT.
When TR6 was used as a solid-phase molecule instead of in solution, its function
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changed from suppression to promotion of the T-celÏ response, because it no longer
served as blocker btit rather as a cross-linker of LIGHT. Increasing cases of bidirectional
signal transduction between receptors and ligands have been found in biologie systems.
We can take advantage of such a phenomenon by exploiting soluble monomer ligands
(or receptors) without theceil-anchoring ability to block signaling in both directions and
thus modulate biologie responses
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FIGURE LEGENDS
Figure 1. SoÏid phase TR6-Fc prontotes protiferation of anti-cD3-stimulated total
spleen cetts, and CD4 and D8 T ceits
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Mouse spleen ceils (A), CD4 celis (B,C) or CD8 cells (D,E) were stimulated with solid
phase anti-CD3 and TR6-Fc. When anti-CD3 was used at different doses, TR6-Fc and
its control, TR1Ï-Fc, were tested at an optimal dose of 10 g/L. When TR6-Fc was used
at different doses, anti-CD3 was used at a suboptimal dose of 0.2 Lg/mL. These
concentrations referred to those used during the well-coating process. Ceil proliferation
was measured by 3H-thymidine uptake between 48 and 64 hours after the initiation of
culture. Means ± SD of the counts per minute from triplicate samples are shown. The
experiments were performed more than 3 times, and a representative set of data is
presented.
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Figure 2. TR6-Fc strongly augments lymphokine production by anti-C’D3-stimutated
spleen ceils.
Mouse total spleen celis were stimulated with solid-phase anti-CD3 and TR6-Fc. The
culture conditions were the same as descnbed in figure 1. The culture supernatants were
harvested at 48 hours after the initiation of the culture and were tested for lymphokines
with ELISA. Samples werc studied in duplicate, and the means ± SD of lymphokine
levels are shown. The expenments were conducted at least twice with similar resuits. A
representative set of data is shown.
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figure 3. TR6-fc strongly augments tymphokine production by anti-CD3-stimulated
CD4 cetts
Mouse spleen CD4 celis were stimulated with solid-phase anti-CD3 and TR6-Fc, and
cytoldnes in the supematants were measured with ELISA, as described in Figure 2. Data
are represented as means ± SD.
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CD4 Celis
figure 4. TR6-Fc strongty augments tymphokine production by anti-cD3-stimutated
CD8 ceits
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Mouse spleen CD8 celis were stimulated with solid-phase anti-CD3 and TR6-Fc, and
cytokines in the supernatants were measured with ELISA, as described in Figure 2. Data
are represented as means ± SD.
Figure 5. Effect of LIGHT reverse signating oit CTL devetoprnent
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2C mouse spleen cells (4 x 106 cells/2 ml/well) were mixed with an equal amount of
mitomycin C treated BALB/c mouse spleen cells (4 x 106 cells/2 mIJwell) and seeded
in flat-bottomed 24-well plates, which were precoated with TR6-FC (10 cg/mL) or
normal human IgG (NhIgG, 10 gImL) as a control. Soluble human LIGHT (20 ig/inL)
was added at the beginning of the culture in certain samples as indicated. The cells were
cultured in the presence of 10 UImL IL-2 for 6 days. CTL activity in the stimulated ceils
was then measured by a standard 4-hour 51Cr-release assay, using P815 celis as targets.
The samples were tested in tnplicate, and means ± SD of percentage of target ccli lysis
are shown. The experiments were performed twice with similar resuits, and the data of a
representative expenment are presented.
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figure 6. Anti-Ii uinan LIGHT mAb binds to mouse LIGHT and costimutates mouse T
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A. Anti-LIGHT inAb binds to mouse T ceits according toflow cytornetiy
Resting BALB/c spleen ceils or spleen cells activated by Con-A (2 Lg!mL) for 24 hours
were cross-linked with anti-CD3 and anti-CD28 hamster mAb followed by goat-anti
hamster IgG. After fixing with 3.7% formalin, the celis were stained with anti-human
LIGHT mAb (clone 1.2.2) followed by PE-F(ab)2 of goat anti-human IgG, along with
fITC-anti-Thyl.2. In some samples, soluble human LIGHT (5 ugIsample) or TR6
without the Fc tag (5 sg/sample) was added as inhibitors during the staining process.
The cells were analyzed by 2-color flow cytometry, and LIGHT expression on Thy1.2
ceils is shown in the histograms. Shaded areas represent celis stained with an isotypic
control mAb, and solid unes represent cells stained with anti-LIGHT mAb
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B. Anti-LIGHT inAb costiinutates mouse T celi prottferation
Nunc 96-well plates were coated with a suboptimal concentration of anti-CD3
(0.2 igImL) along with goat anti-human IgG (anti-IUgG, 5 g/mL) ovemight at 4°C.
After washing, the wells wcre reacted with normal human IgG (10 ig/mL) or human
mAb against human LIGHT (10 1ugImL) at 37°C for 2 hours. The wells were washed
and BALB/c T celis were seeded into the we)ls at 4 x cells/well. 3H-thymidine
uptake was measured between 4$ and 64 hours. The samples were in tnplicate, and the
means ± SD of counts per minute are shown. The experiments were performed twice
with similar resuits, and the data of a representative experiment are presented.
figure 7. LIGHT rapidly transtocates into caps of TCR and rafis oit the surface of
activated T cetts
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BALB/c spleen T celis were cross-Ïinked wïth anti-CD3 and anti-CD2$ for O or
10 minutes. The locations of TCR (stained with biotin-anti-CD3 followed by Alexa 594-
streptavidin in red), rafts (stained with AÏexa-cholera toxin in red) and LIGHT (stained
with TR6-Fc followed by Alexa 488-anti-human IgG in green) were revealed by
confocal microscopy. Original magnification, x600.
figure 8. Costintulation through LIGHT enhances MAPK activity
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A. !vIAPK activitv is enhcmced ctfter LIGHT costimulatioiz
BALB/c T celis were precultured in medium for 2 hours in the presence of 0.1% DMSO,
or 0.1% DMSO plus 15 M cytochalasin D. After washing, the celis were cultured in
medium (MED), or stimulated with solid phase TR6-Fc, a suboptimal concentration of
anti-CD3, or both, for 90 minutes at 37°C. The levels of phosphorylated p44142 MAPK
and total p44142 MAPK were assessed by immunoblotting with the same membrane.
The 42-kDa hand representing phosphorylated MAPK and the 44-kDa and 42-kDa
hands representing total p44142 MAPK protein are indicated by anows.
B. F44142 MAPK activity is essential for LIGHT-enhanced T-celÏ proÏtferation
BALB/c T celis were cultured in wells coated with TR6-Fc (10 gImL), a suboptimal
concentration of anti-CD3 (0.2 g/mL), or both. The ceils were cultured in medium, or
in the presence of a p44142 MAPK inhibitor PD98059 (15 tM) or its noninhibitory
structural homologue SB202474 (15 KM). The 3H-thymidine uptake of these ceils was
measured between 4$ and 64 hours. The samples were tested in triplicate, and
means ± SD of counts per minute are shown. The experiments were performed twice
with similar resuits, and the data of a representative experiment are presented.
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Article 2.
Death Decoy Receptor TR6IDcR3 Inhibits T-Cell Chemotaxis in vitro and in vivo1
Guixiu Shi, Yulian Wu, Jun Zhang and Jiangping Wu
Journal oflmmunotogy. 2003 Oct 1; 171(7): 3407-14
Note: In this paper, Jun Zhang supplied valuable reagents such as TR6, TR1Ï, TR2 and
LIGHT recombinant proteins, anti-TR6 and anti-LIGHT mAbs. Yulian Wu provided a
supporting figure for the Journal of Immunology reviewers, showing lymphocyte
infiltration in TR6 positive and negative tumors; the figure was quoted as “data not
shown” in the article. Guixiu Shi performed ah the remaining experiments.
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ABSTRACT
TR6/DcR3 is a secreted moiecule belonging to the TNF receptor famiiy. Its Iigands are
LIGHT, FasL and TLYA, ail TNf family members. TR6 is expressed in some tumors,
and is hypothesized to endow tumor ceils with survival advantages by blocking Fas
mediated apoptosis. It can also inhibit T-cell activation by interfenng with 2-way T-cell
costimulation between LIGHT and HveA. In this study, we discovered a nove! function
of TR6: inhibition of T-ceil chemotaxis. Human T ceils pretreated with soluble or solid
phase TR6-Fc showed compromised migration towards CXCL12/stromal cell-derived
factor la in vitro in a Transwel! assay. Such an effect could a!so be observed in T cel!s
pretreated with soluble or solid phase HveA-Fc or anti-LIGHT mAb, suggesting that
LIGHT reverse signaling was likely responsible for chemotaxis inhibition. TR6
pretreatment also led to T-cell chemotaxis suppression in vivo in the mice, confirming in
vivo relevance of the in vitro observation. Mechanistically, a small GTPase Cdc42 failed
to be activated after TR6 pretreatment of human T celis, and further downstream, p38
mitogen-activated protein kinase activation, actin polymenzation and pseudopodium
formation were ail downregulated in the treated T ceils. This study revealed a previously
unknown function of TR6 in immune regulation, and such an effect cou!d conceivably
be explored for therapeutic use in controlling undesirable immune responses.
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INTRODUCTION
TR6/DcR3, a TNFR family member, is a secreted protein due to the lack of the
transmembrane domain in its sequence (1,2). TR6 has three known iigands, Fas ligand
(L) (3), LIGHT (1,4) and TL1A (5), ail of which are TNF famiiy members. fasL binding
by TR6 interferes with the interaction between Fas and FasL. Consequently, FasL
induced apoptosis of lymphocytes or tumor cells can be repressed by TR6 (2). The
consequence of interactïon between TR6 and LIGHT is more compiex. LIGHT is a
ligand of HveA and lymphotoxin t receptor (LTf3R) (1,4,6) in addition to TR6. It is
expressed on the surface of activated T cells (6) and immature dendritic cells (7). Our
recent study has shown that LIGHT is expressed in resting T celis as well according to
confocal microscopy (8). LIGHT costimulates T-cell responses via HveA (7,9,10). We
have demonstrated that LIGHT, although being a ligand, also reversely transduces
costimulatory signals into T ceils (8, 11). Moreover, LIGHT induces apoptosis in ceils
expressing both HveA and LTj3R (12), or LT3R alone (13). Soluble TR6 biocks the two
way costimulation between HveA and LIGHT among T celis (1), while TR6 on solid
phase costimulates T celis via LIGHT reverse signaling (8, 11). TR6 can modulate
dendritic celi maturation (14), whether this effect occurs via LIGHT reverse signaling
remains a matter of debate. TR6 aiso blocks LIGHT-induced apoptosis of LT3R-bearing
celis (4). Sïnce LTf3R is not expressed on lymphocytes, such an effect does flot have
significant relevance in the immune system. The third TR6 ligand, TL1A, is
predominantly expressed on endothelial ceils (5). TL1A is also a ligand of DR3 and can
enhance T-cell alloresponses via DR3 in vivo (5). TR6 strongly inhibits TLYA
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augmented T-cell proliferation and lymphokine secretion, and also inhibit TL1A-
riggered tumor ce!! apoptosis (5).
TR6 mRNA and protein are detectable in some malignant tumors (15). The inhibition of
apoptosis and repression of T ceil costimulation obviously represent plausible
mechanisms for TR6-secreting tumors to gain survival advantage by avoiding apoptosis
and evading immune surveillance. In this study, we discovered yet another function of
TR6 in the immune system. We demonstrated that TR6 inhibited T-cell chemotaxis both
in vitro and in vivo, and such an effect was probab!y mediated by reverse signaling
through LIGHT. A cascade of signaling and effector events such as Cdc42 activation,
p38 mitogen-activated protein kinase (MAPK) activation, actin po!ymenzation and
pseudopodium formation in CXCL12/stromal cell-derived factor lcx (SDF-la)
stimulated T celis was inhibited by TR6 pretreatment. The physiological significance of
these findings is discussed.
MATERIALS AND METHODS
Recombinant prote ins and mAb
The recombinant proteins, i.e., TR6 fused with Fc (TR6-Fc), HveA fused with Fc
(HveA-Fc), and TR11/GITR fused with Fc (TRi 1-Fc), was descnbed in our previous
publication (1). Because TRi 1-Fc had no effect on T-cell migration, compared with PBS
or normal human IgG, it was used as a control protein for TR6-Fc. The Fc sequence in
the recombinant protein was mutated, so that it did not bind to FeR on the ceil surface.
The endotoxin levels in ail the recombinant proteins were below 10 endotoxin units/mg
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(1). Human mAb against LIGHT was described in our earlier publication (8).
Preparation and culture ofhwnan T ceils and mouse spleen ceils
Aduit PBMC were prepared by Lymphoprep gradient (Nycomed, Oslo, Norway), and T
cells were prepared from PBMC by negative selection (deletion of ceils positive for
CD1Ïb, CDI6, CD19, CD36 and CD56) with magnetic beads (Miltenyi, Auburn, CA)
according to the manufacturer’s instructions. Blood samples from different donors were
used to prepare T ceils for repeated experiments. Mouse total spleen ceils were prepared
by lysing RBC with 0.84% NH4C1 among the ceils flushed out from the spleen. The cells
were cultured in serum-free medium.
In vitro T-cell migration assay
In vitro migration assays were performed in Transwell chambers (6.5-mm in diameter, 5
JLm-pore size; Costar Corp., Cambridge, MA). The lower chamber contained 600 tI
serum-free medium in the presence of CXCL12/SDF-la (80 ng/ml) or CCL21 (400
ng/ml; both from R & D Systems, Minneapolis, MN). The upper chamber held 100 jil
serum-frec medium containing 0.3 x 106 T ceils pretreated (16 h preincubation) with
TR6-Fc, a control fusion protein, TRi 1-Fc (both at 20 j.tg/ml), or a p38 MAPK inhibitor,
SB203580, or its nonfunctional structural analog, SB202474 (both at 5 RM). In some
experiments, cross-linked human anti-LIGHT mAb was also used: the celis were
preincubated with anti-LIGHT mAb (clone 1.2.2, 20 ig/ml) along with goat anti-human
IgG (10 ig/ml). The Transwell ensemble was then incubated at 37°C for 2 h, and T celis
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migrating into the lower chamber were counted by flow cytometry. Ail the samples were
in duplicate.
Ftow cytometry
For F-actin staining, 1 x 106T celis from PBMC were incubated with CXCLY2/SDF-1Œ
for 1 min at 37°C, and then fixed with 3.7% formalin for 30 min at room temperature.
The celis were stained with Alexa Fluor-488-conjugated phalloidin (Molecular Probes,
Eugene, OR). For CXCR4 staining, T celis were first stained with biotinylated anti
human CXCR4 (clone 44716.111, R & D Systems), followed by streptavidin-conjugated
Alexa Fluor-48$ (Molecular Probes). For CD69 staining, T ceils were stained with PE
conjugated anti-CD69 mAb (clone FN5O, BD PharMingen, Mississauga, Ontario,
Canada). Mouse pentoneal exodus celis (PEC), including CFSE (Molecular Probes)
labeled ceils, were stained with PE-conjugated anti-CD3 mAb (clone 2C11). The celis
were analyzed with a Coulter Epics-XL flow cytometer (Coulter, St.-Laurent, Quebec,
Canada).
In vivo T-celt migration assay
BALB/c spleen celis were incubated ovemight with serum-free medium contaïning
TR6-Fc or TR11-Fc (both at 20 tgJml). The ceils were then labeled with CFSE (5 tM)
for 10 min at room temperature. After washing, 6 x labeled cells in 0.2 ml FLBSS
were injected i.v. into the tau vein of a BALB/c mouse, and 1 tg of CXCL12/SDF-ldn
2 ml PBS was injected i.p. 2 h later. The mice were sacrificed after another 20 h. Their
peritoneal cavities were rinsed with $ ml PBS, and PEC in PBS were analyzed by flow
cytometry for total cell number, total CD3 celi number, and CD3CSFE ceil number.
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For each experiment, three mice were used in each group, and three independent assays
were perfotmed.
Confocat microscopy
Human T celis were cultured ovemight in the presence of TR6-Fc or a control protein
Fc (TRY1-Fc, both at 20 j.gIm1). These ceils were then stimulated with CXCLI2/SDF-
la (80 nglml) for 1 min at 37°C, and fixed with 3.7% formalin for 30 min at room
temperature. They were stained with Alexa Fluor-488-conjugated phalloidin (Molecular
Probes) for 30 min on ice, and mounted on siides with Prolong Anti-fade Mounting
Medium (Molecular Probes) for examination by confocal microscopy. Digital images
were processed with Photoshop (Adobe, Seattie, WA).
Inununobtotting
Human T celis were cultured ovemight in serum-free medium in 12-well plates at 5 x
106 cells/well in the presence of TR6-Fc or TRi l-Fc (both at 20 jtg/m1). After washing,
the ceils were stimulated with SDF-ia ($0 nglml) in serum-free medium at 37°C for 10
min. The remainder of the immunoblotting procedure was detailed in our previous
publication (16). Briefly, the ceils were washed, and lysed in lysis buffer for 10 mm; the
cleared lysates were resolved by 10% SDS-PAGE. The proteins were then transferred to
Immobilon-P (Millipore, Bedford, MA) membranes, which were sequentially hybridized
with rabbit anti-phospho-p3$ MAPK and anti-p38 MAPK Ab (New England Biolabs,
Mississauga, Ontario, Canada). Immunoreactive protein bands were visualized by HRP
conjugated goat anti-rabbit IgG, followed by ECL.
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Rac-] and Cdc42 ctctivitv assavs
Twenty-rnillion T celis were preincubated ovemight with TR6-Fc or TRII-Fc (both at
20 .tg/m1). After washing, the celis were stimulated with CXCL12/SDF-la (80 nglml)
for 5 min at 37°C. The celis were lysed, Rac-1 and Cdc42 activity in the lysates were
measured by PAK-1 pull-down assays (Upstate Biotech, Lake Placid, NY), according to
the manufacturer’s instructions. Bnefly, GTP-Ioaded active Rac-1 and Cdc42 were
precipitated with PAK-1 PBD-conjugated agarose beads, and resolved in 12% SDS
PAGE. They were then detected with mouse mAb anti-Rac-1 and Cdc42, respectively in
immunoblotting.
RESULTS
TR6 inhibits T ceil chernotaxis in vitro
In the course of our study into TR6’s effect on T celis, we noticed that TR6-treated T
celis presented an altered morphology upon mitogen stimulation. This prompted us to
examine whether T-cell mobility was affected by TR6. T celis from PBMC were
pretreated with TR6-Fc or a control fusion protein TR11-Fc overnight in semm-free
medium, and then Ioaded in the upper Transwell chamber. A chemokine CXCL12/SDF-
la, which is known to induce T-cell chemotaxis, was added to the bottom chamber at
different concentrations. T ceils were allowed to migrate for 2 h at 37°C. As illustrated
in Figure lA, CXCL12/SDf-la dose-dependently induced T-cell migration into the
lower chamber. At 80 nglml CXCL12/SDF-Ïa, T celis precultured in plain medium or
in the presence of TRi l-Fc showed similar migration rates, but those precultured in the
presence of TR6-Fc manifested a significantly reduced rate. Decreased migration of
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TR6-precultured T ceils was also observed with CXCLI2/SDF-IŒ at 20 ng/rnl and 5
ng/ml (p<0.01 for ail the 3 concentrations, one-way ANOVA variance analysis
foiiowed by Tukey muitiple-comparisons test).
The reduced migration rate was flot due to the toxic effects of TR6 pretreatment. The
viability of TR6-Fc or TRi 1-Fc precultured T ceils, according to trypan blue dye
exclusion, was simiiarly between 90% and 95% (data flot shown). To further prove this
point, T ceiis precuitured in the presence of TR6-Fc or TR11-Fc, or precultured in plain
medium for 24 h, were washed, and restimulated with soluble anti-CD3 (0.2 jiglml).
After additional culture for 16 h, ail the ceils were gated and analyzed for their
expression of a T ceii activation marker CD69. As seen in Figure lB, CD69 expression
in ail anti-CD3-stimulated groups was increased drasticaiiy, compared to ceils without
stimulation (medium (Med) 24-40h), but there was no statistical difference among ceils
pretreated with plain medium, TRi l-Fc or TR6-Fc (p>O.O5, one-way variance analysis
followed by Tukey test for 2 by 2 companson of ail groups). This indicates that
precultunng with TR6-Fc did flot affect T-cell viabiiity. Was the inhibited migration due
to repression of CXCL12/SDF-la receptor CXCR4 expression on TR6-Fc treated T
celis? Approximateiy 40% of fresh T celis expressed low intensity CXCR4 (Figure 1C).
After ovemight culture in plain medium, CXCR4 celis increased to 90% with a
concomitant rise in CXCR4 intensity. T ceils treated with either TR6-fc or TRi l-Fc
showed simiiar up-reguiation of CXCR4 as T celis cultured in plain medium Fc (p>O.O5,
one way variance analysis followed by Tukey test for 2 by 2 comparison of ail groups),
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indicating that TR6-Fc treatment did flot affect CXCR4 expression. This resuit also
confirms that T ccli viabiiity was flot impaired by TR6-Fc pretreatment.
The efJct ofTR6 on T cett migration was likety mediated by LIGHT
TR6 can bind to FasL and LIGHT, both of which are expressed on T ceils. Our recent
study revealed that TR6 is capable of triggeiing reverse signaling through LIGHT and
such an effect resuits in T-ceÏl costimulation (8, 11). We investigated here whether the
inhibition of T-cell migration by TR6 involved LIGHT. For this purpose, human anti-
LIGHT mAb was crosslinked by goat anti-human IgG in solution (human anti-LIGHT
mAb at 20 tg/ml and goat anti-human IgG at 10 tg/ml were added to the culture at the
same time), and was used in place of TR6-Fc during preincubation. As shown in Figure
2A, crosslinked anti-LIGHT mAb pretreatment also suppressed T-cell migration in
response to CXCL12/SDF-la in the Transwell assay, compared with crosslinked normal
human IgG as a control (p<O.Ol, one-way ANOVA variance analysis followed by Tukey
multiple-compansons test). This suggests that such an effect involves LIGHT.
To further prove the involvement of LIGHT, HveA, which binds to LIGHT but flot to
FasL (6), was used to pretreat the T cells. As shown in Figure 2B, when HveA-Fc was
used in solution to pretreat the T celis, it could inhibit T-cell migration provoked by
CXCL12ISDF-la (p<O.001, one-way ANOVA variance analysis followed by Tukey
muhiple-comparisons test), similar to TR6-Fc. This suggests that LIGHT is implicated
in the process.
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To understand whether such inhibition was due to TR6-treggered reverse signaling
through LIGHT, or due to disruption of existing interaction between LIGHT and HveA,
we used solid phase anti-LIGHT mAb, TR6-Fc or HveA-fc to condition the T ceils. As
shown in Figure 2C, when T ceils were cultured in well coated with these reagents, their
subsequent migration towards CXCL12/SDf-la in the Transwell assay were
significantly reduced (p<O.Ol for ail three reagents, one-way ANOVA variance analysis
followed by Tukey multiple-comparisons test)
The amount of reagents coated on the wells was minute, and there were unlikely
sufficient molecules to ieak from solid phase into solution to block the LIGHT and
HveA interaction. This was proved as follows. Media were put in wells coated with
TR6-Fc, HveA-Fc, aLIGHT mAb or control normal human IgG for 24 h, and these
conditioned media were then used to culture T ceils ovemight. However, as shown in
figure 2D, T celis cultured in these conditioned media had no difference in their
migration capability towards CXCL12/SDF-la (p>O.00l, one-way ANOVA variance
anal ysis followed by Tukey multiple-comparisons test). This confirms that the
ïnhibitory effect seen with solid phase TR6-Fc, HveA-Fc and anti-LIGHT mAb is not
due to leaching of these molecules from the solid phase and suggests that that TR6
triggers reverse signaling through LIGHT on the T-cell surface, and results in
compromised T-cell migration.
The observed migration inhibition by TR6-Fc and HveA-Fc was not due to
contaminating endotoxin in the protein preparation, because their inhibitory effect could
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be destroyed by 5-min boiling (Figure 23; p>0.05 for boiled TR6-Fc vs. medium and for
boiled HveA-Fc vs medium, one-way ANOVA variance analysis followed by Tukey
multiple-compansons test). To assess whether TR6 affected the general mobility of T
ceils and the observed effect was only restricted to CXCLÏ2/SDF-la stimulation, we
testcd the T-cell response to another chemokine, CCL2I. After incubation with TR6-Fc
but not with a control fusion protein (TRi 1-Fc), T celis showed a significantly reduced
migration rate towards CCL21 in the Transwell assay (Figure 2E; p<0.Oi, one-way
ANOVA variance analysis followed by Tukey multiple-comparisons test). Therefore, it
seems that TR6 pretreatment inhibited the general mobility of T cells.
TR6 inhibits T-cell cÏzemotaxis in vivo
To confirm that the observed inhibitory effect of TR6 on T-cell migration in vitro had
physiological relevance, we established an in vivo T-cell chemotaxis model. BALB/c
spleen celis were first precultured ovemight in the presence of TR6-Fc or TR11-Fc, and
then labeled with CFSE. The labeled cells were injected i.v. into syngeneic BALB/c
mice. Two hours later, CXCL12/SDF-la was injected i.p. After another 20 h, PEC were
analyzed for their total number, total T-cell number, total CFSE-labeÏed T-cell number,
and percentage of CFSE-labeled T celis among total T cells. As shown in Fig 3,
CXCL12/SDF-1Œ injection into the pentoneal cavities resulted in a drastic increase of
total PEC and T cells in PEC (Figures 3A and 3B). There was no significant difference
in these parameters in mice that received TR6-Fc-, TR11-Fc- or plain medium
precultured celis (p>O.O5, one-way ANOVA variance analysis followed by Tukey
multiple-comparisons test), reflecting the fact that the majonty of the exodus cells were
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of host ongin (as CFSE-labeled donor celis showed difference, to be elaborated below).
When CFSE-labelcd exodus T ceils were analyzed, there was a significant decrease in
their number in mice receiving celis pretreated with TR6-Fc compared with mice
receiving ceils pretreated with TRÏ1-Fc or plain medium (Figure 3C; p<O.00Y, one-way
ANOVA variance analysis followed by Tukey multiple-compansons test). Such a
reduction in T-cell number was also reflected in the percentage abatement of CFSE
labeled T celis among total exodus T ceils (figure 3D; p<OEOOt, one-way ANOVA
variance analysis followed by Tukey multiple-compansons test), because the number of
the latter remained similar in mice receiving spleen celis with the different treatments
(Figure 3B). These data showed the in vivo relevance of compromised T-cell chemotaxis
after exposure to TR6.
TR6 pretreatment of T celÏs represses their actin potyrnerization upon CXCL]2/SDF-]a
stimulation
T-cell chemotaxis depends on cytoskeleton reorganization, for which actin
polymerization plays an essential role. We, therefore, examined actin polymerization
upon SDf-Ïa stimulation in T ceils with or without TR6 pretreatment. The f-actin
staining of T celis precultured in plain medium without subsequent CXCL12/SDF-1Œ
stimulation was considered as background (0% positive, Figure 4A). When such ceils
were stimulated by CXCL12/SDF-la for 1 mm, 65.9% of them became F-actin positive.
Preculturing the ceils in the presence of TRi 1-Fc ovemight had no apparent effect on
actin polymerization upon subsequent CXCL12/SDF-la stimulation, and 65% of the
ceils were positive for F-actin staining. However, ovemight TR6-Fc pretreatment
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significantly reduced F-actin-positive celis to 29.4% (p<O.Ol, one way variance analysis
followed by Tukey test for 2 by 2 comparison of ail groups). This resuit shows that TR6
conditioning of T celis leads to compromised actin polymerization.
Consistent with the status of actin polymerization, CXCL12/SDF-larapidly (with in 1
mm) induced pseudopodium formation in T ceils (Fig. 4B, companng upper left panel
with upper nght panel; quantitative assessment of fig. 4B is shown as a bar graph in
Figure 4C). T celis cultured ovemight in medium or TRi 1-Fc had similar degree of
pseudopodium formation upon CXCLY2/SDF-Ïa stimulation (Fig, 4B, upper right panel
vs lower left panel), but TR6-Fc pretreatment of the celis significantly inhibited this
process (lower left panel versus lower right panel; p<O.001, one-way ANOVA variance
analysis followed by Tukey multiple-comparisons test). Thus, it appears that T celis
receivïng TR6 preconditioning have modified signaling pathways that lead to
compromised actin polymerization, pseudopodium formation, and, eventuafly,
chemotaxi s.
TR6 pretreatrnent of T ceÏts compromises p38 MAPK activation
p38 MAPK is an upstream signaling molecule essential for actin polymerization (17). Its
activity in TR6-treated T celis was investigated. T celis were precultured ovemight in
the absence (Med) or presence of TR6-Fc or TRi 1-fc. The cells were washed and
stimulated with 80 ng/ml CXCL12/SDF-la for 10 min. p38 MAPK tyrosine
phosphorylation, which represents p38 MAPK activation, and total p38 MAPK in these
ceils were assessed by immunoblotting. As shown in Fig. 5A, CXCL12/SDF-1o
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stimulation resulted in similar up-regulation of p38 MAPK tyrosine phosphorylation in
T celis precultured in plain medium or in the presence of TRI1-Fc. However,
preculturing in the presence of TR6-Fc prevented such up-regulation.
To ascertain that p38 MAPK activation was a relevant event that controlled T-cell
chemotaxis upon CXCL12/SDF-la stimulation, T ceils were treated with a p38 MAPK
specific inhibitor, SB20358 (5 iiM), for 2 h and then evaluated for their chemotaxis by
the Transwell assay. The p38 MAPK inhibitor but not its nonfunctional structural
analog, SB202474, suppressed the T-cell chemotaxis upon CXCL12/SDF-la
stimulation (Fig. 5B), as expected, indicating that the compromised p38 MAPK
activation in TR6-treated T celis is relevant and responsible for T-cetl chemotaxis
inhibition.
Compromised Cdc42 activation in T cetis pretreated with TR6-Fc
Small G proteins Rac-1 and Cdc42, which are signaling molecues upstream of p38
MAPK, are important in cytoskeleton reorganization, which in turn controls
pseudopodium formation and celi mobility (18). The activity of Rac-1 and Cdc42 of
TR6-treated T celis was examined using PAK-1 pull-down assay. T celis were
preincubated overnight in the presence of TR6-Fc or TR-1 1-Fc, and then stimulated with
CXCL12/SDF-la for 5 min. The activated GTP-associated Rac-1 or Cdc42 was putled
down using solid phase (agarose beads) PAK-1, which is a substrate of and binds to
GTP-associated Rac-1 and Cdc42. As shown in Fig. 6, Rac-1 activation, which was
reflected by the levels of GTP-associated Rac-1, was flot modulated by SDF-1
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stimulation; TRI 1-Fc or TR6-fc pretreatment did flot affect its activity. In contrast,
Cdc42 was rapidly activated by CXCLI2/SDF-la; TR6-Fc but flot control TRi 1-Fc
pretreatment prevented its activation. The selective inhibition of Cdc42 activation,
which is important in filopodium formation (18), by TR6 thus represents a plausible
mechanism for the repressive effect of TR6 on T-cell chemotaxis.
DISCUSSION
In this study, we showed for the first time that TR6 could inhibit T-cell chemotaxis both
in vitro and in vivo. Mechanïstically, such an effect was likely mediated by reverse
signaling from TR6 to LIGHT on the T-cell surface. T cells treated with TR6 failed to
mobilize the signaling pathway leading from Cdc42 to p38 MAPK to actin
polymerization, upon encountering CXCL 1 2ISDF-1 c.
There are two possible mechanisms to explain the T-cell migration inhibition caused by
TR6. In the first possible mechanism, constitutive interaction between LIGHT and HveA
on T cells promotes T-cell mobility; soluble TR6-Fc, anti-LIGHT mAb or HveA-Fc
interferes with such interaction, and leads to inhibited T-cell mobility. To examine
plausibility 0f this mechanism, we coated TR6-Fc, anti-LIGHT mAb or HveA-Fc on
solid phase. In this case, only a minute amount of those molecules were actually
adsorbed to the plate surface, and there were unlikely sufficient molecules leaking into
the solution to block the LIGHT and HveA interaction (indeed, media conditioned in
TR6-Fc-, anti-LIGHT mAb- or HveA-fc-coated wells had no effect on T-cell
migration). Moreover, these molecules fixed on a flat surface would probably not be
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able to interfere with the three dimensional interaction between LIGHT and HveA on the
celi surface. We showed that thosc solid phase molecules could stiil inhibit T-cell
chemotaxis, suggesting that this first mechanism does flot seern plausible.
The second possible mechanism dictates that TR6 triggers a negative signal reversely
transmitted through a TNF family member(s) on the ceil surface, most likely through
LIGHT, and such signaling results in reduced T-cell mobility. There are a couple of
lines of evidence supporting this mechanism. First, we have recently proved that TR6
can transduce costimulation signals reversely via LIGHT into T celis (8, 11); such
reverse signaling is not entirely out of norm and has been reported for several other TNF
family members, e.g., CD4OL (19), CD3OL (20), TNF-Œ (21), TRANCE (22), FasL (23)
and TRAIt (24). Second, when TR6-Fc, anti-LIGHT mAb or HveA-Fc was put on solid
phase, they could also inhibit T-cell chemotaxis, as descnbed above, likely by
crosslinldng their binding partners on the T-cell surface. These data strongly suggest that
the second mechanism is in operation. If so, how do we explain that TR6-Fc, HveA-Fc
and anti-LIGHT mAb in solution could inhibit T-cell chemotaxis? It is possible that a
low-degree of crosslinking by the bivalent TR6-Fc or HveA-Fc, or their aggregates, is
enough to tngger reverse signaling. For the anti-LIGHT mAb in solution, it was only
effective after being crosslinked by anti-human IgG, and without crosslinking, the mAb
was flot effective in solution (data not shown), suggesting the necessity of LIGHT
crosslinking for the T-cell migration inhibition.
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TR6 could in theory reversely signal through LIGHT or FasL to achieve its effect in
chemotaxis inhibition. Which one mediates such an effect of TR6? Our following
observation is worth mentioning in this regard. 1) HveA-Fc, which binds to LIGHT but
flot FasL, had a similar effect as TR6-Fc (Fig. 2, B and C), suggesting that the effect
could be achieved through LIGHT without FasL. 2) Anti-LIGHT mAb could inhibit T
ceil migration (Fig. 2, A and C), further suggesting that LIGHT mediated the effect. 3)
LIGHT is expressed on resting T ceils as we demonstrated before (8), and this provides
a basis for TR6 to act on resting T cells. 4) The binding of TR6-Fc to T ceils was
predominately through LIGHT, because TR6-Fc could associated with > 80 % wild-type
T celis, and only with < 20% LIGHT’ T ceils (data flot shown). Taking together, these
data suggest that LIGHT but flot FasL is the main mediator for the observed effect of
TR6 in chemotaxis inhibition. With that said, we cannot totally exciude the possibility
that reverse signaling through FasL, or maybe some so far unidentified TR6-binding
partner on the T-cell surface, contribute to a lesser extent to the observed T-cell
chemotaxis inhibition by TR6. In this regard, it is worth mentioning that soluble TR6
have been shown to suppress soluble FasL-induced chemotaxis of microglial ceils in
Transwell assay (25). In that system, the proposed mechanism is the blockage of forward
signaling from FasL to Fas on microglial celi surface by soluble TR6. However, it wiÏl
be interesting to know whether such inhibition is the resuit of the general decrease of
ceil mobility by TR6 treatment.
We have identified signaling alternation in T ceils treated with TR6. Selective change
was revealed in one of the small GTPases, Cdc42, known to be essential in filopodium
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formation (18). This was foilowed by inability of p38 MAPK activation, which is
essentiai for actin polymebzation. Largely remaining unknown is how signais are
initiated from LIGHT in the first place. LIGHT has a short featureiess cytopiasmic tau
(6), and certainiy has no signaling capability by itseif. It is reasonable to hypothesize
that signaling from LIGHT depends on the adaptor molecules it associates with and such
a hypothesis is under investigation.
TR6 is secreted by several kinds of tumors (15). In addition to its effect of biocking Fas
mediated apoptosis of tumor cells (15) and interfenng with the two-way T ceil
costimulation mediated by HveA and LIGHT, TR6 now has a newly found function:
inhibition of T-cell chemotaxis. Consistent with this finding, in the rat glioma with
forced expression of exogenous TR6, tumor-infiltrating T celis are significantly reduced
compared with tumors without TR6 expression (25); ouf additionai study discovered that
serum TR6 levels of gastric cancer patients were ïnversely correlated to degree of
lymphocyte infiltration in their tumor mass (data flot shown). Therefore, T-cell
chemotaxis inhibition seems to be an additional strategy TR6-secreting tumors employ
to evade immune surveillance by keeping potential tumor-infiltrating T cells at bay.
Although tumors might deploy TR6 to promote their survival, TR6 could also be used
for a good cause. We previousiy demonstrated, in a mouse heart transplantation model,
that TR6 administration results in proionged heart ailograft survival (1). Such a
beneficial effect was initially explained by inhibition of LIGHT to HveA forward
costimulation (1), and later by inhibition of the two-way costimulation between HveA
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and LIGHT on T celis by TR6 (1,8). Obviously, our current finding provides an
additional mechanism to explain the prolonged graft survival. Under the influence of
TR6, alloresponsive T ceils have reduced chemotaxis towards the allograft or its
draining lymphoid organs and this will repress T-cell activation, which eventually
translates into reduced graft rejection force. Such a property of TR6 could be exploited
in the future to repress local or systemic immune responses.
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incubation at 37°C, cells in the lower chamber were collected and counted by flow
cytometry. Samples were in duplicate in each experiment. Means ± SD of four
measurements from two independent experiments are shown. The asterisks indicate
highly significant differences (p <0.01, one-way ANOVA followed by Tukey’s multiple
compansons test) between TR6-fc- and control TRi 1-Fc-treated samples.
B. T celÏs pretreated with TR6-fc can be normatly activated by mitogens
T ceils were pretreated with medium (Mcd), TR11-Fc, or TR6-Fc for 24 h and then
stimulated overnight further (24—40 h) with or without soluble anti-CD3 (0.2 gIml), as
indicated. At 40 h after the initiation of culture, the expression of a T ceil activation
marker, CD69, was analyzed with flow cytometry. The expenments were performed
three times, and histograms of a representative experiment with percentages of CD69-
positive T ceils are shown. The percentage of CD69-positive celis in the second, third,
and fourth panels has no statistical difference according to pooled data from three
independent experiments (p > 0.05, one-way ANOVA analysis followed by Tukey’s test
for 2 X 2 comparison on ail groups).
C. TR6 pretreatment does not affect the expression of the cXcL]2/SDF-1 a receptor
CXCR4
Fresh T celis or T celis cultured in the absence (Mcd) or presence of TRi 1-Fc or TR6-Fc
ovemight were stained with fITC-conjugated anti-CXCR4 mAb. Percentages of
CXCR4-positive celis are indicated. The experiments were performed three times and a
representative set of data is shown. The percentage of CXCR4-positive cells in second,
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third, andfottrth panels has no statistical difference according to pooled data from three
independent experiments (p > 0.05, one-way ANOVA followed by Tukey’s test for 2 X 2
comparisons on ail groups).
Figure 2. Chentotaxis inhibition by TR6 is ntediated by LIGHT and is ïtot spectjïc to
CXCLJ2/SDF-1 a
Samples were in duplicate in each experiment and the experiment was performed twice.
Means ± SD of four measurements from two independent experiments are shown. The
asterisks indicate highly signïficant differences (p <0.01, one-way ANOVA followed by
Tukey’s multiple comparisons test) between the test group (treated with anti-LIGHT
mAb, HveA-Fc, or TR6-Fc) and control normal human IgG (NhIgG)-treated samples.
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A. Crosslinkecl anti-LIGHT inAb in soltttion inÏzibits T-cell cÏze,notaxis
T celis were cultured ovemight in the absence (Med) or presence of human anti-LIGHT
mAb (20 gIml) plus goat anti-human IgG (10 [tgIml), and chemotaxis of these ceils
toward CXCLI2/SDF-la ($0 nglml) was tested by the Transwell assay as described in
fig. lA. Normal human IgG was similarly cross-linked by goat anti-human IgG and was
used as control.
B. Soluble HveA-Fc inhibits T-cell cheinotaxis similar to TR6-Fc, and these proteins tost
theirfunction afler heat inactivation
T ceils were cultured ovemight in the absence or presence of soluble HveA-Fc or TR6-
Fc (both at 20 tLgIml). In some samples, HveA-Fc and TR6-Fc were heat inactivated for
5 min at 100°C before use. Chemotaxis of the treated T cells toward CXCL12/SDF-la
($0 nglml) was assayed by the TransweÏl assay..
C. Solid phase TR6-Fc, HveA-Fc and anti-LIGHT mAb inhibit T-cetÏ Chemotaxis
TR6-Fc, HveA-fc, anti-LIGHT mAb or normal human IgG were coated on wells at 1
igI100 d/we1l ovemight at 4°C and the wells were then washed. T ceils were cultured
in these precoated wells ovemight and then used in the Transwell assay using
CXCL12ISDF-la (80 ng/mI) in the lower chamber.
D. Media conditioned in TR6-Fc-, HveA-Fc, or anti-LIGHT mAb-coated wells had no
effect in T celt migration toward cXCLJ2/SDF-la.
Complete medium was incubated in TR6-Fc-, HveA-Fc-, or anti-LIGHT mAb-coated
wells for 24 h, The media were harvested and used to culture T celis in uncoated wells
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ovemight. The celis were then used in Transwell assay using CXCL12/SDF-lcr (80
nglml) in the lower chamber.
E, TR6-fc preculturing inhibits T cett chemotaxis toward CCL2].
T celis were cultured ovemight in the absence (Mcd) or presence of soluble TR6-Fc or
TRi i-Fc (both at 20 .tgIm1) as indicated. Chemotaxis cf these ceils toward CCL21 (400
ng/ml) in the lower chamber was examined by the Transwell assay as described in Fig.
lA.
figure 3. TR6-fc inhibits mouse T cett chemotaxis in vivo
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BALB/c spleen celis were cultured overnight in medium (Med) or in the presence of
TR6-Fc or TRi l-Fc (both at 20 gIml). The celis were then labeled with CFSE for 10
min at room temperature and injected i.v. into BALB/c mice. After 2 h, 1 tig of
CXCL12/SDF-la was administered i.p. The mice were sacrificed after another 20 h, and
their total PEC (A), the percentages of total T celis among total PEC (B), CfSE-labeled
peritoneal exudate T celis (C), and percentages of CFSE-labeled T cetis among total
peritoneal exudate T ceils (D) were analyzed. Each group consisted of three mice;
similar resuits were obtained from three independent experiments; and a set of
representative data is presented. PBS: mice receiving CSFE-labeled spleen ceils cultured
in medium alone without subsequent CXCL12/SDF-la but with PBS administration;
Med—,CXCLI2: mice receiving CFSE-labeled spleen ceils precultured in medium,
followed by CXCL12 injection (1 igImouse) i.p; TR11-Fc—,CXCL12: mice receiving
CFSE-labeled spleen celis precultured in the presence of soluble TRi 1-fc (20 g/ml),
followed by CXCL21 injection i.p.; TR6-Fc—CXCL21: mice receiving CFSE-labeled
spleen cells precultured in the presence of TR6-Fc (20 gIml), followed by CXCL12
injection i.p.
Figure 4. TR6-Fc inhibits cXcLl2/SDF-1 a-i,zduced T-cett actin potymerization and
pseudopodium formation
Human T celis were cultured overnight in the absence (Med overnight (ON)) or presence
ofTRll-Fc (TR11-fc ON) or TR6-Fc (TR6-Fc ON) (both at 20 gIm1). After washing,
the ceils were incubated with CXCL21/SDF-la (80 nglml) for 1 mm, stained with Alexa
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Fluor-488-conjugated phalloidin and analyzed by flow cytometry as well as confocal
microscopy.
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A. Flow cytometry analysis ofF-actin
F-actin staining of T ceils cultured ovemight in medium without subsequent
CXCL12/SDF-lû simulation was used as a negative control, with its F-actin intensity set
at 0%. Percentages of F-actin-positive ceils among ceils with different treatments, as
indicated, are shown. The experiments were performed three times and a set of
representative histograms are presented. The percentage of F-actin-positive celis in
panel 4 is significantly Iower than that of panels 2 and 3 according to pooled data from
the three independent experiments (p < 0.01, one-way ANOVA followed by Tukey’s
test for 2 X 2 comparisons on all groups).
4 C7O4/%
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B. ConJcaÏ inicroscopv of T-cet! actin potvmerization anci morpÏzologv
The same set of T celis as described in A was examined with confocal microscopy. The
pseudopodium formation in celis precultured in medium or TRi 1-Fc was similar upon
SDF-1 a stimulation (ttpper right panel vs lower teft panel, respectively), but
preculturing ceil in the presence of TR6-Fc reduced pseudopodium formation compared
with ceil pretreated with TR11-Fc (tower lefi panel vs lower rigÏzt panel). The
experiments were performed three times and a set of representative data is presented.
C. Quantitative assessrnent of T-celÏ pseudopodium formation
The ceils in B were quantified for pseudopodium-positive celis. Three view fields
(containing i00 celÏs/field) per sample were examined, and the means ± SD of the
percentages of pseudopodium-positive celis among total ceils are indicated. The asterisk
indicates a highly significant difference between the test group and the TRi 1-fc control
(p < 0.0 1, one-way ANOVA followed by Tukey’s test for 2 X 2 comparison on ah
groups). The experiment was performed twice and pooled data from the two independent
experiments are shown.
figure 5. Compromise of p38 MAPK activation by TR6 treatment resutted in
chemotaxis inhibition
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A. Immunoblotting of activated and total p38 MAPK
Human T celis were cultured ovemight in the absence (Mcd) or presence of TRi 1-Fc or
TR6-Fc (both at 20 igIml). After washing, the ceils were stimulated for 10 min with
CXCL12/SDF-la ($0 nglml). The ceil lysates were resolved in 10% SDS-PAGE and
blotted membranes were sequentially hybridized with anti-phospho-p3$ MAPK and
anti-total p38 MAPK. Anows indicate 38-kDa phospho-p38 MAPK and total p38
MAPK. The expenments were performed three times and a set of representative data is
presented.
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+
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B. p38 MAPK inhibitor represses CXCL]2/SDF-] a-induced T-cell chemotcLïis in
Transwell assav
Human T ceils were cultured in serum-free medium for 2 h in the presence of 5 tM p38
MAPK inhibitor SB2035$0 or its nonfunctional structural analog SB202474. After
washing, the Transwell assay was performed as described in Fig. lA.
figure 6. TR6 inhibits Cdc42 activation in T cetts
Adfivated Rac 1
—
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—
—
—
—
5% Input Cdc 42—* —
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TR11-Fc
-
- ±
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CXCLL2
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T celis were precultured ovemight in serum-free medium or in the presence of TR6-Fc
or a control fusion protein TR11-Fc (both at 20 tgIml) and were then stimulated with
CXCL12/SDF-la (80 nglml) for 5 min. The activated GTP-binding Rac-1 and Cdc42
was absorbed by PAK-1 PBD-conjugated agarose beads and resolved in 12% SDS
PAGE. Rac-1 and Cdc42 were then detected with anti-Rac-1 and Cdc42 mAbs,
respectively, in immunoblotting. Five percent of the input lysates were examined to
confirm similar Ïevels of total Cdc42 in each sample. The experiments were performed
three times and a set of representative data is presented.
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Article 3.
Tumor vaccine based on ceil surface expression of DcR3tfR6
Guixiu Shi, Guang Yu, Jun Zhang and Jïangping Wu
To be pubtished in the Journal of Immunotogy; it is undergoing the second revision
to address two reinaining concerns of mie reviewer.
Note: In this paper, Guang Yu performed in vitro T celi costimulation assays, which
were presented as Figure 2B. Jun Zhang suppÏied valuable reagents, such as LIGHT and
TR6-Fc recombinant protein, anti-TR6 mAb, and LIGHT’ mice. Guixiu Shi carried out
ail the remaining experiments.
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ABSTRACT
DcR3/TR6, a secreted protein belonging to the TNF receptor superfamily, interacts with
LIGHT, FasL and TL1A, ail members of the TNF superfamily. Solid phase TR6 can
tngger reverse signaling of LIGHT and fasL expresscd on T ceils, and lead to T-ce!!
costimulation. In this study, we engineered tumor celis to express celi surface TR6, and
used these ceils as a tumor vaccine. We demonstrated that mastocytoma P815 celis
expressing surface TR6 (TR6-P815) effective!y augmented the T-ce!ls response in vitro
and ex vivo in terms of proliferation, as well as IL-2 and 1NF-y secretïon. TR6-P815
ceils had reduced tumorigenicity compared with parental P815 celis. When inactivated
TR6-P815 ceils were employed as a vaccine, they protected the mice from challenge
with live parental P815 ceils, and eliminated established P815 tumors. The ceil surface
TR6-based tumor vaccine was also effective against Iow antigenicity tumors, such as
B16 melanoma; co-administration of Bacillus Calmette Guenn further enhanced the
vaccine’s efficacy. Thus, ce!l surface TR6 expression is a useful addition to our tumor
vaccine arsenal.
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INTRODUCTION
DcR3/TR6 belongs to the TNF receptor superfamily (1-3). It is a secreted protein due to
the lack of transmembrane domain in its coding sequence (3). TR6 has 3 Iigands, i.e.,
FasL, LIGHT and TLÏA. As a secreted protein, it does flot transduce signais into ceils,
although it is a member of the TNF receptor family, but is capable of interfering with
the function of its ligands: TR6 can inhibit fasL-, LIGHT- and TLIA-induced apoptosis
(3-5), and LIGHT-tnggered T-ceil costimulatïon via a LIGHT receptor, HveA.
LIGHT, which beiongs to the TNF superfamiiy, It binds to three members of the TNF
receptor famiiy, i.e., HveA (6,7), LTf3R (8,9) and TR6 (3). In the immune system,
LIGHT is expressed on activated T lymphocytes, natural idiier cells (10,11), and
immature dendritic celis (12). We have demonstrated that resting T ceils also express a
considerable amount of LIGHT on their surface, but it is better detected by confocai
microscopy than by flow cytometry (13). LIGHT can induce apoptosis in ceils
expressïng both HveA and LT3R (3), or LT3R aione (14). Recent studies have shown
that LIGHT can costimulate T-cell responses via its receptor HveA in vitro and in vivo
(15). Transgenic mice overexpressing LIGHT have augmented immune responses (16),
and LIGHT knockout (KO) mice present defects in cytotoxic T-ceIl activity (15,17,18).
Taken together, these unes of evidence indicate that LIGHT acts on HveA for T-ceii
costimulation.
Certain ceil surface iigands can receive stimuli from their receptors, and transduce
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SHI 122
signais into the ceil. Such a phenomenon is termed “reverse signalling”, as in this case
the ligands function as receptors, while the receptors function as Iigands. Some
members of the TNf superfamily are capable of reverse signalling. Lanier (19) and
Gray (20) have demonstrated that CD4OL transduces costimulation signais into T celis.
Wiley (21) reported that CD3OL crossiinking activates neutrophils, and Cerutti (22)
showed that such reverse signailing inhibits 1g class switch in B ceils. Reverse
signaliing through membrane TNF-a confers resistance of monocytes and macrophages
to LPS (23). Crosslinking of TRANCE enhances WN-y secretion by activated Thi celis
(24). Reverse signalling through fasL can promote maximal proliferation of CD8
cytotoxic T ceiis (25-27). Crossiinking of TRAIL by its solid phase death receptor 4
increases IFN-y production and T-ceii proliferation (2$). In the case of CD4OL, its
ligation results in generai protein tyrosine phosphorylation, Ca influx, and Lck, PKC,
JNK and p38 MAPK activation in EM thyoma cells (29,30). TRAIL crosslinidng also
induces p38 MAPK activation (2$). Our studies proved that LIGHT can reverseiy
transduce signais into T ceils when stimulated with solid phase TR6, and such signaliing
can costimulate T celis (13,31). With these new findings on LIGHT reverse signaling,
the resuits from LIGHT transgenic and knockout mice can be reinterpreted. Increased
LIGHT reverse signaling might contribute to the augmented immune responses
observed in LIGHT transgenic mice (16); conversely, elimination of such reverse
signaiing might contnbute to the abated immune responses seen in LIGHT knockout
mice (15,17,18). Such reinterpretation does flot refute the importance of forward LIGHT
costimuiation mediated by HveA.
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Most tumors express unique antigens due to genetic alterations, or express tissue
specific antigens andlor developmental antigens owing to epigenetic effects. However,
tumor celis have strategies to evade immune surveillance: down-modulating antigen
processïng and presentation to T celis; secreting soluble factors (e.g., cytokines and
decoy receptors) to dampen or deviate immune responses; inducing T-cell tolerance
through multiple pathways (32-38). Several expenmental approaches have been
employed to enhance the immunogenicity of tumors and to break T-cell tolerance in
tumor-bearing animals or humans (38,39). One such approach is to express, on tumor
celis, costimulatory molecules, such as B7-1 (40,41), B7H (42), 4-YBBL (43), or anti-4-
1BB 1g heavy chain (44). Costimulatory molecules have also been coexpressed on
tumor celis with other immune enhancing factors, for example, B7-1 plus IL-2 (45), B7-
1 plus CD2 ligand (46), B7-1 plus B7-2 plus 4-1BB (47); this strategy can even work
for tumors with Iow antigenicity (43,48-50). Animais inoculated with such manipulated
tumor celis show retarded tumor growth and prolonged survival, compared with those
receiving wild type tumor ceils (40,42,43,51-53). When such tumor cells are used as
vaccines, they can generally protect mice from the challenge of parental wild type
tumors. In a limited number of cases, when animais are vaccinated with tumors
expressing anti-4-1BB mAb single chain (44), or inoculated with double recombinant
adenovirus expressing B7-Ï and IL-2 in the tumor mass (45), the existing tumors
manifest significant regression. These findings imply that although therapeutic
vaccination might not be effective with ail costimulating molecules, it does have in
certain cases therapeutic effects. This is important in clinical situations, in which tumor
burden ïnevitably already exists.
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We have reasoned that it is advantageous to use membrane-bound TR6 to enhance T
celi costimulation and augment tumor antigenicity because, in theory, solid phase TR6
can act on at least two reverse signaling pathways, i.e., via LIGHT and FasL, to achieve
T-cell costimulation. In this study, we engineered the surface expression of normally
soluble TR6 on tumor cells and explored their usefulness as a tumor vaccine.
MATERIALS AND METHODS
Mice and cett unes
Six- to eight-week-old female DBN2 and C57BL16 mice were purchased from Charles
River (St-Constant, Montreal, Quebec, Canada). The munne mastocytoma line P815
and the melanoma line B16-f10 were obtained from ATCC. The human 293 primary
embryonic kidney ceils were procured from Qbiogene (Carlsbad, CA, USA). The celi
unes were cultured in complete DMEM medium containing 10% FCS, L-glutamine and
antïbiotics.
Plasmid construct for celi suiface TR6 expression
The coding sequence of human TR6 minus the stop codon was retrieved by PCR and
fused with the coding sequence of the human EphB6 transmembrane domain (E591-
R621, ref. (54)) followed by a stop codon; the ensemble was cloned into pAdenoVator
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(Qbiogene) downstream of the CMV promoter. The insert and junctions were verified
by sequencing. The construct tvas named pCMV-TR6Mem.
Stable transfection oftwnor ceils with pCMV-TR6Meni
pCMV-TR6Mem and pcDNA III were introduced into P815 celis, 293 ceils and B16
ceils at a 10:1 ratio (20 ig pCMV-TR6Mem and 2 ig pcDNA per 5x106 celis) with
electroporation (350V, 960 tF). The transfected celis were then selected with $00 jig/ml
G418 for 2 weeks. The stable transfectants, named TR6-P815, TR6-293 and TR6-B16,
were used for expenments after cdl surface expression of TR6 was confirmed by flow
cytometry. The parental celis were transfected with the empty vector pAdenoVator, and
the resulting celis were named vector-293, vector-P815 and vector-B16.
Mouse and hurnan T-cett isolation and culture
Ceils were flushed from the mouse spleen, and red blood ceils were lysed with 0.84%
NH4C1, as described elsewhere (13). The resulting celis were referred to as spleen celis.
Human PBMC were prepared with density gradients using Lympholyte-H (Cedarlane,
Hornby, ON, Canada). Mouse and human T celis were punfied from spleen cells and
PBMC, respectively, with human and mouse T-celI purification columns according to
the manufacturer’s instructions (Cedarlane). In some expenments, mouse T celis were
further fractionated into CD4 and CD$ celis by magnetic bead positive selection
(Miltenyi Biotech, Auburn, CA) according to manufacturer’s instructions. The punty of
the CD4 and CD8 celis was about 97% according to llow cytometry. In other
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU SHI 126
experiments, CD4 or CD8 celis were deleted from spleen T celis with the magnetic
beads. The ceils were cultured in RPMI 1640 supplemented with 10% FCS, L-glutamine
and antibiotics. 3H-thymidine uptake was measured as described previously (13,55).
Lynzphokiize assays
IL-2, IL-4 and WN-y in culture supematants were measured with ELISA kits from R&D
Systems (Minneapolis, MN, USA) according to the manufacturers instructions.
Confocat microscopy
The binding of TR6-Fc to LIGHY’ or LIGHT’ T celis was demonstrated using
confocal microscopy, as detailed in our previous publication (13). Bnefly, spleen celis
were crosslinked with anti-CD3 and anti-CD28 for 2 mm, and the cells were stained
with Alexa-594-anti-CD3 for the TCR complex, and stained with TR6-Fc followed by
Alexa-488-anti-human IgG for TR6 binding. Three view fields from confocal
microscopy were randomly selected, and TR6-binding cefls in green and TCR positive
cells in red were counted. The percentage of TR6 celi among CD3 celis was
calculated.
Ftow cytometry
Celi surface expression of TR6 on pCMV-TR6Mem-transfected celis was assessed by
flow cytometry. The ceils were stained with rabbit anti-TR6 polyclonal Ah followed by
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PE-conjugated goat anti-rabbit Ab (Cedarlane). Propidine iodine-negative live ceils
were gated for analysis. Vector-transfected celis served as controls.
Cytotoxic T lymphocyte (CTL) assay
DBAJ2 mice (H-2”) were immunized s.c. with 1x106 mitomycin C-treated TR6-P815
celis (H2d) on days 1 and 7. On day 15, spleen celis from these immunized mice were
stimulated with mitomycin C-treated wild type P815 celis at a 1:1 ratio in 24-weli plates
(8x10614 miIweii). CTL activity of the cultured ceils was assessed 6 days later by
standard 51Cr release assay, as descnbed previousiy (13), using 51Cr-iabeied P815 ceils
(H-2’’) as targets at different effector/target ratios. The lysis percentage of the test
sample was caicuiated as foiiows:
% lysis = (cpm of the test sample - cpm of spontaneous release)/(cpm of maximal
release - cpm of spontaneous release).
Tumorigenicity and tumor challenge assays
For tumorigenicity assay, DBAJ2 mice were inoculated s.c. with 5x104 syngeneic
parental P815 celis. Tumor size was measured q. 2d until day 30 after inoculation. For
tumor challenge assays, DBAJ2 mice were vaccinated twice with lx 106 mitomycin C
treated TR6-P815 celis on days 1 and 7. On day 15, the mice were challenged with
5x104 syngeneic parental P815 celis or 5x105 SP A120 myeloma ceils (H-2’’). The
product of the iongest and shortest tumor diameters was taken as tumor size in this and
ail other experiments.
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Tïierapeutic vaccination
DBAJ2 and C57BU6 (H-2’) mice were first inoculated with 5x104 live wild type P815
ceils and 1x103 B16 (H2b) ceils, respectively on day 0. On days 3 and 8, the mice were
vaccinated with 5x106 mitomycin C-treatedTR6-P815 orTR6-B16 celis.
RESULTS
Cett surface expression ofTR6
The coding sequence cf human TR6 lacks the transmembrane domain, and
consequently, TR6 is a secreted protein. To allow TR6 to anchor on the ceil surface,
we fused the coding sequence of the human EphB6 transmembrane domain (E591-
R621) to the 3’ end of the TR6 coding sequence (Figure lA). The fused sequences
were cÏoned into pAdenoVator downstream of the CMV promoter, and the resulting
construct was named pCMV-TR6Mem. This construct was stably transfected into
human 293 embryonic kidney ceils, high antigenic P815 mouse mastocytoma ceils,
and low antigenic mouse B16 melanoma ceils.
Surface TR6 expression cf the transfectants was venfied by flow cytometry. As shown
in Figure lB, 55.8% cf 293 cells, 70.3% of P815 celis, and 68.7% of B16 celis became
ce!! surface TR6-positive after stab!e transfection, while the wild type ce!Is or celis
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transfected with control vectors remained TR6-negative. These pools cf transfected celis
without furthet cloning (to avoid selecting clones with diffet-ent antigenicity) were used
for in vitro of in vivo studies.
T-celÏ costimulation bv celi surface TR6 in vitro
We have previously demonstrated that when TR6 was placed on the solid phase of
culture wells, it was able to costimulate T cells activated with a suboptimal
concentration cf anti-CD3. To assess whether this feature of TR6 could serve as a tumor
vaccine, we first tested in vitro whether ceIl surface TR6 could similarly costimulate T
cells. When human T celis were stimulated with mitomycin-C treated parental or control
vector-transfected allogeneic 293 lddney ceils, little proliferation was detected from
days 3 to 5 (Figure 2A, left panel), indicating that 293 cells are not effective in
costimulation, even though the antigen on 293 cells was alloantigenic with respect to
PBMC. When TR6-293 celis were used as stimulators, they induced drastic T-cell
proliferation; this shows that ceil surface TR6 expression provides T celis with potent
costimulation. Similar findings were made with mouse P815 cells. In the presence of a
suboptimal concentration of soluble anti-CD3, T cells from DBAJ2 mice failed to
proliferate in response to stimulation from syngeneic parental P815 or vector-P815 cells
(Figure 2A, right panel). When TR6-P815 celis were tested as stimulators, they
tnggered significant proliferation from days 3 to 5, suggesting that the ceil surface TR6
acts as an effective costimulating molecule.
In figure 2B, we demonstrated in a same expenment that TR6-Fc coated on wells or
expressed on celi surface could both costimulate T-cell proliferation. In the left panel, T
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ceils proliferation was enhanced by TR6 on celis in the presence of suboptimal anti
CD3 (0.8 ig/ml for coating), while anti-CD3, TR6-Fc, or normal human lgG (used as a
control for TR6-Fc) alone had minimal effect. In the right panel, surface TR6 expressed
by P815 celis in the presence of soluble anti-CD3 (5 nglml, suboptimal)was shown to
costimulate T cells as well, while soluble anti-CD3 at this concentration, wild type P815
plus anti-CD3, or vector-transfected P815 plus anti-CD3 failed to do so. It is to be noted
that the magnitude of T-cell proliferation costimulated by TR6 on wells and by TR6 on
ceil surface does flot reflect the potency of these two ways of costimulation, as the
concentration and the route of CD3 administration, which are major factors in
determining the strength of proliferation, in these two systems were totally different.
We further showed that highly purified CD4 and CD8 celis similarly responded to TR6-
P815 costimulation (Figure 2C) in term of proliferation. This indicates that celi surface
TR6 directly costimulates CD4 and CD8 ceils without involvement of non-T ceils.
Culture supematants from the above-descnbed expenments were harvested on days 2, 3
and 4 for lymphokine assay. Responding to parental 293 or vector-293 ceils, human T
cells secreted negligible amounts of WN-y, IL-2 and IL-4; they produced high levels of
WN-y and IL-2 but flot IL-4 when stimulated with TR6-293 celis (Figure 2D). The
Iymphokine production of mouse T celis responding to P815 celis was very similar to
that of human T celis: TR6-P815 celis were able to stimulate WN-y and IL-2 but flot IL-
4 secretion, while parental and vector-transfected P815 ceils were not effective (Figure
2D). These findings corroborate the T-ceIl proliferation data, and suggest that ceil
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surface TR6 is capable of costimulating T celis and inducing Thi-like lymphokine
secretion. It is worth mentïoning that our ELISA was sufficiently sensitive to detect IL-
4 produced by T celis after anti-CD3 and anti-CD28 stimulation (data flot shown),
indicating that the failed detection of IL-4 in TR6-293- or TR6-P815-stimulated T cells
was not due to the lack of assay sensitivity.
We next investigated the nature of ce!! surface ligand with which TR6 interacted. We
showed that soluble human LIGHT (10 igIm!) effectively blocked TR6-P815-tnggered
costimulation in this system (Figure 2E). Moreover, using spleen celis from LIGHT
gene knockout mice, we demonstrated that TR6 bound to 83% wild type T cells (Figure
2F), but only about 18% LIGHT’ T cells. Taken these results together, along with our
previous studies related to the ligand of TR6 on T cells (13,31), it seems that LIGHT on
the T-ceIl surface is, at least, an important signal recipient of the cell surface TR6.
Spleen T cetÏs from mice immunized with TR6-P815 ceils presented an augmented
response to in vitro re-stirnulation
Next, we assessed whether surface TR6 could augment the in vivo T-cell response to
tumor celis. DBAI2 mice were vaccinated with syngeneic mitomycin C-treated TR6-
P815 cells on days 1 and 7. Parental and vector-transfected P815 ceils served as controls.
On day 15, the spleen cells of the vaccinated mice were harvested and re-stimulated
with mitomycin C-treated parental P815 ceils in vitro. The celi prolïferation was
measured by 3H-thymidine uptake on days 4, 5 and 6, lympholdne production of the
culture was assayed on days 3, 4 and 5 by ELISA, and CTL activity was quantified on
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day 6 by 51chromium-release assay. As shown in Figure 3A, parental and vector-P815
ceils failed to prime the immune system in vivo, as the spleen T celis from these mice
did flot respond to secondary in vitro re-stimulation with parental P815 celis in terms of
proliferation (Figure 3A), WN-y and IL-2 production (Figure 3B), and CTL activity
(Figure 3C). However, when the mice were vaccinated with TR6-P815 ceils, their
spleen T celis became highly responsive to in vitro re-stimulation by parental P815 ceils:
T ceils were strongly proliferative on days 4 and 5 (Figure 3A); WN-y and IL-2 but not
IL-4 were detected at high levels in the culture supematants on days 3 and 4 (Figure 3B);
they also showed augmented CTL activity against parental P815 celis when stimulated
wild type P815 (Figure 3C). We further demonstrated that both CD4 and CD8 ceils
were essential during re-stimulation, as spleen ceils from the immunized mice had
significantly reduced CTL against wild type P815 ceils, if CD4 or CD8 cefls were
depleted (Figure 3D). These resuits revealed that TR6 expression on the tumor celi
surface converts the normally ineffective immune response against the tumor ceils into
an effective one in vivo, and the secondary immune response depends on both CD4 and
CD8 ceils. This has established the basis of using tumor ceils with surface TR6
expression as a tumor vaccine.
Reduced tulnorigenicity ofP815 cetts afler surface expression ofTR6
Since P815 ceils with surface TR6 expression could effectively tngger an in vivo T-celI
response, they should have a reduced capability of evading the immune surveillance and,
hence, decreased tumorigenicity. This possibility was investigated here. First, different
numbers of parental P815 ceils were inoculated s.c. into syngeneic DBAI2 mice to
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determine the minimal tumorigenic number (MTN) required to achieve 100% solid
tumor occurrence at the inoculation site. The MTN for P815 was determined to be 1x104
celis, and 5 times MTN (5x101) was used in ail subsequent experiments. As shown in
Figure 4A, ail DBAI2 mice inoculated with the 5xMTN of parental or vector-P815 celis
developed soiid tumors at the injection site, and tumor size reached 400 mm2 within 20
days. The mice were sacrificed at that time according to Canadian Council on Animai
Care guidelines. However, none of the mice inoculated with TR6-P815 celis deveioped
soiid tumors at the injection site du;ing the observation pcriod (30 days), and they had
no visible tumors in their internai organs upon necropsy on day 30. Differences between
the parental P815 versus the TR6-P8 15 group, and between the vector-P8 15 versus the
TR6-P815 group were both highly significant (p<OEOO1, one-way variance analysis
followed by ail pair-wise multiple companson procedures [Tukey test]). Interestingly, 3
out of 6 mice inoculated with TR6-P815 ceils had small (iess than 20 mm2) transient
tumors at the injection site between days 12 and 15, but these tumors disappeared
afterwards; the kinetics of tumor disappearance coincided with that of an effective anti
tumor immune response.
The failed formation of solid tumors by TR6-P815 celis in DBA/2 mice was flot due to
the reduced growth rate of these celis after stable transfection with pCMV-TR6Mem, as
these ceils had a similar in vitro proliferation rate compared with parental or vector
P815 celis (Figure 4B).
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TR6-P8]5 vciccination prevented tinnor developinent on subsequent parental P815 ceil
inoculation anti protection was twnor—specijïc
The failure of so!id tumor formation after live TR6-P815 ce!! inoculation suggested that
the recipient mice deve!oped an effective immune response against the tumor, and
subsequentiy eiiminated the inoculants. If such is the case, inactivated TR6-P$15 ceils
cou!d be used as vaccine to counter the challenge by live wiid type P815 celi inoculation.
This possibility was therefore explored. When live wiid type P815 cefls were inocuiated
into mice previousiy vaccinated with mitomycin C-inactivated wild type P815 ceils or
vector-P$15 ceils, ail them developed tumors at the injection site after 14 days, and the
tumors reached 400 mm2 around day 24 (Figure SA). In contrast, none of the TR6-P815-
vaccinated mice developed tumors upon the tive parental P815 cell chalÏenge._The
differences between the parental P815- versus the TR6-P815-vaccinated groups, and
between vector-P815- versus the TR6-P815-vaccinated groups were highly significant
(p<O.001, one-way variance analysis followed by ail pair-wise multiple companson
[Tukey test]). This indicates that mice vaccinated with inactivated TR6-P815 ceils, but
not parental P815 or vector-P$15 ceils, mounted an effective secondary anti-tumor
immune response, which eliminated subsequenUy inoculated live parental P815 tumor
celis.
Is this anti-tumor response specific? To answer this question, DBAJ2 mice were
inoculated with 5xMTN of live syngeneic SP A120 myeloma celis (5x105 cells/mouse).
These cells rapidly developed into solid tumors in the injection site in 7 days, and by
day 14, the tumors reached 400 mm2 in naïve DBA/2 mice as well as in DBAI2 mice
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vaccinated with TR6-P$15 ceils (Figure 53). This demonstrates that the anti-tumor
immune response by TR6-P815 vaccination is tumor-specific.
TR6-P8]5 vaccine was effective in eliminating pre-existing P815 tumors
In most clinical cases, tumor vaccines will be administered to patients already dïagnosed
with tumors. Therefore, a tumor vaccine wiil only be realisticaily useful if it can
eliminate pre-existing tumors. To this end, we inoculated DBAJ2 mice with live parental
P815 celis s.c. on day 0, and administered tumor vaccination twice, on days 3 and $ in
the opposite flank. As shown in Figures 6A and 6B, ail mice vaccinated with parental
P815 or vector-P815 celis developed tumors, and the ldnetics were similar to those seen
in mice without vaccination, as illustrated in Figure 3A. However, tumor development
in 7 out of the 10 mice vaccinated with TR6-P815 cells was totally prevented; 3 mice in
this group did deveiop tumors, but tumor development was deiayed for about 4 days
(Figure 6C). The differences between the parental P8 15- versus the TR6-P815-
vaccinated groups, and between the vector-P815- versus the TR6-P815-vaccinated
groups were highly significant (p<O.00l, one-way variance analysis followed by ail
pair-wise multiple companson [Tukey test]). This resuit demonstrates that tumor celis
engineered to express cefl surface-anchored TR6 can be used as a therapeutic vaccine.
TR6-B]6 vaccine in combination with adjuvant was effective in eliminating pre-existing
low antigenic tuniors
P815 mastocytoma is a highly antigenic tumor, while many tumors in humans are of
iow antigencity. To explore the general utility of cell surface TR6 in tumor vaccines, we
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expressed TR6 on the ceil surface of B16 (H2b), a low antigenic melanoma une. The
resulting une was named TR6-B16, and was tested alone or in combination with
Bacillus Calmette Guerin (BCG) as a tumor vaccine against parental 316 tumors.
C57BU6 mice (H2b) were inoculated s.c. with 5xMTN (1x105 ceils/mouse) of live
parental B16 tumors on day 0. These mice were mock vaccinated with PBS (Figure 7A)
or vaccinated with vector-B16 (Figure 7B) on days 3 and 8. The two groups had similar
tumorigenic ldnetics and tumor incidence: ail the mice developed palpable soiid tumor
at the injection site around day 11, and none of the mice were tumor-free on day 17. In
mice vaccinated with TR6-B16 cells, the tumorigenic kinetics of parental 316 celis
were delayed (Figure 7C); this was demonstrated more clearly when the data were
expressed as % of mice with tumors (Figure 7F) and as % of mice with tumors reaching
400 mm2 at different days after inoculation (Figure 7G). Statistical analysis showed that
the differences were highly significant or significant (p=O.001 between the mock
vaccinated and the TR6-B16 groups; p=0.024 between the vector-P815 and the TR6-
P815 groups; one-way variance analysis followed by ail pair-wise multiple companson
[Tukey test]). When BCG was administered in combination with TR6-B16 ceils, the
effect became more pronounced: 5 out of 9 mice were tumor-free in this group,
compared with O out of 8 mice being tumor free in the groups with mock vaccination or
with vector-B16 vaccination (p<O.001 between the mock vaccinated and the TR6-B16 +
BCG groups; p=0.006 between the vector-P815 and the TR6-P815 + BCG groups; one
way variance analysis foilowed by ail pair-wise multiple comparison [Tukey testi).
BCG is known to moderately enhance immune responses to certain types of tumors (56).
However, the significant effect of tumor elimination in the TR6-B16 plus BCG-treated
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group could flot be attributed to BCG alone, as the BCG-treated group had about only
two-day delay in their tumor development (Figure 7E), compared with the mock
vaccinated group, and none of the BCG-treated mice was tumor free. This indicates that
TR6-B16 and BCG have additive or synergistic effect as a therapeutic tumor vaccine.
DISCUSSION
Low antigenicity and lack of costimulatory molecules are some of the reasons why
tumor ceils are invisible to immune surveillance. One of the approaches often taken to
overcome these problems is to express costimulating molecules, usually from the 1g
superfamily or TNF superfamily, on the tumor surface (57-59). We developed a novel
strategy in this regard based on costimulation of T cells by the celi surface expression of
TR6, which is a soluble protein of the TNF receptor superfamily.
In our previous study, we demonstrated that when TR6 is coated on wells, it enhances
the T-cell response to suboptimal stimulation of TCR. Those in vitro assays are subject
to criticism that any molecule that can physically increase contact force between the
culture well, on which anti-CD3 or anti-TCR is coated, and T-cells bas the potential to
augment T-cell responses; such a molecule might flot fali into a more strict definition of
costimulatory molecules. In this study, we proved that when TR6 was anchored on the
tumor cell surface, it augmented T-cell responses triggered by tumor antigen in vitro and
in vivo. Therefore, TR6 on the ceil surface can now be qualified as a genuine
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costimulatory molecule, albeit an artificial one, as it is flot normally expressed on the
ceil surface.
Celi surface TR6-based tumor vaccine Iikely depended on adaptive immunity. First, in
vitro study showed enhanced response of naïve T ceils to TR6-293 and TR6-P$15
costimulation (figure 2); secondly, T ceils from TR6-P815 vaccinated mice had
augmented response to wïld type P815 ceils, and such augmented response was reduced
when CD4 or CD8 celis were deleted in vitro; thirdly (Figure 3), TR6-P815 vaccinated
mice rejected parental P815 tumors but not a different tumor, i.e., SP A120 myeloma
celis (Figure 5); finally, our data (flot shown) showed that NK celi activity was flot
modulated by either solid phase or soluble TR6.
TR6 employed is of human origin, and mice do flot have orthologous counterpart of
human TR6. Was the observed tumor immunity in mice due to the xenoantigenic nature
of human TR6? Although we used TR6-P815 or TR6-B16 for immunization, the ceils
used for challenging or inoculation to generate solid tumors (e.g., in the P815
challenging assay (Figure 5), in the P815 therapeutic assay (Figure 6), and in the B16
therapeutic assay (Figure 7)) were all wild type tumor cells carrying no TR6, yet the
tumor immunity could curb their growth in vivo, or eliminate them after the tumors
were pre-inoculated. If one argues that the TR6 as xenoafltigen enhanced the general
non-specific immune status, which led to tumor rejection, we have shown in Figure 5B
that a difference tumor une SP A120 was not affected by the vaccine. Therefore, the
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enhanced immune response is tumor-specific, but flot related to the xenoantigenicity of
TR6.
TR6 bas three ligands, i.e., LIGHT, FasL and TL-1A, and the former two are capable of
reverse signaling and costimulating T ceils. According to our genome search, mice do
flot have an orthologous gene coiresponding to human TR6. Therefore, we used human
TR6 for both in vitro and in vivo study in a mouse model, as human TR6 can bind to
mouse LIGHT and FasL (4,60). We have shown that soluble LIGHT effectively blocks
TR6-P815 tnggered costimulation, and LIGHT’ T ceils had significantly reduced
binding to TR6, compared to LIGHT” T ceils (a decrease from 83% to 18%). These
results along with our previous study (13,31) suggest an important role of LIGHT in the
costimulation. With that said, we cannot exciude possible reverse signaling via FasL
(25-27) or other so far un-identified TR6 ligands on T celis, as TR6 can still bind to
about 18% LIGHT’ T cells according to confocal microscopy.
Our previous data showed that soluble and solid phase TR6 decreases T-cell chemotaxis
(55). This is a possible mechanism to explain that tumors secreting soluble TR6 have
less lymphocyte infiltration (61), and the tumor evasion of the immune surveillance,
because when T cells encounter soluble TR6 outside the tumor, they will decrease they
migration toward the tumor. However, in our current model, TR6 is expressed on the
tumor celi surface; T celis would flot have chances to interact with the celi surface TR6
until they enter the tumor. Hence, the immune surveillance should flot be hampered, but
possibly augmented by the cell surface TR6.
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We have proved in this mouse mode! that tumor ceils engineered to express surface TR6
could be used as a therapeutic vaccine. In humans, some patients with gastrointestinal
tumors have e!evated serum TR6; for some tumors, such as gastric, liver, ga!lb!adder
and colon tumors, the serum TR6-positive incidence reaches 50-70% (61); serum TR6 is
secreted by the tumors (2,61). Conceivabiy, free serum TR6 might compete with celi
surface TR6 in the ccli surface TR6-based vaccine, and reduce its efficacy. Therefore,
such vaccine might be more effective in tumors that do flot secrete soluble TR6. Our
study shows that lung and breast cancers have a much lower incidence of serum TR6
positiveness (!ess than 20%) (61), and patients with these cancers should be optimal
candidates for a surface TR6-based therapeutic tumor vaccine. Moreover, we have also
shown that in tumors with high semm TR6 levels, tumor resection leads to complete
disappearance serum TR6 in 3-4 weeks; this will be the best time window for
administration of surface TR6-based tumor vaccine, as tumor-specific T ccli immunity
can develop in the absence of TR6 interference in such a time window.
In summary, tumor celis engineered to express surface TR6 are a useful addition in our
arsenal of therapeutic tumor vaccines.
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FIGURE LEGENDS
Figure 1. TR6 Expressioit on the cet! surface
Figure 1
-1
H 1633
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A. Construct exp ressing membrane-bound TR6
The full-length TR6 cDNA coding sequence minus the stop codon was fused to
the coding sequence of the EphB6 transmembrane domain (EphB6-TM) followed
by a stop codon. This cassette was cloned into the polylinker of pAdenoVator
downstream of the CMV promoter. The resulting construct was named pCMV
TR6Mem.
1R6
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Figure 1
B
Surface 1R6
B. TR6 expression on the 293, P815 and B16 ceti sutface
Human embryo kidney 293 cells, mouse mastocytoma P815 ceils, and mouse
melanoma B16 ceils were stably transfected with pCMV-TR6Men or the parental
vector, and surface TR6 expression on these celis was detected by flow cytometry.
The fluorescence intensity of untransfected wild type celis (grey area) was used to
determine background staining. Solid lines represent ceil surface TR6 expression
on pCMV-TR6Mem- or vector-transfected ceils. The percentage of TR6-positive
celis after deduction of background is indicated.
figure 2. Cet! surface TR6 expression costiinutates T ce!! in vitro
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Mitomycin C-treated sut-face TR6-293 celis or TR6-P815 cells were used to
stimulate human T ceils from PBMC or DBAJ2 spleen T celis, respectively. Vector
293 ceils, vector-P815 cells, parental 293 cells or parental P815 cells served as
controls. For mouse T-celI culture, a suboptimal concentration of soluble anti-CD3
(clone 2C1 1, 20 nglml) was present. Thc celis were pulsed with 3H-thymidine for 16
h before being harvested on days 3, 4 and 5, as indicated.
B. TR6 coated on wetts or expressed on cetÏ surface costimulated T ceils
On the left panel, TR6-Fc (10 tg/ml for coating), normal human IgG (NHIgG; as a
control for TR6-Fc; 10 pg/mI for coating), andlor suboptimal anti-CD3 (0.8 tg/ml
for coating) were coated on the wells as indicated; DBA/2 T cells were added to the
wells at 4x105/200il/well. On the nght panel, DBAI2 T cells and mitomycin-C
treated tumor cells (parental P815 ceils, vector-P815 ceils, or TR6-P815 ceils) were
mixed at 3:1 ratio and cultured at a final total density of 4x105/200jil/well; the first
3 columns showed proliferation in the absence of soluble anti-CD3, while anti-CD3
was present at 5 nglml for the last 4 columns. The cells were pulsed with 3H-
thymidine for 16 h before being harvested on days 4.
C. Pro!iferation of Magnetic beads-purified inouse CD4 and CD8 cetts
Magnetic bead-purified mouse CD4 and CD8 ceils (about 97% pure) were
stimulated with TR6-P815 in the presence of a suboptimal concentration of anti
CD3 (20 nglml) as descnbed above, and the celis were pulsed with 3H-thymidine
for 16 h before being harvested on days 4.
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Flgure2
D
z
D. Lymphokine production.
Supematants of the ccli cultures described in Figure 2A were harvested on days 2, 3
and 4, as indicated, and IFN-y, IL-2 and IL-4 in the supematants were measured by
ELISA.
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E. Soluble LiGHT blocks celi surface TR6-augrnente T ceit proliferation
The experiment was conducted as described in Figure 2A, using TR6-P815 ceils as
stimulators, and DBAI2 T celis as responders, in the presence of a suboptimal
concentration of soluble anti-CD3 (clone 2C11, 20 nglml). Empty columns represent
cultures conducted in the presence of 10 igIml soluble human LIGHT. Thymidine
uptake was measured on day 4.
F. LIGHT T cells significantly reduced their binding to TR6
Spleen cells from LIGHT’ or wild type (LIGHT) mice were stained with anti
CD3 and TR6-Fc using 2 color fluorescence, and the percentage of TR6-positive
cells among CD3 positive ceils according to three randomly chosen fields of
confocal microscopy was shown.
Figure 2
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figitre 3. Spleen T ceils front mice vaccinated with TR6-P815 cetls muntfest
augmented response to in vitro re-stimulation
DBAI2 mice were vaccinated with mitomycin C-treated TR6-P815 ceils on days 1 and 7.
Vector-P815 ceils or parental P815 ceils were used as controls. On day 15, spleen T
celis (A and B), or total spleen ceils (C and D) from the vaccinated mice were harvested
and stimulated with mitomycin C-treated parental P815 cells.
Figure 3
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The culture as described above was pulsed with 3H-thymidine for 16 h before
harvesting, and the ceils were harvested on days 4, 5 and 6 for the measurement of
thymidine uptake. Samples were in triplicate, and mean ± SD is presented.
Figure 3
B. Lyrnphokine production
Supematants from the culture described above were harvested on days 3, 4, and 5 as
indicated, and WN-y, iL-2 and IL-4 in the supernatants were measured by ELISA.
Samples were in duplicate, and the mean ± SD is presented.
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Figure 3
C
C. Cytotoxic T-lymphocyte activity of TR6-P815-primed spleen ceils
Total spleen celis from vaccinated DBAJ2 mice (mock vaccination with PBS;
vector-P815; TR6-P815) were stimulated with mitomycin C-treated parental P815
ceils for 6 days, and the CTL activity of the culture was measured by 51Cr-release
assay, using P815 cells as targets.
Figure 3
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D. CTL activitvfroni TR6-P815-priinecl inice clepencis on both CD4 cmcÏ CD8 ceits
Spleen celis from TR6-P815-vaccinated DBA/2 mice were used as a whole, or
depleted of CD4 or CD8 celis, as indicated. These celis were stimulated with
mitomycin C-treated parental P815 cel]s for 6 days, and the CTL activity of the
culture was measured by 51Cr-release assay, using P815 ceils as targets. Naïve
spleen: total spleen celis from mice with mock vaccination (PBS); immunized
spleen: total spleen celis from mice immunized with TR6-P815; CD4 deletion: CD4-
deleted spleen cells from TR6-P815-immunized mice; CD8 deletion: CD8-deleted
spleen ceils from TR6-P815-immunzed mice.
Experiments were performed more than twice with similar results, and a set of
representatÏve data is presented.
Figure 4. TR6-P815 ceits were tess turnorigenic than parental P815 cetts
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A
P815 Vector-P815 TR6-P815
(n=5, tumor fte.e=0) (n=6, tumor freezO) (n=6, himor free=6) MouS #
r4 45Q 450
_____________
100
E 400 440 j
___
___
j
___
___
____ _ ____ _
250
_____
60 I-.À—31
I 40
100 I 20
Pays
A. In vivo tumor growth
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Live TR6-P815 celis, vector-P815 celis or wild type P815 celis were inoculated s.c.
ïnto the Ieft flank of DBAJ2 mice (5x104 cells/mouse). Tumor size was recorded q.
2d for 30 days and plotted. The resuits underwent one-way variance analysis
followed by ail pair-wise multiple companson (Tukey test). The TR6-P815-
inoculated group was highly significantly different from the vector-P815- or P8 15-
inoculated groups (p<O.001 in both comparisons; one-way variance analysis
followed by ail pair-wise multiple comparison procedures [Tukey test]).
Figure 4
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B. TR6-P815 ceils, vector-P815 and parental P815 celis had similar growth rates
in vitro
The three above-mentioned types of cells were cultured in 6-welI plates
(5x104110 ml medium). The cdl numbers in each well were determined in
triplicate daily by flow cytometry. Total cell numbers in culture from days O to 4
were plotted. The expenments were performed three times with similar resuits,
and a set of representative data is shown.
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figure 5. Protective effect of TR6-P815 vaccine against subsequent tumor cet!
inocutatioit
Figure 5
A. Mice vaccinated with TR6-P815 celis resisted parental P815 ceti challenge
DBA/2 mice were vaccinated with 5x106 mitomycin C (MMC)-treated P815-
TR6 celis on days 1 and 7 s.c. on the left flank. On day 15, live parental P815
celis (5x104 ceils) were inoculated s.c. on the right ftank. Vector-P815 celis and
wild type P815 celis were used as mock vaccines. Tumor size was registered q.
2d for 30 days and plotted. Differences between the TR6-P815 versus the P815,
and the TR6-P815 versus the vector-P815 groups were highly significant (one
way variance analysis followed by ail pair-wise multiple comparison [Tukey
test], p<O.001 in both compansons).
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Figure 5
B. The protective effect of TR6-P8]5 vaccination was tumor-speczficDBAl2 mice
were vaccinated with MMC-treated TR6-P815 ceils as described. Naïve DBAI2
mice served as controls. On day 15, live SP A/20 myeloma celis were inoculated
s.c. (5x105/mouse) on the opposite flank. Differences between the TR6-P$15-
vaccïnated and the naïve groups were not significant (one-way variance analysis
followed by ail pair-wise multiple comparison [Tukey test], p>O.05).
figttre 6. TR6-P815 cetts were effective as a therapeutic titrior vaccine
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Figure 6
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DBAI2 mice were inoculated with 5x104 live parental P815 celis s.c. on the left flank.
On days 3 and 8, 5x106 Ivll\4C-treated P815-TR6 ceils were inoculated on the right flank
as a therapeutic vaccine. Parental P815 or vector-P815 celis were used as controls.
Differences between the TR6-P815 versus the P815, and the TR6-P815 versus the
vector-P815 groups were highly signifïcant (one-way variance analysis followed by ail
pair-wise multiple comparison [Tukey test], p<0.001 in both compansons).
figure 7. Low antigenic B16 cetis expressiizg surface TR6 were effective as u
therapeutic tumor vaccine
Live parental low antigenic B16 cells were inoculated s.c. on the ieft flank of syngeneic
C57BU6 mice (1x105 ceiis/mouse) on day 0. On days 3 and 8, 5x106 mitomycin C-
C
(n=1O, tumor free=7) Mouse #
-I-5
-4_7
—s
—9
-i-10
MMC-treated Vector-P8 15
liveP8l5
MMC-treated TR6-P815
FACULTÉ DES ÉTUDES SUPÉRIEURES UNIVERSITÉ DE MONTRÉAL GUIXIU 5h 162
treated TR6-B16 ceils (C), BCG (0.5 mg/mouse) alone (E), or both (D) were inocuÏated
on the right flank as therapeutic vaccine. Mice with mock vaccinated (A; with PBS) or
vector-B 16-vaccination (B) served as additional controls. Tumor size, registered q. 2d
until day 30, was plotted.
A-E. Tumor size of individual nice with dtfferent treatrnents
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Figure 7
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F-G. % of mice developing tumors as examined on day 30 (F), and % of mice with
2.tumors reacizing 400 mm in size until day 30 (G).
Differences between the TR6-P8 15 versus mock vaccination, and between the TR6-
P815 versus the vector-P815 groups were highly significant (p=O.001) and significant
(p=O.O24), respectively; differences between the TR6-P815 + BCG versus the mock
vaccinated groups, and the TR6-P815 + BCG versus the vector-P815 groups were
highly significant (p<O.001 and p=O.006, respectively; one-way variance analysis
followed by ail pair-wise multiple comparison [Tukey test]).
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III. DISCUSSION
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III. Discussion
In this project, the role of TR6 in immune regulation was investigated. In the in vitro
study, TR6 coated on plates or expressed on tumour ce!! surface enhances TCR
stimulated T-cell proliferation, and Thi cytokine production. TR6 on solid phase can
significantly enhance mouse spleen celi CTL activity. In vivo study showed that TR6
expressed on tumour ce!! surface reduces tumourigenicity, increases tumour antigenicity,
and e!icits specific anti-tumour immunity; the therapeutic effects of TR6-based tumour
celi vaccine in treating established tumour is enhanced by BCG adjuvant. We also
proved, for the first time, that soluble TR6 inhibits chemokine-induced human T-ce!1
migration in vitro, and mouse T-cel] migration in vivo. TR6 pretreatment reduces
SDF1a-stimulated T ceil Cdc42 activity, actin polymerization and pseudopodium
formation. At the mo!ecular level, we found that LIGHT is co-localized with clustered
lipid raft in activated T ceils, and that LIGHT reverse costimu]atory signaling enhances
mouse T ccli p44142 MAPK actÏvity.
1. Reverse signaling through TR6 Iigands
Many ce!! surface ligands can work as receptors to transduce signaIs reversely into cells.
These ligands include: ta) some TNF family members, such as FasL, CD4OL, CD3OL,
OX-40L, TRANCE, TRAIL, DR4 and LIGHT; (b) certain Eph ligands, such as ephrin
Bi and ephrin B2 (410, 411); (c) some other ligands, such as celi surface IL-15 (412)
and B7 (413).
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During our study of TR6 in regulation of immune responses, we found that TR6 can
reversely transduce signais into T ceil through its ligands. As described in section 1,
TR6 lias three identified ligands, LIGHT, FasL and TL1A. TLYA is mainly expressed
on endothelial ceils. So it is flot relevant to TR6-regulated T-ceIl responses. LIGHT and
FasL are both expressed on activated T-cell surface and are inducible dunng T-cell
activation (286). Our study proved that LIGHT is also expressed on resting T celis by
confocal microscopy (8). The costimulation function of soiid phase TR6 from LIGHT or
FasL reverse signaling, or from both? We showed that anti-human LIGHT mAb on
solid phase enhances mouse T-cell proliferation, and that cross-linked anti-LIGHT
antibody pretreatment inhibits T-cell migration. Unlike TR6, which binds to both
LIGHT and FasL, the anti-human LIGHT monoclonal antibody can only binds to
LIGHT (8). This directly proves that LIGHT reverse signaiing is involved in the
observed TR6 functions. FasL, another ligand of TR6, expressed on T ceil surface, is
able to reversely transduce costimulatory signais into T celis when it is engaged with
Fas. It was reported that FasL reverse costimulatory signaling occurs immediately on T
ccii receptor ligation and correlates with the upregulation of FasL expression on CD8
and naive CD4 ceils, both of which are sensitive to the FasL costimulatory signais (94).
As the recombinant TR6 protein can bind to FasL (116), it is possible that TR6 on solid
phase ligates both LIGHT and FasL on the T ceIl surface. To address this question, we
stained activated mouse lymph node ceils from LIGHT knockout mice and wild type
mice. Resuits showed that the binding of TR6 to LIGHT’ T ceils is reduced 80%, using
wild type T celis as controis. This indicates that the main binding partner of TR6 on T
ceils is LIGHT, but it might also bind to other molecuies. Using spleen ceils from
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LIGHT knockout and FasL mutant mice (gldlgld), we found that with solid phase TR6
costimulation, the proliferation rate is reduced in both LIGHT knockout or FasL mutant
spleen celis, compared with wild type spleen cells, and the reduction is more sïgnificant
in LIGHT knockout spleen cells (>50%) (data not shown). These resuits suggest that
both LIGHT and FasL reverse signaling contributes to the enhanced immune responses,
But the majonty of the reverse signaling is thought LIGHT. Results from other group’s
studies indicate that TR6 bas other undefined ligand(s), which might reversely transduce
signais into ceils. Hsu TL, et al (117). reported that TR6-Fc binds to freshly isolated
CD14 monocytes and reversely tranduces signals into those celis, but anti-LIGHT,
anti-LTc, and anti-FasL Abs do flot. Chang YC, et al (119). found that TR6 binds to
macrophages and modulates their activation and differentiation, but the known TR6
Iigands FasL, LIGHT and TL1A are undetectable in these ceils by flow cytometry or by
Western blot analysis. Together, these studies suggest that TR6 might have other
unidentified ligand(s). It will be interesting in our model to use LIGHL’ and FasL’
double nuil mutant T cells to see whether TR6 can still trigger reverse signaling. Such
an experiment will support or refute the existent of the so far unidentified TR6 ligands
on T ceils.
Our resuits clearly proved that TR6 can reversely tranduce signals into T cells through
its ligands, mainly through LIGHT. The molecular mechanisms of such reverse
signaling are not clear. In this study we found that LIGHT is co-localized with TCR in
anti-CD3 plus anti-CD28 costimulated T celis in the clustered lipid rafts. Solid phase
TR6 costimulation enhances ERKÏ activity in the T ceils (8). Upon SDF-ÏŒ-stimulation,
we found reduced Cdc42 and p38 MAPK activities and repressed actin polymerization
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in soluble TR6 pretreated T cells (125). These resuits indicate that the Cdc42, MAPK
and cytoskeleton reorganization are involved in LIGHT reverse signaling. Since the
cytoplasmic tau of LIGHT is short and incapable of signaling on its own (33), we
studied the possible association of adoptor proteins with LIGHT using
immunoprecipitation. We found the Grb2, but not Cbl, Vav or PI-3K, is associated with
LIGHT. It is possible that Grb2 is a molecule mediating downstream signaling
involving Cdc42 and MAPK. Cdc42 is an important Rho GTPase, it regulates T celi
polanzation towards antigen-presenting ceils (APCs) through inducing localized actin
polymenzation at the site of APC binding (414, 415), and is also essential for
chemokine-induced lymphocyte migration (125, 416, 417). The downstream signaling
pathways of Cdc42 is still an unresolved question (415). In our study, we found that
TR6-pretreated T cells have impaired Cdc42 and p38 MAPK activities after SDF
la stimulation. This indicates that p38 MAPK might be a downstream signaling
molecule of Cdc42 in LIGHT reverse signaling dunng SDF-la stimulation. However,
in T cells activated by TCR, we found increased p42144 MAPK activity upon LIGHT
reverse signaling. Although it is flot known whether the small GTPase are repressed or
activated in the presence of TCR activation. It is possible that the effect of LIGHT
reverse signaling on GTPase depends on the other signais T celis receive. In the case of
SDF-la, stimulation the GTPase and the downstream actin polymerization are repressed,
while in the case of TCR stimulation, it might be the opposite. This hypothesis is worth
investigating.
2. The mechanisms of tumour celi-surface TR6-triggered anti-tumour immunity
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It is wïdely recognized that tumour immunity is mainly a cell-mediated immune
response. The critica! role of tumour antigen-specific T celis in the eradication of
cancer has been demonstrated in numerous animal models. Data compiled from both
in vitro systems and human clinical trials indicate the existence of tumour antigen
specïfic T ceils (338). We have demonstrated in this study that tumour celis with
forced expression of ce!! surface TR6 can be used as tumour vaccine. The
underlying cellular mechanisms are discussed here.
Our in vitro experiments showed that surface TR6 expressing tumour ce!!s cou!d
costimulate both human and mouse T-cell proliferation and Thi cytokine production.
This finding is consistent with our data using TR6 coated on cultured wells (8).
Furthermore we found that T ce!!s from P815-TR6 immunized mice have significantly
enhanced pro!iferation, Thi cytokine secretion and CTL activity in response to wild
type P815 tumour ceil restimulation. This proves that after vaccination, specific anti-
P815 tumour T celis are primed. There are two kinds of T ceils involved in specific celi
mediated immune response, i.e., CD4 and CD8 ce!!s. Which of the two T ccli
populations is responsib!e for the TR6 surface expressing tumour ccli vaccination
induced anti-tumour immunity? Our in vitro data from T celis cultured in TR6 precoated
plates or with MMC-treated TR6 surface expression tumour celis, indicate that TR6
directly costimulates both CD4 and CD8 proliferation. Further, we demonstrated that
either CD4 or CD8 deletion reduces the anti-P815 CTL activity of spleen ceils from
P815-TR6 immunized mice. These results proved that both CD4 and CD8 ceil are
required for the ceil-surface TR6-tnggered anti-tumour immunity. Our in vivo data aiso
showed that P815-TR6 immunized syngenic DBA2 mice specifically resisted the
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challenge of wild type P815 tumour ceils, but not that of SP A/20 myeloma celis. This
proves that P815-TR6 vaccination induces specific anti tumour immunity.
The above evidence clearly demonstrates that ceil-surface TR6-based tumour vaccine
depends on adaptive immunity. However, we could flot exciude the possibility that the
innate immunity is also involved during T-ce!! priming. Indeed, both LIGHT and FasL
arc expressed on NK ceils, and LIGHT is also expressed on DCs. It is possible that
P815-TR6 stimulates DCs through their surface LIGHT, or/and stimulates NKs through
their surface LIGHT andlor FasL.
It was reported that soluble TR6 modulates DCs differentiation and activation; TR6
pretreated DCs skew naive T-cell differentiation towards a Th2 phenotype (117). It wifl
be interesting to study whether solid phase TR6-treated DCs can drive T ceils to
differentiate into an opposite phenotype, i.e., Thi, which enhances tumour immunity.
We showed that Vaccination with B16-TR6 in combination with adjuvant BCG greatly
increases the efficacy of the vaccine. It is possible that BCG adjuvant causes
inflammation at the injection sites; such inflammation would, in turn recruits APCs and
stimulates APCs activation. The activated APCs then, could capture tumour antigens
released from the tumour vaccine and indirect!y present the captured tumour antigens to
tumour-specific T celis. It is also possible that the inflammatory cytoldnes directly
promote the function of tumour-specific T ce!!s.
3. The physiological and pathophysiological rote of TR6
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TR6 is secreted by activated normal T ceils. The peak of TR6 secretion is 24 to 4$
hours after T-cell activation (136). We also proved that soluble TR6 inhibits T-ce!!
aggregation (136) and T-cell chemotaxis (125). These resuits collectively suggest
that TR6 plays a very important role in T-ce!! responses. TR6 secreted by activated
T ceils can terminate the costimulation by interfering with the interaction between
TR2 and LIGHT, LTf3R and LIGHT, and between Fas and FasL. Such function of
TR6 can also reduce the activation-induced T ce!! death. As a result of these
blocking functions, TR6 might enhance the survival of activated T ce!!s in
inflammation sites, and enable these T cel!s to fight with invaded pathogens for a
longer time, or to differentiate into memory T cells.
The chemotaxis inhibition by T celI secreted TR6 might discontinue the flux of T
ce!!s to the inftammatory sites once T ceil activation is near complete. This seems to
be another mechanism to control the scale of an immune response. TR6 also inhibits
aggregation of activated T ceils. A possible physiologica! ro!e of this effect is that
TR6 secreted by activated T ce!ls will disengage T cells from APC, and disperse the
T ce!!s to their destination in the form of effector cells. Taking together, TR6
produced by activated T cells might play a very important role in modulating T-ce!!
responses and memory T-cell deve!opment.
TR6 is over-expressed in many malignant tumours, which include tumours of esophagus,
stomach, g!ioma, long, colon, !ymphoma and rectum (49, 50, 110, 111, 112). Many
cancer patients have high serum TR6 !eve!s, which are correlated to the grade of
malignancy, and to TNM (UICC cancer staging system. TNM represent: Primary
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tumour (T), Regional lymph nodes (N), Distant metastasis (M)) pathological
classification (109). This suggests that TR6 might p!ay a role in tumour progression and
immune evasion.
As a decoy TNF receptor, TR6 can neutralize the biological function of FasL, LIGHT
and TL1A by interfenng with the interaction of them with their respective receptors.
Sïnce TR6 can block Fas-, LTf3R- and DR3-mediated apoptosis (120, 121, 124), it can
protect tumour ceils from apoptosis mediated by these receptors. As Fas-mediated
apoptosis is involved in immune cell-mediated killing, blocking this pathway will
impair the tumour specific CTL to !dll tumour celis, and he!p tumour cells evade the anti
tumour immune attack.
TR6 secreted by tumour ceils can reduce the anti tumour immune responses by blocking
T-ce!! costimu!ation. TR6 can b!ock T-ce!! costimulation through HVEM, (the receptor
of LIGHT), which is constitutively expressed on T ceils. Blocking this pathway will
inhibit T-cell responses. TR6 can a!so reduce T-cell responses by blocking LIGHT and
FasL reverse signa!ing co-stimulatory signais. Moreover, TR6 can block another T-cell
costimulation pathway through the interaction between TLYA and DR3 (418). Such
blockage of T-ce!! costimulation wi!1 certainly attenuate anti tumour immunity. Another
function of TR6 is to inhibit T-ce!! chemotaxis. Indeed, we found that high !evel TR6-
secreting tumour have !ess lymphocyte infiltration in the tumour mass compare with low
TR6 secreting tumours (data not shown). This suggests that TR6 will help tumour ce!l
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evade anti tumour immune attack by preventing anti tumour T ceils to migrate into
tumour sites.
A recent study showed that TR6 can induce angiogenesis by neutralizing TL1A-induced
angiostatic action through its receptor DR3 (121). This resuit indicates that TR6
released by tumours flot only prevents tumour ce!! from apoptosis and immune celi
mediated ki!!ing, it also help tumour survival by inducing angiogenesis. Taking together,
TR6-secreting tumour can gain survival advantage by using TR6 to block apoptosis,
inhibit anti tumour immune responses and induce angiogenesis.
As mentioned in the Introduction, TR6 is a secreted member of the TNF receptor fami!y.
There is no so!id phase TR6 under physio!ogical conditions. In order to study the
reverse signa!ing of its ligands, we put TR6 on solid phase to cross!ink its ligands
expressed on the T celi surface. In the first part of this project, we proved that TR6 on
the solid phase reverse!y transduces signa!s into T ce!!s through its ligand(s), and we
proved that LIGHT, one of the TR6 !igands, is mainly responsible for the effect. This
bas !ed us to explore the therapeutic applications of the so!id phase TR6 by expressing it
on tumour celi surface as a therapeutic tumour vaccine, and finding that it does enhance
antitumour immunity.
4. Future perspectives
Severa! transiational studies based on the functions of TR6 in the immune system are
worth exploring.
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We have demonstrated that soluble TR6 can inhibit T-cell chemotaxis, and soluble TR6
can block T-celÏ costimulation. These functions of TR6 can be used to treat graft
rejection or autoimmune diseases by either adminïstering soluble TR6, or expressing
TR6 on tumour cdl surface by recombinant virus vectors to enhance anti tumour
immunity.
We have proved in animal models that surface TR6-expressing tumour celis could be
used as a therapeutic vaccine to treat both high and low immunogenic tumours. It is
feasible to apply this approach to human tumour therapy. TR6 protein can be anchored
on autologous tumour celi surface by bifunctional reagents, which could link TR6
protein on tumour cell surface, or by recombinant virus infection. In order to enhance
the therapeutic effects, the vaccine could be used in combination with adjuvant, like
BCG. The therapeutic effects can be improved by coexpressing some other
costimulating molecules, such as B7-1, ICOS, 4-1BB, LIGHT etc., or coexpressing
some cytokine(s), such as GM-CSF, IL-12.
Because LIGHT only has a short intraceflular tau, which has no enzymatic activity, it us
likely that LIGHT reversely transduces signals into T cells through adaptor proteins it
associated with. To understand the mechanism of LIGHT reverse signaling, we have
demonstrated that LIGHT is indeed associated with an adaptor protein Grb2; additional
LIGHT-associated proteins related to its signaling can be identified by very sensitive
mass spectrometry analysis which is currently available.
5. The contribution of this study to science
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In this project we have studied the biological functions of TR6 and revealed
undocumented features of this protein in regulating T-ce!! responses. It is the first time
that the reverse costimuiatory signaling is applied in tumour vaccine development. Our
resuits showed that TR6-based tumour vaccine can treat both high and Iow
immunogenic tumours in mouse modeis. Since many ce!! surface ligand molecuies can
reversely transduce costimu!atory signais into T ceils, this finding has opened a new
area in tumour vaccine development. We have a!so demonstrated, for the first tïme, that
TR6 inhibits T-ce!! chemotaxis. This finding couid explain why there is Iess lymphocyte
infi!tration in TR6-secreting tumour mass, and this property of TR6 may contnbute to
the evasion of tumours from immune survei!!ance.
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VI. Appendix
Some explanations related to the published articles are provided herewith.
J. The advantages ofusing 2C Tcell as responder ceÏl in CTL activfly assay. In the first
paper of this project, 2C mice spleen celis are used as responder ccl! in the CTL
assay. The 2C TCR transgenic mice, which carry functionally rearranged TCR c
and 13-chain genes from a cytotoxic T ce!! c!one 2C, were bred in our anima! faci!ity
The TCR is specific for class I MHC Ag L’ (1). The offspring of the founder
transgenic mice have been backcrossed with C57BL!6 for more than 25 generations
and are now of H2b background. The majority (85%) of their peripheral T celis are
CD8, and almost al! the CD8 ceils express clonotypic TCRs recognized by mAb
1B2 (1). The transgenic 2C T celis are functional inthat they cou!d deve!op into Le’
specific cytotoxic T ce!!s in vitro (2, 3). Because ofthe high frequency of antiH2d T
celis in the 2C spleen cells, this system provides an enhanced signal/noise ratio and
sensitivity in the CTL assay.
2. Tue controiprotein NhIgG and TRi] are interchangeable in our experiments. In our
initia! experiments, we used TRi 1 and NhIgG as controt proteins for TR6-Fc. We
found that both proteins on so!id phase had no function in terms of T ceil
costimulation; therefore, in the subsequent experiments, these two control proteins
were used interchangeably.
3. The details of LIGHT knockout mice. LIGHT mice described in the article were
generated by Dr Lieping Chen (4), and were provided to us by our collaborator Dr
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Jun Zhang (Human Genome Sciences mc). The description and data related to these
mice are now provided in revised article 3.
4. TR6 based tumor celi vaccine is a promising approach in cancer immun otherapy.
As mentioned in the Introduction and the third article, many costimulatory
molecules, such as, B7-1 and B7-2 (5), B7h (6, 7), CD4OL (8, 9, 10), OX4OL (11),
4-YBBL (12), CD27L (13) and LIGHT (14, 15), can 5e expressed on the tumor ceil
surface to initiate and enhance host antitumour immunity. Among these
costimulatory molecules, only CD4OL, CD27L and LIGHT are reported to induce
anti-tumour immunity to tumor celis of low antigenicity. For the other costimulatory
molecules, it is necessary to coexpress more than one costimulatory molecules or to
coexpress the costimulatory molecule with cytokines to achieve rejection of low
antigenic tumours. Our resuits show that TR6 expression on the tumor celi surface
induces strong antitumor immunity against tumors with both high and low
antigenicity tumours. It is possible that such antitumour immune responses can be
further enhanced by coexpressing TR6 with other costimulatory molecules or
cytokines on tumour ceil surface.
5. The anti-human LIGHT ,nAb 1.2.2 most likely binds to mouse LIGHT In the first
article of this thesis, we used anti-human LIGHT mAS 1.2.2 to study the LIGHT
reverse signaling in mouse T ceils. Based the following reasons, we believe that
mAb 1.2.2 binds to mouse LIGHT. First, as mentioned in article, mouse LIGHT
shares 67% homology with human LIGHT in its amino acid sequence. Data from Dr
Wu’s group have proved using a Biocore assay that human TR6 recombinant protein
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binds to mouse LIGHT (16). Secondly, the binding profile of the anti-human LIGHT
mAb is consistent with the LIGHT expression kinetics on the T celis. LIGHT
expression is inducible on the T ccli surface during T ce!! activation, simi!ar!y, the
binding of the anti-LIGHT mAb was only detectable on activated T cel!s but not
resting T celis. Third!y, we did immunoprecipitation (data not show) using mAb
1.2.2 and detected the protein by Western b!ot using a rabbit anti-human LIGHT
polyciona! Ah. We found that both human LIGHT protein (as positive contro!) and
the protein precipitated by mAb 1.2.2 cou!d be detected by the po!yclonal anti-
LIGHT Ah, and the size of the precipitated hand is the same as that of mouse
LIGHT. Taken together, these resu!ts indicate that the anti-human LIGHT mAb
1.2.2 binds to mouse LIGHT on the T celi surface. Fina! proof of the specificity of
the anti-human LIGHT mAb against mouse LIGHT will be obviously corne from an
experiment in which rnouse recombinant LIGHT is emp!oyed.
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